<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
  <meta name="author" content="" />
  <meta name="keywords" content="" />
  <meta name="description" content="PATIENT CARE IN RADIOGRAPHY 2023" />
  <title></title>
  <style>
    body {
      margin: 0;
      padding: 0;
      overflow: hidden;
    }
    #bookmarks {
      width: 197pt;
      height: 100vh;
      position: absolute;
      top: 0;
      left: 0;
      overflow-y: auto;
    }
    #content {
      margin-left: 197pt;
      height: 100vh;
      overflow: auto;
    }
    #content-inner {
      margin-right: 20pt; /* Добавлено свойство margin-right */
    }
	
	.title
{
  font-family: Arial, Helvetica, sans-serif;
   font-size: 14px;
   font-weight: bold;
   color: #000000;
   text-decoration: none;
   margin: 1pt;
   text-align: left;
   position: fixed;
   white-space:nowrap;
   width: 10px;
   height: 10px;
   -webkit-transform:rotate(90deg);
   -moz-transform:rotate(90deg);
   -ms-transform: rotate(90deg);
   -o-transform: rotate(90deg);
   transform: rotate(90deg);
}
.data
{
   margin: 1pt;
   text-align: left;
   padding-top: 3pt;
   margin-left: 12pt;
}
a
{
   font-family: Arial, Helvetica, sans-serif;
   font-size: 14px;
   font-weight: normal;
   color: #0f0f0f;
   background-color: #E5E6EA;
   text-decoration: underline;
   cursor: pointer;
   margin: 1pt;
}
span
{
   margin: 1pt;
}
a
{
display: block;
}
	
	
  </style>
</head>
<body>
  <div id="bookmarks">
  
<div class="title">Заголовки</div><div class="data"><a target="content" href="#a0" style="padding-left: 30pt;">The Basics of Thyroid and Neck Ultrasound</a><a target="content" href="#a1" style="padding-left: 30pt;">Overview of the Bethesda System for</a><a target="content" href="#a2" style="padding-left: 30pt;">Fine Needle Aspiration: Role of Molecular</a><a target="content" href="#a3" style="padding-left: 30pt;">Thyroid Gland Ultrasonography: Hashimoto’s, Graves’, Thyroiditis,</a><a target="content" href="#a4" style="padding-left: 30pt;">Anatomy and Selected Non-thyroid</a><a target="content" href="#a5" style="padding-left: 10pt;">Basic Ultrasound Physics</a><a target="content" href="#a6" style="padding-left: 10pt;">Equipment</a><a target="content" href="#a7" style="padding-left: 10pt;">Transducer Selection</a><a target="content" href="#a8" style="padding-left: 10pt;">Patient Positioning and Scanning Techniques (Image 1.6)</a><a target="content" href="#a9" style="padding-left: 10pt;">Potential Scanning Pitfalls</a><a target="content" href="#a10" style="padding-left: 20pt;">Thyroid Anatomy (Image 1.7)</a><a target="content" href="#a11" style="padding-left: 20pt;">Normal Thyroid Texture (Image 1.8)</a><a target="content" href="#a12" style="padding-left: 20pt;">Thyroid Nodules</a><a target="content" href="#a13" style="padding-left: 20pt;">Simple Cysts (Image 1.14)</a><a target="content" href="#a14" style="padding-left: 10pt;">Other Neck Masses</a><a target="content" href="#a15" style="padding-left: 10pt;">Parathyroid Glands</a><a target="content" href="#a16" style="padding-left: 10pt;">Salivary Glands (Image 1.26)</a><a target="content" href="#a17" style="padding-left: 10pt;">Branchial Cleft Cyst</a><a target="content" href="#a18" style="padding-left: 10pt;">Carotid Body Tumor</a><a target="content" href="#a19" style="padding-left: 10pt;">Further Reading</a><a target="content" href="#a20" style="padding-left: 30pt;">Case Presentation</a><a target="content" href="#a21" style="padding-left: 10pt;">Risk Calculators Versus Clinical Practice Guidelines</a><a target="content" href="#a22" style="padding-left: 20pt;">American Thyroid Association (ATA)</a><a target="content" href="#a23" style="padding-left: 20pt;">EU-TIRADS</a><a target="content" href="#a24" style="padding-left: 20pt;">K-TIRADS</a><a target="content" href="#a25" style="padding-left: 20pt;">C-TIRADS</a><a target="content" href="#a26" style="padding-left: 20pt;">Malignancy Risk Estimation of Lesions with AUS/ FLUS</a><a target="content" href="#a27" style="padding-left: 20pt;">Thyroid Nodule Malignancy Risk Calculator: Spain</a><a target="content" href="#a28" style="padding-left: 20pt;">The Thyroid Nodule App: TNAPP</a><a target="content" href="#a29" style="padding-left: 20pt;">Case Conclusion:</a><a target="content" href="#a30" style="padding-left: 10pt;">Introduction</a><a target="content" href="#a31" style="padding-left: 30pt;">Case Presentation</a><a target="content" href="#a32" style="padding-left: 10pt;">Solutions and Media</a><a target="content" href="#a33" style="padding-left: 10pt;">Thyroid Nodule Biopsy</a><a target="content" href="#a34" style="padding-left: 10pt;">Lymph Node</a><a target="content" href="#a35" style="padding-left: 10pt;">Biopsy Techniques</a><a target="content" href="#a36" style="padding-left: 20pt;">Preparation</a><a target="content" href="#a37" style="padding-left: 20pt;">US Guidance Techniques (Fig. 3.9)</a><a target="content" href="#a38" style="padding-left: 10pt;">FNA Specimens</a><a target="content" href="#a39" style="padding-left: 10pt;">Molecular Markers</a><a target="content" href="#a40" style="padding-left: 10pt;">Thyroid Cyst Aspiration and Sclerosis</a><a target="content" href="#a41" style="padding-left: 10pt;">Procedure</a><a target="content" href="#a42" style="padding-left: 10pt;">Lymph Node Aspiration</a><a target="content" href="#a43" style="padding-left: 10pt;">FNA vs Core Biopsy</a><a target="content" href="#a44" style="padding-left: 10pt;">Parathyroid Adenomas</a><a target="content" href="#a45" style="padding-left: 10pt;">Further Reading</a><a target="content" href="#a46" style="padding-left: 10pt;">Discussion</a><a target="content" href="#a47" style="padding-left: 20pt;">Nondiagnostic</a><a target="content" href="#a48" style="padding-left: 20pt;">Benign</a><a target="content" href="#a49" style="padding-left: 20pt;">Atypia of Undetermined Significance (AUS)/ Follicular Lesion of Undetermined Significance (FLUS)</a><a target="content" href="#a50" style="padding-left: 20pt;">Follicular Neoplasm (FN)/Suspicious for a Follicular Neoplasm (SFN) (Specify if Oncocytic/Hürthle Cell Type)</a><a target="content" href="#a51" style="padding-left: 20pt;">Suspicious for Malignancy (SFM)</a><a target="content" href="#a52" style="padding-left: 20pt;">Malignant</a><a target="content" href="#a53" style="padding-left: 10pt;">Further Reading</a><a target="content" href="#a54" style="padding-left: 10pt;">Introduction</a><a target="content" href="#a55" style="padding-left: 10pt;">Immunohistochemical Staining</a><a target="content" href="#a56" style="padding-left: 10pt;">Genetic Translocations</a><a target="content" href="#a57" style="padding-left: 10pt;">MicroRNA (miRNA) Analysis</a><a target="content" href="#a58" style="padding-left: 10pt;">Identification of Benign Nodule Characteristics</a><a target="content" href="#a59" style="padding-left: 10pt;">Genetic Testing and NIFTP Lesions</a><a target="content" href="#a60" style="padding-left: 10pt;">Further Reading</a><a target="content" href="#a61" style="padding-left: 10pt;">Introduction</a><a target="content" href="#a62" style="padding-left: 30pt;">Case Presentation 1</a><a target="content" href="#a63" style="padding-left: 30pt;">Additional Imaging Examples of Hashimoto’s Thyroiditis</a><a target="content" href="#a64" style="padding-left: 30pt;">Case Presentation 2</a><a target="content" href="#a65" style="padding-left: 30pt;">Additional Imaging Examples of Graves’ Disease</a><a target="content" href="#a66" style="padding-left: 30pt;">Case Presentation 3</a><a target="content" href="#a67" style="padding-left: 30pt;">Additional  Imaging  Examples  of  Non-Autoimmune, Destructive Thyroiditis:</a><a target="content" href="#a68" style="padding-left: 10pt;">Discussion</a><a target="content" href="#a69" style="padding-left: 10pt;">Further Reading</a><a target="content" href="#a70" style="padding-left: 30pt;">Case Presentation</a><a target="content" href="#a71" style="padding-left: 30pt;">Thyroid Nodule Composition: Additional Examples</a><a target="content" href="#a72" style="padding-left: 10pt;">Discussion</a><a target="content" href="#a73" style="padding-left: 10pt;">Further Reading</a><a target="content" href="#a74" style="padding-left: 10pt;">Introduction</a><a target="content" href="#a75" style="padding-left: 30pt;">Case Presentation</a><a target="content" href="#a76" style="padding-left: 30pt;">Additional examples of different thyroid echogenicity pat terns from a variety of conditions are presented in</a><a target="content" href="#a77" style="padding-left: 10pt;">Discussion</a><a target="content" href="#a78" style="padding-left: 10pt;">Further Reading</a><a target="content" href="#a79" style="padding-left: 10pt;">Introduction</a><a target="content" href="#a80" style="padding-left: 30pt;">Case Presentation</a><a target="content" href="#a81" style="padding-left: 30pt;">Thyroid Nodule Margins and Shape: Additional Examples</a><a target="content" href="#a82" style="padding-left: 10pt;">Discussion</a><a target="content" href="#a83" style="padding-left: 10pt;">Further Reading</a><a target="content" href="#a84" style="padding-left: 10pt;">Introduction</a><a target="content" href="#a85" style="padding-left: 30pt;">Case Presentation 1</a><a target="content" href="#a86" style="padding-left: 30pt;">b</a><a target="content" href="#a87" style="padding-left: 10pt;">Discussion</a><a target="content" href="#a88" style="padding-left: 30pt;">Case Presentation 1</a><a target="content" href="#a89" style="padding-left: 30pt;">Case Presentation 2</a><a target="content" href="#a90" style="padding-left: 30pt;">Case Presentation 3</a><a target="content" href="#a91" style="padding-left: 10pt;">Discussion</a><a target="content" href="#a92" style="padding-left: 10pt;">Introduction</a><a target="content" href="#a93" style="padding-left: 10pt;">Parathyroid Embryology and Anatomy</a><a target="content" href="#a94" style="padding-left: 20pt;">Parathyroid Adenomas: Additional Examples</a><a target="content" href="#a95" style="padding-left: 20pt;">Associated Thyroid Diseases Complicating Parathyroid Adenoma Localization (Images 12.14, and 12.15)</a><a target="content" href="#a96" style="padding-left: 20pt;">4DCT</a><a target="content" href="#a97" style="padding-left: 10pt;">Further Reading</a><a target="content" href="#a98" style="padding-left: 10pt;">Introduction</a><a target="content" href="#a99" style="padding-left: 30pt;">Malignant</a><a target="content" href="#a100" style="padding-left: 30pt;">Case Presentation</a><a target="content" href="#a101" style="padding-left: 10pt;">Further Reading</a><a target="content" href="#a102" style="padding-left: 30pt;">Case Presentation 1</a><a target="content" href="#a103" style="padding-left: 30pt;">Case Presentation 6</a><a target="content" href="#a104" style="padding-left: 30pt;">Case Presentation 7</a><a target="content" href="#a105" style="padding-left: 10pt;">Discussion</a></div>
  
  
    <!-- Вставьте произвольный фрагмент HTML-кода здесь -->
  </div>
  <div id="content">
    <div id="content-inner">
	
<p style="text-indent: 0pt;text-align: left;"><span><img width="791" height="1117" src="Image_001.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_002.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_003.png"/></span></p><p class="s1" style="padding-top: 8pt;padding-left: 5pt;text-indent: 0pt;line-height: 93%;text-align: left;">Handbook of Thyroid and Neck Ultrasonography</p><p class="s2" style="padding-top: 39pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">An Illustrated Case  Compendium with Clinical  and Pathologic Correlation</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><span><img width="51" height="56" src="Image_004.png"/></span>	<span><img width="169" height="43" src="Image_005.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s4" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;line-height: 15pt;text-align: left;">Hospital</p><p class="s4" style="padding-left: 10pt;text-indent: 0pt;line-height: 15pt;text-align: left;">Boston, MA, USA</p><p class="s4" style="padding-top: 8pt;padding-left: 10pt;text-indent: 0pt;line-height: 15pt;text-align: left;">Jeffrey R. Garber</p><p class="s4" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Department of Endocrinology Harvard Vanguard Medical Associates/Atrius Health and Harvard Medical School Boston, MA, USA</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s4" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Boston, MA, USA</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s4" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;line-height: 15pt;text-align: left;">ISSN 2523-3785            ISSN 2523-3793</p><p class="s4" style="padding-left: 10pt;text-indent: 0pt;line-height: 15pt;text-align: left;">Contemporary Endocrinology</p><p class="s4" style="padding-left: 10pt;text-indent: 0pt;line-height: 15pt;text-align: left;">ISBN 978-3-031-18447-5      ISBN 978-3-031-18448-2</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 15pt;text-align: left;"><a href="https://doi.org/10.1007/978-3-031-18448-2" class="s5">https://doi.org/10.1007/978-3-031-18448-2</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s6" style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023</p><p class="s6" style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.</p><p class="s6" style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.</p><p class="s6" style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s6" style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">This Springer imprint is published by the registered company Springer Nature Switzerland AG</p><p class="s6" style="padding-left: 10pt;text-indent: 0pt;line-height: 13pt;text-align: left;">The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s7" style="padding-top: 12pt;padding-left: 193pt;text-indent: 0pt;text-align: left;">Solly, Sarah, Bram, and Pierce for their support</p><p class="s7" style="padding-left: 280pt;text-indent: 0pt;line-height: 20pt;text-align: left;">—Jeffrey R. Garber</p><p class="s7" style="padding-top: 9pt;padding-left: 193pt;text-indent: 0pt;text-align: left;">To my dad Dr. Orlando Vitale, who embraced and supported my interests in medicine, and to my loving husband Roberto Laver, Esq, a staunch supporter of my career</p><p class="s7" style="padding-left: 281pt;text-indent: 0pt;line-height: 20pt;text-align: left;">—Nora M. V. Laver</p><p class="s7" style="padding-top: 9pt;padding-left: 193pt;text-indent: 0pt;text-align: left;">To our patients</p><p class="s7" style="padding-left: 246pt;text-indent: 0pt;text-align: left;">—Gregory W. Randolph</p><p class="s7" style="padding-top: 9pt;padding-left: 193pt;text-indent: 0pt;text-align: left;">To my wife, Yvonne, who patiently tolerated the hours in front of my computer</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_006.png"/></span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Neck ultrasonography plays a key role in the evaluation of thyroid nodules and parathyroid disease. This handbook arose from regu lar multidisciplinary clinical-pathological medical education con ferences centering on patients with thyroid and parathyroid disease that the editors participated in over a number of years. Our goal was to make it a clinically anchored, case-based, easy to use, concise volume that covers key points that endocrinologists, radi ologists, surgeons, and pathologists feel are most important to know about neck ultrasonography.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Chapters cover major types of thyroid nodule ultrasound fea tures: composition, echogenicity, shape, margins, rim calcifica tions, echogenic foci, and vascularity; parathyroid, lymph node, and non-thyroid neck masses. Characteristic ultrasound images, cytology and histopathology images along with representative cases and key clinical data are presented. Differential diagnoses are reviewed, and suggested references are provided.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Our intended audience is the clinician wishing to become pro ficient in the evaluation of patients with thyroid and parathyroid disease, who may also be interested in performing thyroid and neck ultrasound exams. We welcome our readers’ feedback and suggestions for improving and updating our first edition.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Boston, MA, USA Boston, MA, USA Boston, MA, USA Boston, MA, USA Boston, MA, USA</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_007.png"/></span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Point of care (or, using the regular English, bedside) ultrasound is rapidly becoming a widely used tool in many medical and surgical specialties. Endocrinologists have been using ultrasonography for assessing thyroid anatomy for several decades, since its introduc tion in the 1960s. More recently, training in thyroid and neck ultrasound, including its use in the course of fine needle aspiration (FNA) biopsy of thyroid nodules, has become a universal feature in endocrine fellowship training programs. Although ultrasonog raphy used by endocrinologists is primarily directed toward the assessment of thyroid anatomy, other structures in the neck, such as parathyroid glands, lymph nodes, large vessels, and inciden tally discovered lesions, can be also observed and assessed.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">All of these issues, as well as many other aspects of thyroid and neck ultrasonography, are covered comprehensively yet con cisely in the current volume of the <i>Contemporary Endocrinology </i>series. A multidisciplinary writing crew is comprised of endocri nologists, surgeons, pathologists, and radiologists with extraordi nary depth of expertise (full disclosure: one of the editors, Dr. Jeffrey Garber, was my mentor when I was an endocrine fellow almost 40 years ago).</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">This guide for students and practitioners in all relevant special ties is highly recommended and, in my opinion, is destined to become a classic.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">New York, NY, USA</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_008.png"/></span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">As editor-in-chief, I would like to express my sincere gratitude to my colleagues for all of their contributions and insights toward this project: Dr. Jeffrey R. Garber, for first proposing the concept of a clinical, case-based handbook for ultrasound education and providing much support throughout all stages of this project; Dr. Barry Sacks, for providing invaluable contributions not only to chapters he authored, but also supplying images and feedback related to all of the images in the Handbook, and for keeping me on my toes; Dr. Nora M. V. Laver, for providing her expertise for all of the pathology images in the Handbook, and for her moral support; and finally, Dr. Gregory W. Randolph, for collaborating with our surgical and radiology colleagues as well as providing razor-sharp feedback to improve our design and final product. It was a pleasure working with each of you.</p><p style="padding-left: 25pt;text-indent: 0pt;text-align: justify;">Leslie S. Eldeiry</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_009.png"/></span></p><ol id="l1"><li data-list-text="1"><p class="s9" style="padding-top: 5pt;padding-left: 38pt;text-indent: -24pt;text-align: left;"><a name="a0">The Basics of Thyroid and Neck Ultrasound</a></p><p style="padding-left: 38pt;text-indent: 0pt;text-align: left;">Nora S. Call, Alison M. Savicke, and Barry Sacks</p></li><li data-list-text="2"><p class="s9" style="padding-top: 9pt;padding-left: 38pt;text-indent: -24pt;text-align: left;">Ultrasound Scoring Systems, Clinical Risk Calculators, and Emerging Tools <span class="p">Priyanka Majety and Jeffrey R. Garber</span></p></li><li data-list-text="3"><p class="s9" style="padding-top: 8pt;padding-left: 38pt;text-indent: -24pt;text-align: left;">Thyroid Fine Needle Aspiration and Biopsy Techniques for Lesions in the Neck <span class="s10">. . . . . . . . . . . . . . . </span><span class="p">Barry Sacks</span></p></li><li data-list-text="4"><p class="s9" style="padding-top: 8pt;padding-left: 38pt;text-indent: -24pt;text-align: left;"><a name="a1">Overview of the Bethesda System for</a></p><p class="s9" style="padding-left: 38pt;text-indent: 0pt;text-align: left;">Reporting Thyroid Cytopathology <span class="s10">. . . . . . . . . . . . . . . </span><span class="p">Teresa H. Kim and Jeffrey F. Krane</span></p></li><li data-list-text="5"><p class="s9" style="padding-top: 8pt;padding-left: 38pt;text-indent: -24pt;text-align: left;"><a name="a2">Fine Needle Aspiration: Role of Molecular</a></p><p class="s9" style="padding-left: 38pt;text-indent: 0pt;text-align: left;">Testing <span class="s10">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</span></p><p style="padding-left: 38pt;text-indent: 0pt;text-align: left;">James V. Hennessey</p></li><li data-list-text="6"><p class="s9" style="padding-top: 9pt;padding-left: 38pt;text-indent: -24pt;text-align: left;"><a name="a3">Thyroid Gland Ultrasonography: Hashimoto’s, Graves’, Thyroiditis,</a></p><p class="s9" style="padding-left: 38pt;text-indent: 0pt;text-align: left;">Toxic Multinodular Goiter <span class="s10">. . . . . . . . . . . . . . . . . . . . . . </span><span class="p">Preethika S. Ekanayake, Omonigho Aisagbonhi,</span></p><p style="padding-left: 38pt;text-indent: 0pt;text-align: left;">and Karen C. McCowen</p></li><li data-list-text="7"><p class="s9" style="padding-top: 9pt;padding-left: 38pt;text-indent: -24pt;text-align: left;">Thyroid Nodule Composition<span class="s10">. . . . . . . . . . . . . . . . . . . . </span><span class="p">Leslie S. Eldeiry</span></p></li><li data-list-text="8"><p class="s9" style="padding-top: 8pt;padding-left: 38pt;text-indent: -24pt;text-align: left;">Echogenicity of the Thyroid <span class="s10">. . . . . . . . . . . . . . . . . . . . . </span><span class="p">Pamela L. Mok</span></p></li></ol><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_010.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l2"><li data-list-text="12"><p class="s9" style="padding-top: 11pt;padding-left: 43pt;text-indent: -33pt;text-align: left;">Parathyroid Imaging<span class="s10">. . . . . . . . . . . . . . . . . . . . . . . . . . . </span><span class="p">Barry Sacks</span></p></li><li data-list-text="13"><p class="s9" style="padding-top: 8pt;padding-left: 43pt;text-indent: -33pt;text-align: left;">Cervical Lymph Nodes <span class="s10">. . . . . . . . . . . . . . . . . . . . . . . . . </span><span class="p">Hien Tierney</span></p></li><li data-list-text="14"><p class="s9" style="padding-top: 8pt;padding-left: 43pt;text-indent: -33pt;text-align: left;"><a name="a4">Anatomy and Selected Non-thyroid</a></p></li></ol><p class="s9" style="padding-left: 43pt;text-indent: 0pt;text-align: left;">Neck Findings <span class="s10">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</span></p><p style="padding-left: 43pt;text-indent: 0pt;line-height: 110%;text-align: left;">Mary Beth Cunnane, Greg Randolph, and Amy Juliano</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Index<span class="p">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</span></h3><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_011.png"/></span></p><h3 style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Omonigho Aisagbonhi, MD, PhD <span class="p">Department of Pathology, University of California, San Diego, San Diego, CA, USA</span></h3><h3 style="padding-top: 8pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Chelsey Baldwin, MD <span class="p">Division of Endocrinology and Metabo lism, The George Washington University, Washington, DC, USA</span></h3><h3 style="padding-top: 8pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Nora S. Call, BS, RDMS, RT(R) <span class="p">Department of Ultrasound, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA</span></h3><h3 style="padding-top: 8pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Mary Beth Cunnane, MD <span class="p">Department of Radiology, Massa chusetts Eye and Ear Institute, Boston, MA, USA</span></h3><h3 style="padding-top: 8pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Preethika S. Ekanayake, MD <span class="p">Division of Endocrinology, Dia betes and Metabolism, University of California, San Diego, San Diego, CA, USA</span></h3><h3 style="padding-top: 8pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Leslie S. Eldeiry, MD <span class="p">Department of Endocrinology, Harvard Vanguard Medical Associates/Atrius Health and Harvard Medical School, Boston, MA, USA</span></h3><h3 style="padding-top: 8pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Jeffrey R. Garber, MD <span class="p">Department of Endocrinology, Atrius Health/Harvard Vanguard Medical Associates and Harvard Medi cal School, Boston, MA, USA</span></h3><h3 style="padding-top: 8pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Chia A. Haddad, MD <span class="p">Harvard Vanguard Medical Associates, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA</span></h3><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_012.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 11pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Angeles, CA, USA</p><h3 style="padding-top: 9pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Matthew J. Levine, MD <span class="p">Division of Diabetes and Endocrinol ogy, Scripps Clinic, La Jolla, CA, USA</span></h3><h3 style="padding-top: 8pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Priyanka Majety, MD <span class="p">Beth Israel Deaconess Medical Center, Boston, MA, USA</span></h3><h3 style="padding-top: 8pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Karen C. McCowen, MD <span class="p">Division of Endocrinology, Diabetes and Metabolism, University of California, San Diego, San Diego, CA, USA</span></h3><h3 style="padding-top: 8pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Pamela L. Mok, MD <span class="p">Department of Radiology, Atrius Health, Boston, MA, USA</span></h3><h3 style="padding-top: 8pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Michael D. Otremba, MD <span class="p">Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA</span></h3><h3 style="padding-top: 8pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Rachel Pessah-Pollack, MD <span class="p">Division of Endocrinology, Diabe tes and Metabolism, NYU School of Medicine, New York, NY, USA</span></h3><h3 style="padding-top: 8pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Greg Randolph, MD <span class="p">Department of Otorhinolaryngology, Head and Neck Surgery, Massachusetts Eye and Ear Institute, Boston, MA, USA</span></h3><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_013.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">cal School, Boston, MA, USA</p><h3 style="padding-top: 9pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Hien Tierney, MD <span class="p">Atrius Health/Harvard Medical School, Bos ton, MA, USA</span></h3><p style="padding-left: 385pt;text-indent: 0pt;text-align: left;"><span><a href="http://crossmark.crossref.org/dialog/?doi=10.1007/978-3-031-18448-2_1&amp;domain=pdf"><img width="69" height="61" src="Image_014.png"/></a></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s11" style="padding-left: 19pt;text-indent: 0pt;text-align: left;">Key Points</p><ul id="l3"><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Ultrasound is entirely operator-dependent. As a result, it is critical for the operator to be thorough, identify, and document both normal structures and abnormalities while obtaining high quality images.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Knowledge about the clinical presentation, past exams, and labs will result in a more insightful imaging study.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: left;">Thyroid nodules should be carefully evaluated for suspi cious features. This is particularly important for each nodule in a multinodular goiter.</p></li></ul><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="226" height="1" src="Image_015.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_016.png"/></span></p><p class="s12" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">N. S. Call · A. M. Savicke</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Department of Ultrasound, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA</p><p class="s58" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;"><a href="mailto:nasulliv@bidmc.harvard.edu" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">e-mail: </a>nasulliv@bidmc.harvard.edu<a href="mailto:asavicke@bidmc.harvard.edu" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">; </a><a href="mailto:asavicke@bidmc.harvard.edu" target="_blank">asavicke@bidmc.harvard.edu</a></p><p class="s12" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">B. Sacks (<span class="s13">*</span>)</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Department of Radiology, Beth Israel Deaconess Medical Center,</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Boston, MA, USA</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><a href="mailto:bsacks@bidmc.harvard.edu" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">e-mail: </a><a href="mailto:bsacks@bidmc.harvard.edu" target="_blank">bsacks@bidmc.harvard.edu</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">© The Author(s), under exclusive license to Springer Nature Switzerland AG 2023</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">L. S. Eldeiry et al. (eds.), <i>Handbook of Thyroid and Neck Ultrasonography</i><a href="https://doi.org/10.1007/978-3-031-18448-2_1" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">, Contemporary Endocrinology, </a><a href="https://doi.org/10.1007/978-3-031-18448-2_1" target="_blank">https://doi.org/10.1007/978-3-031-18448-2_1</a></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_017.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><span><img width="575" height="130" src="Image_018.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="575" height="2" src="Image_019.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 13pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">ing structures in the neck, including the thyroid, lymph nodes, salivary glands, arteries/veins, and musculature, due to their superficiality and the ability to obtain image clarity. Ultrasound is entirely operator-dependent. As a result, it is critical for the opera tor to optimize images, understand the patient’s clinical presenta tion, and know what additional information should be sought based on the findings.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: justify;">Ultrasound is a medical imaging modality utilizing sound waves at a frequency of over 20 KHz (beyond/higher than the audible range), to create high resolution images of anatomical structures.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l4"><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">US is cost-effective, noninvasive, with no known detrimental bioeffects.</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">With the proper equipment, transducers, and settings, the diag nostic capabilities are invaluable.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_020.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a5">Basic Ultrasound Physics</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Almost all clinical ultrasound is performed using a B-mode (bright ness) scanner, producing real time, two-dimensional images.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Each transducer contains numerous piezoelectric crystals, which emit brief sequential pulses of energy into the underly ing tissue.</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">A liquid medium, or gel, is necessary to attain contact between the transducer and skin.</p></li></ul><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_021.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="575" height="2" src="Image_022.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Usually the word “artifact” has a negative connotation. However, many ultrasound artifacts can actually be helpful.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l5"><li data-list-text="•"><p class="s8" style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">Posterior Acoustic Enhancement: <span class="p">In fluid-filled structures (anechoic) the speed of the pulse accelerates causing the deeper structures to increase in echogenicity (posterior enhancement).</span></p></li><li data-list-text="•"><p class="s8" style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">Acoustic Shadowing: <span class="p">A calcification, bone, or surgical clip will entirely reflect the sound beam, and the result is a “shadow,” deep to the structure. Air also disperses the beam, which nearly completely obscures the image.</span></p></li><li data-list-text="•"><p class="s8" style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Reverberation Artifact: <span class="p">Occurs when the sound beam encoun ters a highly reflective surface and reflects multiple times. This can occur when structures are very close to the transducer, as an example, the trachea during a thyroid study.</span></p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">Reverberation is also seen in the setting of a colloid crystal/ inspissated colloid within a cyst. The punctate echogenic foci within produce a “ring-down” or “comet-tail” artifact.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_023.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a6">Equipment</a></h1></li><li data-list-text="•"><p style="padding-top: 17pt;padding-left: 25pt;text-indent: -19pt;text-align: justify;">There  are  several  high  quality,  sophisticated ultrasound machines, providing a large selection of transducer options and image optimization functions (Image <span style=" color: #00F;">1.1</span></p><p style="padding-left: 45pt;text-indent: -19pt;line-height: 110%;text-align: justify;">–  Produced by a number of companies including General Electric, Philips, Samsung, and Siemens.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;line-height: 16pt;text-align: justify;">They are expensive, require regular servicing, and each has</p><p style="padding-left: 25pt;text-indent: 0pt;text-align: justify;">strengths and weaknesses, depending on the specific ultra sound study being performed (small parts, abdomen, obstet</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_024.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s16" style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="287" height="481" alt="Two photographs of sophisticated ultrasound machines with display monitors, several transducers, and image optimization functions." title="Two photographs of sophisticated ultrasound machines with display monitors, several transducers, and image optimization functions." src="Image_025.jpg"/></span> <span><img width="278" height="483" alt="Two photographs of sophisticated ultrasound machines with display monitors, several transducers, and image optimization functions." title="Two photographs of sophisticated ultrasound machines with display monitors, several transducers, and image optimization functions." src="Image_026.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 1.1 <span class="s12">Two examples of top-of-the-line ultrasound units</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 10pt;padding-left: 30pt;text-indent: 0pt;text-align: justify;">rics,  etc.).  Selection  of  equipment  should  be  based  on optimizing the quality of images for the majority of exams being performed at the operator’s site.</p><ul id="l6"><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: justify;">For offices or departments with limited budgets, refurbished or leasing machines are viable options.</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;line-height: 110%;text-align: justify;">Point-of-care handheld ultrasound system technology is rap idly evolving (Image <span style=" color: #00F;">1.2</span>).</p><ul id="l7"><li data-list-text="–"><p style="padding-left: 49pt;text-indent: -19pt;line-height: 16pt;text-align: justify;">Advantages: Images display on a smartphone or tablet, pro</p><p style="padding-left: 49pt;text-indent: 0pt;text-align: justify;">viding convenience, transportability, and lower cost.</p></li><li data-list-text="–"><p style="padding-left: 49pt;text-indent: -19pt;text-align: justify;">Disadvantages: Small display size, reduced image quality, limited transducer versatility and hardware options.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_027.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s16" style="padding-left: 15pt;text-indent: 0pt;text-align: left;"><span><img width="194" height="114" alt="3 photos. 1. A photograph of a handheld ultrasound system and an i Phone that displays a sonogram. 2 and 3. Two sonograms of the thyroid." title="3 photos. 1. A photograph of a handheld ultrasound system and an i Phone that displays a sonogram. 2 and 3. Two sonograms of the thyroid." src="Image_028.jpg"/></span> <span><img width="345" height="114" alt="3 photos. 1. A photograph of a handheld ultrasound system and an i Phone that displays a sonogram. 2 and 3. Two sonograms of the thyroid." title="3 photos. 1. A photograph of a handheld ultrasound system and an i Phone that displays a sonogram. 2 and 3. Two sonograms of the thyroid." src="Image_029.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_030.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a7">Transducer Selection</a></h1><p style="padding-top: 17pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Transducers used in ultrasound differ in frequency, footprint size, and shape.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li></ul></li></ul></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Transducer frequency is directly related to image quality, as it determines image resolution. The higher the frequency, the better the resolution, but at the expense of limited deep pene tration.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: left;">For imaging of the neck, high-frequency transducers are opti mal, preferably a 12-18 MHz linear array, providing both opti mal image quality and adequate penetration. Linear transducers provide a rectangular image, but some have the ability to widen the field of view to a trapezoidal shape, which is helpful in cases of thyromegaly.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">In cases with suboptimal penetration, such as a thick neck or large multinodular goiter, a linear 7–9 MHz transducer can provide acceptable image quality. The lower frequency allows for greater penetration to visualize the deeper tissue.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">Alternatively, a lower frequency 5 MHz curved transducer will provide a larger field by emitting a fan-shaped beam, but at the expense of reduction in resolution.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;line-height: 110%;text-align: justify;">It is important to have a variety of transducers available to fully assess each individual’s anatomy (Images</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;line-height: 110%;text-align: justify;">Bottom row: Curved transducers for deeper penetration and larger field of view.</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_031.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s16" style="padding-left: 20pt;text-indent: 0pt;text-align: left;"><span><img width="272" height="121" alt="Four photographs of the variety of transducers for superficial structures." title="Four photographs of the variety of transducers for superficial structures." src="Image_032.jpg"/></span> <span><img width="267" height="121" alt="Four photographs of the variety of transducers for superficial structures." title="Four photographs of the variety of transducers for superficial structures." src="Image_033.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s16" style="padding-left: 20pt;text-indent: 0pt;text-align: left;"><span><img width="318" height="121" alt="Four photographs of the variety of transducers for superficial structures." title="Four photographs of the variety of transducers for superficial structures." src="Image_034.jpg"/></span> <span><img width="225" height="121" alt="Four photographs of the variety of transducers for superficial structures." title="Four photographs of the variety of transducers for superficial structures." src="Image_035.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 1.3 <span class="s12">Top row: Linear array transducers for superficial structures</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s16" style="padding-left: 17pt;text-indent: 0pt;text-align: left;"><span><img width="256" height="178" alt="Two sonograms of an enlarged thyroid gland. Left. The double-headed arrow passes from the left top to the right bottom corner. Right. The sonogram has bright areas in the center-left." title="Two sonograms of an enlarged thyroid gland. Left. The double-headed arrow passes from the left top to the right bottom corner. Right. The sonogram has bright areas in the center-left." src="Image_036.gif"/></span> <span><img width="292" height="178" alt="Two sonograms of an enlarged thyroid gland. Left. The double-headed arrow passes from the left top to the right bottom corner. Right. The sonogram has bright areas in the center-left." title="Two sonograms of an enlarged thyroid gland. Left. The double-headed arrow passes from the left top to the right bottom corner. Right. The sonogram has bright areas in the center-left." src="Image_037.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Image 1.4  <span class="s12">Enlarged thyroid gland. Left: Linear array transducer utilizing a wide angle beam to increase the field of view; Right: Curved C-5 probe which has a naturally divergent beam was used to produce a wider, complete image</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_038.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="333" alt="2 sonograms of a gland that extends to the thoracic inlet. Two C T images illustrate the axial and sagittal views of right-sided goiter. The axial C T image displays a dark curved area representing goiter." title="2 sonograms of a gland that extends to the thoracic inlet. Two C T images illustrate the axial and sagittal views of right-sided goiter. The axial C T image displays a dark curved area representing goiter." src="Image_039.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 1.5  <span class="s12">Top row: Transverse (left) and sagittal (right) ultrasound images of a large gland extending into the thoracic inlet, requiring a C-5 curved trans ducer to measure the entire sagittal length of the lobe; Bottom row: CT show ing axial and sagittal images of the same large, right-sided goiter</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_040.png"/></span></p><h1 style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;line-height: 82%;text-align: left;"><a name="a8">Patient Positioning and Scanning Techniques (Image </a><span class="s18">1.6</span>)</h1></li><li data-list-text="•"><p style="padding-top: 18pt;padding-left: 25pt;text-indent: -19pt;text-align: left;">The patient is placed in a supine position with a towel or pillow behind the shoulders to extend the neck, creating a large imag ing window.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: left;">As indicated in the diagram below, transverse scans are ini tially obtained from superior to inferior bilaterally with the transducer notch facing the patient’s right side, first with the head in neutral position, and repeated rotating the head to left for the right lobe and to the right for the left lobe.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Sagittal scans are obtained bilaterally, medial to lateral, with the transducer notch pointed superiorly.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Color Doppler images should be documented to determine vascularity of the gland.</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_041.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 12pt;text-indent: 0pt;text-align: left;"><span><img width="567" height="125" src="Image_042.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="•"><p style="padding-top: 4pt;padding-left: 30pt;text-indent: -19pt;text-align: left;">All pathologic lesions should be documented in transverse and sagittal planes and color Doppler included.</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;line-height: 110%;text-align: left;">If available, cine loops should be obtained. These are extremely valuable, allowing review of the entire study during reporting.</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 19pt;text-align: justify;">Two additional techniques can be helpful in adding specificity to the ultrasound assessment of thyroid nodules. These include <i>elastography and ultrasound contrast enhancement</i></p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Tissue or nodule firmness has always been considered a bio marker of tissue pathology. Thyroid elastography is a method that evaluates the stiffness of the tissue, a capability available on most new US machines. Since all firm thyroid nodules on palpation are suspicious for malignancy, the ability to assess whether a nodule is firm on US adds diagnostic value in determining that malig nancy potential. Having this capability provides an additional technique to evaluate thyroid nodules, particularly those deep within the thyroid substance, not easily palpable. During the stan dard US exam, after documenting the normal ultrasound and color Doppler images, the elastography is activated and provides color images of the nodule. Depending on the color profile, the degree of softness or firmness of the nodule can be determined. This technology has also been referred to as “electronic palpation.” There are two types, strain elastography (SE) and shear wave elas tography (SWE), essentially two different mechanisms to evalu</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_043.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">SonoVue consists of sulfur hexafluoride microbubbles (2–10 which is injected intravenously as a small bolus. The microbub bles stay in circulation for a limited period. Immediately follow ing the injection continuous real time scanning is performed over the lesion of interest. The microbubbles in the blood flow reach the lesion, reflecting unique prominent echoes very different to the surrounding tissue. There is a pattern of increased echo genicity into a contrast-enhanced image of the region of interest (ROI) that represents the bubbles in the microvasculature. The microbubbles last only 5–10 min in circulation because they are taken up either by immune system cells, liver, or spleen. Previous studies have shown enhancement patterns that were different in benign and malignant lesions. Ring enhancement was predictive of benign lesions, whereas heterogeneous enhancement was help ful in suggesting the possibility of malignant lesions.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: justify;">Although both of these technical advancements have provided additional ways of improving nodule assessment, they have thus far not caught on for routine use in the day-to-day evaluation of thyroid or neck lesions.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_044.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a9">Potential Scanning Pitfalls</a></h1><ul id="l8"><li data-list-text="•"><p style="padding-top: 17pt;padding-left: 25pt;text-indent: -19pt;text-align: left;">Air and bone attenuate the ultrasound waves; as a result, a vari ety of maneuvers may be necessary to obtain adequate diag nostic images. These include angling the transducer from an unusual direction or opposite side, rotating the patient’s head</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_045.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s8" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">for those exams, to provide the referring clinician all the necessary information to make therapeutic decisions or determine the need for additional studies. For in-depth discussions of the specific find ings, please refer to the chapters dedicated to each subject.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-top: 13pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a10">Thyroid Anatomy (Image </a><span class="s19">1.7</span>)</h2><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">A normal thyroid gland has a homogenous texture and is typically more echogenic than surrounding musculature. It is important to recognize that images from various manufacturers will have slight</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="295" src="Image_046.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 1.7 <span class="s12">Important anatomic structures (see diagram below)</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_047.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 25pt;text-indent: 0pt;text-align: left;">The recurrent laryngeal nerves are extremely important struc tures, not identifiable on ultrasound, but their approximate location is labeled with the blue circles.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: left;">The carotid arteries and internal jugular veins are lateral to the thyroid bilaterally.</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-top: 12pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a11">Normal Thyroid Texture (Image </a><span class="s19">1.8</span>)</h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="261" alt="Four sonograms of the normal thyroid texture at different contrast levels and settings. In sonograms 1 and 3, a dome structure is visible." title="Four sonograms of the normal thyroid texture at different contrast levels and settings. In sonograms 1 and 3, a dome structure is visible." src="Image_048.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 1.8  <span class="s12">Different presentations of a normal thyroid appearance—slightly different settings, contrast levels, and image presentation. Left images are transverse; right images are sagittal views. Note the difference in contrast between the thyroid gland and muscles above it between the top and bottom images</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_049.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="125" src="Image_050.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">mus (arrows), common in Hashimoto’s</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="568" height="103" alt="Three sonograms of the later stages of Hashimoto&#39;s patchy heterogeneity of the gland. Sonogram 2 displays a dome-shaped gland in the center. Sonogram 3 has a circular dark area on the top left." title="Three sonograms of the later stages of Hashimoto&#39;s patchy heterogeneity of the gland. Sonogram 2 displays a dome-shaped gland in the center. Sonogram 3 has a circular dark area on the top left." src="Image_051.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Image 1.10  <span class="s12">Later stages of Hashimoto’s. Patchy heterogeneity of the gland. Middle panel: More severe and diffusely enlarged gland; Right panel: A fibrotic, atrophic gland, often representing the end stage</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="109" alt="A sonogram of the textural changes in the thyroid parenchyma. On the right, a color doppler image of the same region displays scattered bright areas." title="A sonogram of the textural changes in the thyroid parenchyma. On the right, a color doppler image of the same region displays scattered bright areas." src="Image_052.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 1.11  <span class="s12">Color Doppler is useful in evaluating the thyroid parenchyma. Increased vascularity is usually indicative of a diffuse process, such as Hashi moto’s thyroiditis or Graves’ disease, or drug effect, particularly lithium therapy</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_053.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s16" style="padding-left: 7pt;text-indent: 0pt;text-align: left;"><span><img width="288" height="238" src="Image_054.png"/></span> <span><img width="274" height="237" alt="1. Two sonograms of the transverse and sagittal over the trachea. An arrow indicates the pyramidal lobe. 2. A C T scan with the 3-D reconstruction of parathyroid adenoma denoted by two arrows." title="1. Two sonograms of the transverse and sagittal over the trachea. An arrow indicates the pyramidal lobe. 2. A C T scan with the 3-D reconstruction of parathyroid adenoma denoted by two arrows." src="Image_055.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 1.12  <span class="s12">Left: US showing a transverse (top) and sagittal (bottom) view of a left pyramidal lobe. Right: 3D reconstruction of CT in a patient with a parathyroid adenoma (red arrow). The patient has an incidental left pyramidal lobe (white arrow)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s16" style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="182" height="117" src="Image_056.png"/></span> <span><img width="143" height="117" src="Image_057.png"/></span> <span><img width="235" height="117" src="Image_058.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 1.13  <span class="s12">Classic thyroglossal duct cysts. Left and middle panels: Trans verse and sagittal views of the lesion located at the midline superior to the thyroid; it is anechoic and avascular (arrows); Right: Color Doppler of a separate thyroglossal duct cyst with a septation (arrow)</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_059.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a12">Thyroid Nodules</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Thyroid nodules vary in composition, from simple cysts, to spon giform, complex solid/cystic, and solid lesions.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-top: 13pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a13">Simple Cysts (Image </a><span class="s19">1.14</span>)</h2><ul id="l9"><li data-list-text="•"><p style="padding-top: 17pt;padding-left: 30pt;text-indent: -19pt;text-align: left;">Thin-walled, fluid filled, avascular, and completely anechoic.</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Low level internal echoes may be due to debris or old hemor rhage.</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s16" style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="286" height="269" src="Image_060.png"/></span> <span><img width="281" height="269" src="Image_061.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 1.14  <span class="s12">Simple thyroid cyst with a dependent colloid crystal/inspis sated colloid (left panel transverse, right panel sagittal). Also note acoustic enhancement posterior to the cyst (arrows)</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_062.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 25pt;text-indent: 0pt;text-align: left;">the appearance of the cross section of a sponge (but the spaces are fluid filled).</p><ul id="l10"><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Highly reflective echoes are commonly found within the cysts, often in the dependent portions.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;line-height: 110%;text-align: left;">Demonstration of a comet-tail artifact projecting behind the echo differentiates colloid from microcalcification.</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s16" style="padding-left: 12pt;text-indent: 0pt;text-align: left;"><span><img width="178" height="148" alt="A set of three sonograms of the spongiform nodules. 1. uniformly microcystic with a marked arrow. 2. Macro-cysts with two marked arrows. 3. Three arrows indicate a comet tail." title="A set of three sonograms of the spongiform nodules. 1. uniformly microcystic with a marked arrow. 2. Macro-cysts with two marked arrows. 3. Three arrows indicate a comet tail." src="Image_063.gif"/></span> <span><img width="163" height="148" alt="A set of three sonograms of the spongiform nodules. 1. uniformly microcystic with a marked arrow. 2. Macro-cysts with two marked arrows. 3. Three arrows indicate a comet tail." title="A set of three sonograms of the spongiform nodules. 1. uniformly microcystic with a marked arrow. 2. Macro-cysts with two marked arrows. 3. Three arrows indicate a comet tail." src="Image_064.gif"/></span> <span><img width="205" height="147" alt="A set of three sonograms of the spongiform nodules. 1. uniformly microcystic with a marked arrow. 2. Macro-cysts with two marked arrows. 3. Three arrows indicate a comet tail." title="A set of three sonograms of the spongiform nodules. 1. uniformly microcystic with a marked arrow. 2. Macro-cysts with two marked arrows. 3. Three arrows indicate a comet tail." src="Image_065.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 1.15  <span class="s12">Spongiform nodules with microcysts (left); middle panel dem onstrates macro-cysts; right panel shows dependent colloid crystals with a “comet tail” (arrows)</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_066.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 19pt;text-align: left;">Any concerning features warrant a lymph node evaluation and biopsy.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s16" style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="163" height="117" alt="Three sonograms of solid nodules. The size of the solid nodule in the second image is the largest and is marked with an arrow." title="Three sonograms of solid nodules. The size of the solid nodule in the second image is the largest and is marked with an arrow." src="Image_067.jpg"/></span> <span><img width="403" height="118" src="Image_068.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Image 1.16  <span class="s12">Examples  of  predominantly  solid  nodules.  Left  panel: Isoechoic,  benign  nodule  with  small  cystic  component;  Middle  panel: Hypoechoic  nodule  for  which  FNA  is  warranted;  Right  panel:  Small, hypoechoic nodule, taller than wide with calcification—FNA is warranted to rule out papillary thyroid cancer (PTC)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s16" style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><span><img width="236" height="148" src="Image_069.png"/></span> <span><img width="333" height="146" src="Image_070.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;"><span class="s17">Image 1.17 </span>Vascularity. Left<i>: </i>Isoechoic nodule with minimal vascularity, mostly peripheral; Right<i>: </i>Hypoechoic nodule with hypervascularity. Both require FNA</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_071.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="148" src="Image_072.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s16" style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><span><img width="292" height="153" alt="Two sonograms of a solid nodule. In contrast to the nodule in the right sonogram, the left sonogram displays a clear, dense calcification." title="Two sonograms of a solid nodule. In contrast to the nodule in the right sonogram, the left sonogram displays a clear, dense calcification." src="Image_073.gif"/></span> <span><img width="264" height="153" alt="Two sonograms of a solid nodule. In contrast to the nodule in the right sonogram, the left sonogram displays a clear, dense calcification." title="Two sonograms of a solid nodule. In contrast to the nodule in the right sonogram, the left sonogram displays a clear, dense calcification." src="Image_074.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 1.19  <span class="s12">Two images of the same nodule. Well-defined hypoechoic nod ule with dense calcification (usually dystrophic—secondary to either necrosis or old hemorrhage), which showed benign cytology</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="199" alt="Two sonograms of the focal thyroid nodule and thyroid capsules. The left sonogram is of the sagittal view with white arrows and yellow stars, and the right sonogram is of the transverse view with 2 marked white arrows." title="Two sonograms of the focal thyroid nodule and thyroid capsules. The left sonogram is of the sagittal view with white arrows and yellow stars, and the right sonogram is of the transverse view with 2 marked white arrows." src="Image_075.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 1.20  <span class="s12">Focal thyroid nodule with anterior extrathyroidal extension (white arrows) into the strap muscles (yellow stars). Red arrows indicate thy roid capsule, which is disrupted at site of extrathyroidal extension</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_076.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">should always be performed.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 12pt;text-indent: 0pt;text-align: left;"><span><img width="574" height="467" alt="An outline sketch of human cervical lymph node levels from 1 to 7. The first part denotes the hyoid bone, and the second part denotes cricoid cartilage." title="An outline sketch of human cervical lymph node levels from 1 to 7. The first part denotes the hyoid bone, and the second part denotes cricoid cartilage." src="Image_077.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 1.21 <span class="s12">Diagrammatic demonstration of the cervical lymph node levels</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_078.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">(increased vascularity) may also be an important indicator of underlying  pathology  (but  is  not  specific—can  also  be inflammatory).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s16" style="padding-left: 12pt;text-indent: 0pt;text-align: left;"><span><img width="225" height="149" alt="2 sonograms of the lymph node assessment in the thyroid nodules. 1. The surrounding areas of the hyoid bone and cricoid cartilage are marked with two arrows. 2. A large node is marked by symbols." title="2 sonograms of the lymph node assessment in the thyroid nodules. 1. The surrounding areas of the hyoid bone and cricoid cartilage are marked with two arrows. 2. A large node is marked by symbols." src="Image_079.gif"/></span> <span><img width="324" height="149" alt="2 sonograms of the lymph node assessment in the thyroid nodules. 1. The surrounding areas of the hyoid bone and cricoid cartilage are marked with two arrows. 2. A large node is marked by symbols." title="2 sonograms of the lymph node assessment in the thyroid nodules. 1. The surrounding areas of the hyoid bone and cricoid cartilage are marked with two arrows. 2. A large node is marked by symbols." src="Image_080.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 1.22  <span class="s12">Normal lymph nodes. Left, longitudinal, long and thin lymph nodes with echogenic hila (arrows). Right, larger node but morphologically normal with well-defined hilar line</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="128" alt="Three sonograms of abnormal lymph nodes. The sonogram on the left contains cysts, the sonogram in the center contains solid lymph nodes, and the sonogram on the right contains microcalcifications." title="Three sonograms of abnormal lymph nodes. The sonogram on the left contains cysts, the sonogram in the center contains solid lymph nodes, and the sonogram on the right contains microcalcifications." src="Image_081.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 1.23  <span class="s12">Abnormal lymph nodes: Variable appearance in metastatic pap illary thyroid carcinoma. Left panel: Cystic lymph node; Middle panel Mostly solid lymph node with microcalcifications; Right panel</span></p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: justify;">cystic with microcalcifications</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_082.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s16" style="padding-left: 15pt;text-indent: 0pt;text-align: left;"><span><img width="233" height="153" alt="Four sonograms of the pathologic lymph nodes. The last sonogram has bright spots." title="Four sonograms of the pathologic lymph nodes. The last sonogram has bright spots." src="Image_083.gif"/></span> <span><img width="321" height="153" alt="Four sonograms of the pathologic lymph nodes. The last sonogram has bright spots." title="Four sonograms of the pathologic lymph nodes. The last sonogram has bright spots." src="Image_084.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s16" style="padding-left: 15pt;text-indent: 0pt;text-align: left;"><span><img width="355" height="163" alt="Four sonograms of the pathologic lymph nodes. The last sonogram has bright spots." title="Four sonograms of the pathologic lymph nodes. The last sonogram has bright spots." src="Image_085.gif"/></span> <span><img width="200" height="162" alt="Four sonograms of the pathologic lymph nodes. The last sonogram has bright spots." title="Four sonograms of the pathologic lymph nodes. The last sonogram has bright spots." src="Image_086.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 1.24 <span class="s12">Pathologic lymph nodes. Above left</span></p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Above right<i>: </i>Metastatic medullary thyroid carcinoma node; Lower left</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">tiple lymphoma nodes. Lower right<i>: </i>Lymphoma with intralesional vascularity</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_087.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a14">Other Neck Masses</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Ultrasound is usually the initial imaging study of choice for other neck masses, including parathyroid glands, salivary glands, bran chial cleft cysts, carotid body tumors, and a variety of soft tissue tumors.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_088.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a15">Parathyroid Glands</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Normal parathyroid glands are not typically visualized on ultrasound, due to their small size. When they are identified, this usually implies enlargement, either due to hyperplasia or parathyroid adenoma.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_089.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="101" src="Image_090.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l11"><li data-list-text="•"><p style="padding-top: 13pt;padding-left: 25pt;text-indent: -19pt;text-align: left;">Parathyroid adenomas vary in size and shape (Image</p><p style="padding-left: 25pt;text-indent: 0pt;text-align: left;">are almost always hypoechoic and hypervascular on color Doppler imaging.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s8" style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Please see the dedicated Parathyroid chapter for detailed information and ultrasound localization techniques.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_091.png"/></span></p><h1 style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a16">Salivary Glands (Image </a><span class="s18">1.26</span>)</h1></li><li data-list-text="•"><p style="padding-top: 17pt;padding-left: 25pt;text-indent: -19pt;text-align: left;">The parotid and submandibular glands are commonly seen on ultrasound and may contain intra-glandular lymph nodes, cal culi, or masses, such as cystic or solid tumors.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;line-height: 110%;text-align: left;">On ultrasound, the glands should appear homogeneous, mini mally vascular, and symmetric in size. Side to side comparison is essential. Heterogeneity, hyperemia, and/or asymmetrical enlargement may indicate signs of an inflammatory process.</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_092.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s16" style="padding-left: 15pt;text-indent: 0pt;text-align: left;"><span><img width="187" height="105" alt="Three sonograms illustrate the salivary gland with lesions. The last sonogram displays an arrow pointing to the biopsy needle in the lesion." title="Three sonograms illustrate the salivary gland with lesions. The last sonogram displays an arrow pointing to the biopsy needle in the lesion." src="Image_093.gif"/></span> <span><img width="253" height="104" alt="Three sonograms illustrate the salivary gland with lesions. The last sonogram displays an arrow pointing to the biopsy needle in the lesion." title="Three sonograms illustrate the salivary gland with lesions. The last sonogram displays an arrow pointing to the biopsy needle in the lesion." src="Image_094.gif"/></span> <span><img width="107" height="105" alt="Three sonograms illustrate the salivary gland with lesions. The last sonogram displays an arrow pointing to the biopsy needle in the lesion." title="Three sonograms illustrate the salivary gland with lesions. The last sonogram displays an arrow pointing to the biopsy needle in the lesion." src="Image_095.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_096.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a17">Branchial Cleft Cyst</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Congenital cysts arising from the head and neck.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l12"><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: justify;">Second branch cleft cysts are most common, accounting for 90-95% of branchial cleft cysts, and are found between the angle of the mandible and the carotid bifurcation.</p></li></ul></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_097.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a18">Carotid Body Tumor</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">A carotid body tumor (also called a chemodectoma or paragan glioma, Image <span style=" color: #00F;">1.27</span>) is usually benign, unilateral, and lying in the carotid artery bifurcation separating the internal and external carotid arteries.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_098.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="150" src="Image_099.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">responding computed tomography angiography (CTA) imaging, confirming the enhancing carotid body tumor within the carotid bifurcation (arrow)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_100.png"/></span></p><h1 style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a19">Further Reading</a></h1><p class="s12" style="padding-top: 17pt;padding-left: 25pt;text-indent: -19pt;text-align: left;">AIUM practice guideline for the performance of ultrasound examinations of the head and neck. J Ultrasound Med. 2014;33(2):366–82.</p><p class="s12" style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Baskin HJ, Duick DS, Levine RA. Thyroid ultrasound and ultrasound-guided FNA. New York, NY: Springer; 2013.</p><p class="s12" style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Jiang H, Tan Q, He F, Yang W, Liu J, Zhou F, Zhang M. Ultrasound in patients with treated head and neck carcinomas: a retrospective analysis for effec tiveness of follow-up care. Medicine. 2021;100(16):e25496.</p><p class="s12" style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Kotecha S, Bhatia P, Rout PG. Diagnostic ultrasound in the head and neck region. Dent Update. 2008;35(8):529–30, 533–4.</p><p class="s58" style="padding-left: 25pt;text-indent: 0pt;line-height: 14pt;text-align: left;">denu.2008.35.8.529<span style=" color: #2B2A29;">. PMID: 19055089.</span></p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Rumack CM, Levine D. Diagnostic ultrasound. Elsevier; 2018.</p><p style="padding-left: 385pt;text-indent: 0pt;text-align: left;"><span><a href="http://crossmark.crossref.org/dialog/?doi=10.1007/978-3-031-18448-2_2&amp;domain=pdf"><img width="69" height="61" src="Image_101.png"/></a></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s11" style="padding-left: 19pt;text-indent: 0pt;text-align: left;">Key Points</p><ul id="l13"><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Currently available tools to risk stratify thyroid nodules include clinical practice guidelines, scoring systems (qualitative or quantitative), web-based calculators, and an interactive algorithm.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Web-based tools provide an easy-to-use and easily mod ifiable approach in evaluating risk of malignancy for thy roid nodules.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Many web-based tools generally do not include clinical considerations.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">TNAPP is a novel attempt to convert a comprehensive clinical practice guideline to a web-based tool that employs clinical and radiologic characteristics.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">The application of AI to evaluate thyroid nodules holds promise for the future.</p></li></ul><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="226" height="1" src="Image_102.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_103.png"/></span></p><p class="s12" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">P. Majety (<span class="s13">*</span>)</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Beth Israel Deaconess Medical Center, Boston, MA, USA</p><p class="s12" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">J. R. Garber</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Department of Endocrinology, Atrius Health/Harvard Vanguard Medical Associates and Harvard Medical School, Boston, MA, USA</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;"><a href="mailto:jgarber@bidmc.harvard.edu" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">e-mail: </a><a href="mailto:jgarber@bidmc.harvard.edu" class="s20" target="_blank">jgarber@bidmc.harvard.edu</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">© The Author(s), under exclusive license to Springer Nature Switzerland AG 2023</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">L. S. Eldeiry et al. (eds.), <i>Handbook of Thyroid and Neck Ultrasonography</i><a href="https://doi.org/10.1007/978-3-031-18448-2_2" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">, Contemporary Endocrinology, </a><a href="https://doi.org/10.1007/978-3-031-18448-2_2" class="s20" target="_blank">https://doi.org/10.1007/978-3-031-18448-2_2</a></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_104.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 19pt;text-align: left;">The evaluation of patients with a suspected or known thyroid nodule should include a careful medical history, physical exami nation, TSH level, followed generally by ultrasound (US) evalua tion. Sonographic characteristics of thyroid nodules have been used to better assess the risk of malignancy (RoM). Currently, the principal tools available to clinicians are: (1) clinical practice guidelines (CPG) from professional societies, (2) scoring systems (qualitative or quantitative), (3) web-based calculators, and (4) an interactive algorithm. Guidelines are large documents with exten sive information. The latter tools are easier to use, interactive, trackable, can be integrated into electronic health records, estab lish the sequence of clinical steps, and generate patient-specific recommendations. To date these tools have been retrospectively, but not prospectively, studied. Artificial intelligence (AI) is emerging as a promising approach to evaluating thyroid ultra sound, but is beyond the scope of this chapter.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-left: 10pt;text-indent: 0pt;text-align: justify;"><a name="a20">Case Presentation</a></h3><p style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">A 51-year-old woman with a past medical history of breast cancer in remission (after treatment with chemotherapy, surgery, and XRT), on anastrozole, was referred for osteopenia management. Her physical exam was notable for an approximately 1 cm right mid-pole thyroid nodule with no lymph nodes of significance. Her TSH was 2.27 mIU/L.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Her mother was diagnosed with papillary thyroid cancer at age 30 and died of complications of advanced disease. Thyroid ultra sound showed a 0.9 × 0.7 × 0.9 cm hypoechoic, posterior right</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_105.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="573" height="415" src="Image_106.png"/></span></p><p class="s21" style="text-indent: 0pt;text-align: left;">a</p><p style="text-indent: 0pt;text-align: left;"/><p class="s21" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><span class="s17">Fig. 2.1  </span>(<b>a</b>–<b>d</b>) US demonstrated a 0.9 × 0.7 × 0.9 cm hypoechoic, posterior right mid-pole nodule with a coarse calcification (arrow in panel</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">ular borders (all panels)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">mid-pole nodule with irregular margins and a coarse calcification (Fig. <span style=" color: #0000F9;">2.1</span>, below). Inferior and adjacent to this, there was a patchy hypoechoic region that was well defined. No abnormal cervical lymph nodes were identified.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: justify;">Given her history of breast cancer and family history of lethal thyroid cancer, she requested a fine-needle aspiration (FNA) of the nodule.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_107.png"/></span></p><h1 style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 87%;text-align: left;"><a name="a21">Risk Calculators Versus Clinical Practice Guidelines</a></h1><p style="padding-top: 18pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">CPGs are important evidence-based, narrative tools that aid clini cians in managing various medical conditions and are used as a basis for medical decision-making in both clinical and adminis</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_108.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">bring guidelines to “point of care.” Unambiguous, sequential rec ommendations are made. They are easier to use, interactive, not very time-consuming and can be used as a tool to engage patients and track data about use and outcomes by being integrated into electronic health records. Unlike CPGs, these are not static docu ments that take substantial effort and time to update. They facili tate testing and validating recommendations prospectively and retrospectively. Expert users’ feedback can continually guide revisions that can be readily and rapidly implemented.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Calculators can be used in a variety of clinical settings, e.g., in solo-practice, large multi-specialty delivery systems, regional and national databases, or research consortiums. There are limitations, however. Features that are key to clinical decision-making (for example, patient anxiety, cosmetic concerns, etc.) are usually omitted from these tools. They are typically introduced in a com panion publication, e.g., an American College of Radiology “white paper” for TI-RADS. They are not as comprehensive and therefore not as instructive as CPGs.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">CIGs have been shown to be effective in additional clinical domains, such as chronic diseases, diabetes, stroke, and hyperten sion. Examples of some of the widely used risk calculators include the fracture risk assessment tool, FRAX (</p><p class="s10" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">ac.uk/FRAX/<a href="https://tools.acc.org/ascvd-risk-estimator-plus/%23!/calculate/estimate/" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 14.5pt;" target="_blank">), and the ASCVD (atherosclerotic cardiovascular disease) risk estimator (</a><a href="https://tools.acc.org/ascvd-risk-estimator-plus/%23!/calculate/estimate/" class="s23" target="_blank">https://tools.acc.org/ascvd- </a>plus/#!/calculate/estimate/<span style=" color: #2B2A29;">). Since the latter employs standardized data, it serves as a prototype calculator to automatically generate cardiovascular risk in electronic health record systems.</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_109.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">The 2016 American Association of Clinical Endocrinologists/ American  College  of  Endocrinology/Associazione  Medici Endocrinologi (AACE/ACE/AME) guidelines were updated in 2021 as a novel interactive electronic algorithmic tool entitled, The Thyroid Nodule App (termed TNAPP). This tool classifies thyroid nodules into 3 categories based on US features: US 1 (low-risk), US 2 (intermediate-risk), and US 3 (high-risk). Tables <span style=" color: #0000F9;">2.1</span>, <span style=" color: #0000F9;">2.2</span>, and <span style=" color: #0000F9;">2.3 </span>and Figs. <span style=" color: #0000F9;">2.2</span>, <span style=" color: #0000F9;">2.3</span>, and <span style=" color: #0000F9;">2.4</span></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">these categories and FNA recommendations.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Table 2.1 <span class="s12">2021 AACE/ACE-AME risk stratification based on clinical fea tures</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.64678pt" cellspacing="0"><tr style="height:18pt"><td style="width:175pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Clinical 1</p></td><td style="width:256pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Clinical 2</p></td></tr><tr style="height:46pt"><td style="width:175pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">One or more of the following clinical factors are against performing FNA:</p></td><td style="width:256pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;padding-right: 9pt;text-indent: 0pt;text-align: left;">One or more of the following clinical factors favor FNA:</p></td></tr><tr style="height:222pt"><td style="width:175pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><ul id="l14"><li data-list-text="•"><p class="s24" style="padding-left: 12pt;padding-right: 6pt;text-indent: -8pt;text-align: left;">Low thyrotropin and not on thyroid hormone</p></li><li data-list-text="•"><p class="s24" style="padding-left: 11pt;padding-right: 30pt;text-indent: -7pt;text-align: left;">Autonomous nodule on imaging</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;padding-right: 24pt;text-indent: -8pt;text-align: left;">Prior benign FNA of the same nodule</p><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Other medical conditions that take precedence at the time</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;padding-right: 10pt;text-indent: -8pt;text-align: left;">History of prior lobectomy with vocal cord paralysis</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;padding-right: 28pt;text-indent: -8pt;text-align: justify;">Significant comorbidity making thyroid surgery high risk at the time</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;padding-right: 28pt;text-indent: -8pt;text-align: justify;">Limited life expectancy (&lt;1 year)</p></li></ul></td><td style="width:256pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><ul id="l15"><li data-list-text="•"><p class="s24" style="padding-left: 12pt;text-indent: -8pt;text-align: left;">Head and neck radiation in the past</p></li><li data-list-text="•"><p class="s24" style="padding-left: 11pt;padding-right: 5pt;text-indent: -7pt;text-align: left;">Compressive symptoms: dysphonia, dysphagia, or dyspnea without another cause</p></li><li data-list-text="•"><p class="s24" style="padding-left: 11pt;padding-right: 32pt;text-indent: -7pt;text-align: left;">Nodule position either posterior or adjacent to thyroid capsule or trachea</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;text-indent: -8pt;line-height: 14pt;text-align: left;">History of documented growth</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;padding-right: 13pt;text-indent: -8pt;text-align: left;">History of progressive growth, i.e., increase in volume in &lt;1 year, especially of the solid component, or 20% increase in 1 dimension</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;text-indent: -8pt;line-height: 14pt;text-align: left;">History of sudden enlargement</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;text-indent: -8pt;text-align: left;">Planned thyroid or parathyroid surgery</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;text-indent: -8pt;text-align: left;">Cosmetic concerns</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;text-indent: -8pt;text-align: left;">Patient preference or anxiety</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;text-indent: -8pt;text-align: left;">Protocol requiring documentation of cancer</p></li></ul></td></tr></table><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_110.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:10.5825pt" cellspacing="0"><tr style="height:12pt"><td style="width:429pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" colspan="3"><p class="s25" style="padding-left: 131pt;padding-right: 134pt;text-indent: 0pt;line-height: 9pt;text-align: center;">2021AACE/ACE-AME risk stra fica on</p></td></tr><tr style="height:34pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#A0C38A"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:349pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" colspan="2" bgcolor="#A0C38A"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#A0C38A"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:34pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#A0C38A"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#A0C38A"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="2" bgcolor="#A0C38A"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s26" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">is present and</p></td><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s27" style="padding-left: 3pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="31" height="1" src="Image_111.png"/></span>	<span><img width="48" height="1" src="Image_112.png"/></span></p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:14pt"><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p class="s26" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Either <u>solid or mixed</u> <b>and </b><u>marked hyperechoic nodule</u>-described as</p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="4" bgcolor="#DFE9D7"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#A0C38A"><p class="s26" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">none of the</p></td><td style="width:294pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p class="s26" style="padding-top: 3pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">&quot;white knight&quot;, is o en seen in a gland with clear features of</p></td></tr><tr style="height:17pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#A0C38A"><p class="s26" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">intermediate or</p></td><td style="width:294pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p class="s26" style="padding-top: 4pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Hashimotos thyroidi s</p></td></tr><tr style="height:4pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="2" bgcolor="#A0C38A"><p class="s26" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">high-risk features</p></td><td style="width:294pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="2" bgcolor="#DFE9D7"><p class="s26" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Comet tail echogenic foci and its variants are present on ultrasound</p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="2" bgcolor="#DFE9D7"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:5pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="2" bgcolor="#A0C38A"><p class="s26" style="padding-top: 3pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">is present</p></td></tr><tr style="height:17pt"><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p class="s26" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Either <u>solid or mixed</u> <b>and </b><u>hyperechoic</u></p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:15pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#A0C38A"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p class="s26" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Either <u>solid or mixed</u> <b>and </b><u>isoechoic nodule</u> <b>and </b><u><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </b></u></p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="5" bgcolor="#DFE9D7"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#A0C38A"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:294pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p class="s28" style="padding-top: 3pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">none of the US 2/3 features such as microcalcifica ons, intranodular</p></td></tr><tr style="height:17pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#A0C38A"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:294pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p class="s28" style="padding-top: 3pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">macrocalcifica ons, peripheral rim calcifica ons, echogenic foci</p></td></tr><tr style="height:17pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#A0C38A"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:294pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p class="s28" style="padding-top: 3pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">difficult to characterize, spiculated or irregular margin, extra-</p></td></tr><tr style="height:20pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#A0C38A"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:294pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p class="s28" style="padding-top: 3pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">thyroidal extension</p></td></tr><tr style="height:50pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="3" bgcolor="#A0C38A"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p class="s26" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Mixed solid cys c nodule thathas reverbera ng ar facts, which is</p><p class="s26" style="padding-left: 3pt;padding-right: 20pt;text-indent: 0pt;line-height: 17pt;text-align: left;">low-riskfeature compared with eccentric mural component (excluded from scoring)</p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p class="s26" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Peripheral vascularity (excluded from scoring)</p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:34pt"><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p class="s26" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Mixed solid cys c nodule has a solid concentric/spongiform like</p><p class="s26" style="padding-top: 6pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">component (excluded from scoring)</p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#DFE9D7"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="2" bgcolor="#FBD864"><p class="s25" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">US 2</p><p class="s25" style="padding-top: 6pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">(intermediate)</p></td><td style="width:349pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" colspan="2" bgcolor="#FBD864"><p class="s26" style="padding-left: 98pt;text-indent: 0pt;text-align: left;">Intermediate risk ultrasound features</p></td></tr><tr style="height:34pt"><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#FDF1CA"><p class="s26" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Margin on ultrasound is irregular with protrusion into adjacent</p><p class="s26" style="padding-top: 6pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">thyroid ssue</p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#FDF1CA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:67pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="3" bgcolor="#FBD864"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s26" style="padding-left: 3pt;padding-right: 6pt;text-indent: 0pt;line-height: 159%;text-align: left;">One or more of the corresponding intermediate-risk features is present and none of the high- risk features is</p><p class="s26" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">present</p></td><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#FDF1CA"><p class="s26" style="padding-left: 3pt;padding-right: 20pt;text-indent: 0pt;line-height: 159%;text-align: left;">Echogenic foci include either intra-nodular macrocalcifica ons or foci that are difficult to characterize or peripheral rim calcifica ons include either interrupted rim calcifica on or uninterrupted rim</p><p class="s26" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">calcifica ons</p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#FDF1CA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:34pt"><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#FDF1CA"><p class="s28" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Composi on is either solid or mixed<span class="s26"> </span><b>and </b>the echogenicity of solid</p><p class="s28" style="padding-top: 6pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">part is either slightly hypoechoic or hypoechoic</p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#FDF1CA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:67pt"><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#FDF1CA"><p class="s28" style="padding-left: 3pt;padding-right: 14pt;text-indent: 0pt;line-height: 159%;text-align: left;">Either solid or mixed nodule <b>and </b>isoechoic <b>and </b><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </b><b> </b><span class="s26">or </span>at least one more US 2 feature such as irregular margin or<span class="s26"> </span>intranodular macrocalcifica ons or foci that are difficult to</p><p class="s28" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">characterize or peripheral rim calcifica  ons<span class="s26"> </span><b>and</b><b> &nbsp;&nbsp;&nbsp;&nbsp; </b></p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#FDF1CA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_113.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.89678pt" cellspacing="0"><tr style="height:34pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="4" bgcolor="#FBD864"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#FDF1CA"><p class="s28" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">characteris cs such as microcalcifica ons, extrathyroidal extension,</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 3pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="102" height="1" src="Image_114.png"/></span></p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#FDF1CA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:34pt"><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#FDF1CA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#FDF1CA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:34pt"><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#FDF1CA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#FDF1CA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:34pt"><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#FDF1CA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#FDF1CA"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#EDAD83"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:349pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" colspan="2" bgcolor="#EDAD83"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#EDAD83"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="2" bgcolor="#F7E2D4"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="2" bgcolor="#F7E2D4"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:1pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="2" bgcolor="#EDAD83"><p class="s26" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">One or more of</p></td></tr><tr style="height:17pt"><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#F7E2D4"><p class="s26" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Echogenicity is profoundly hypoechoic</p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#F7E2D4"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:14pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#EDAD83"><p class="s26" style="padding-left: 3pt;text-indent: 0pt;line-height: 10pt;text-align: left;">the</p></td><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="2" bgcolor="#F7E2D4"><p class="s26" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Microcalcifica ons within the nodule</p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="2" bgcolor="#F7E2D4"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:4pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="2" bgcolor="#EDAD83"><p class="s26" style="padding-top: 3pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">corresponding</p></td></tr><tr style="height:13pt"><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="2" bgcolor="#F7E2D4"><p class="s26" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Shape is taller than wide</p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="2" bgcolor="#F7E2D4"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:4pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="2" bgcolor="#EDAD83"><p class="s26" style="padding-top: 3pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">high-risk features</p></td></tr><tr style="height:14pt"><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#F7E2D4"><p class="s26" style="padding-left: 3pt;text-indent: 0pt;text-align: left;"><u>Solid</u> <b>and </b>h<u>ypoechoic</u> <b>and </b><u>either intranodularmacrocalcifica ons or</u></p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="3" bgcolor="#F7E2D4"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:18pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#EDAD83"><p class="s26" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">present</p></td><td style="width:294pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#F7E2D4"><p class="s28" style="padding-top: 3pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">nonspecific echogenic foci or peripheral rim calcifica ons present</p></td></tr><tr style="height:20pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#EDAD83"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:294pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#F7E2D4"><p class="s26" style="padding-top: 3pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">(excluded from scoring)</p></td></tr><tr style="height:17pt"><td style="width:80pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#EDAD83"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:294pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#F7E2D4"><p class="s26" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Extrathyroidal extension is noted (excluded from scoring)</p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#F7E2D4"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="572" height="367" src="Image_115.png"/></span></p><p class="s30" style="text-indent: 0pt;text-align: left;">Nodule size</p><p class="s31" style="text-indent: 0pt;text-align: left;">&lt; 5 mm</p><p class="s30" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Ultrasound 1</p><p class="s30" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Ultrasound 2</p><p class="s30" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Ultrasound 3</p><p class="s31" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">5 – 10 mm</p><p class="s30" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Ultrasound 1</p><p class="s30" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Ultrasound 2</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;text-align: left;">Clinical 1</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;text-align: left;">Clinical 2</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;text-align: left;">Ultrasound 3</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s31" style="text-indent: 0pt;text-align: left;">&gt;10 – 20 mm</p><p class="s30" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Ultrasound 1</p><p class="s30" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Ultrasound 2</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s30" style="text-indent: 0pt;text-align: left;">Ultrasound 3</p><p class="s31" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">&gt;20 – 40 mm</p><p class="s30" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Ultrasound 1</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s30" style="text-indent: 0pt;text-align: left;">Ultrasound 2</p><p class="s30" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Ultrasound 3</p><p class="s31" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">&gt; 40 mm</p><p class="s30" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Ultrasound 1</p><p class="s30" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Ultrasound 2</p><p class="s30" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Ultrasound 3</p><p style="text-indent: 0pt;text-align: left;"/><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Table  2.3 <span class="s12">2021  AACE/ACE-AME  (TNAPP)  guidelines  regarding FNA. Adapted from 2021 American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi thyroid nodule algorithmic tool by Garber et al.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:67.5822pt" cellspacing="0"><tr style="height:10pt"><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E7E7E7"><p class="s32" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">No follow up                     No follow up</p></td></tr><tr style="height:10pt"><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E7E7E7"><p class="s32" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">No follow up                     No follow up</p></td></tr><tr style="height:10pt"><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E7E7E7"><p class="s32" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Monitor at 18-24 months then stop        Monitor at 18-24 months then stop</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:67.5822pt" cellspacing="0"><tr style="height:10pt"><td style="width:179pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E7E7E7"><p class="s32" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">No follow up</p></td><td style="width:189pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E7E7E7"><p class="s32" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">No follow up</p></td></tr><tr style="height:28pt"><td style="width:179pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF" bgcolor="#E7E7E7"><p class="s32" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Monitor at 18-24 months</p></td><td style="width:189pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E7E7E7"><p class="s32" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Either</p><p class="s33" style="padding-left: 14pt;text-indent: 0pt;text-align: left;">  <span class="s32">Consider FN</span></p><p class="s33" style="padding-left: 14pt;text-indent: 0pt;line-height: 8pt;text-align: left;">  <span class="s32">If no FNA then Monitor at 12-24 months</span></p></td></tr><tr style="height:28pt"><td style="width:179pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E7E7E7"><p class="s32" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Either</p><p class="s33" style="padding-left: 14pt;text-indent: 0pt;text-align: left;">  <span class="s32">Consider FNA</span></p><p class="s33" style="padding-left: 14pt;text-indent: 0pt;line-height: 8pt;text-align: left;">  <span class="s32">If no FNA then Monitor at 18-24 months</span></p></td><td style="width:189pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E7E7E7"><p class="s32" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Either</p><p class="s33" style="padding-left: 14pt;text-indent: 0pt;text-align: left;">  <span class="s32">Consider FN</span></p><p class="s33" style="padding-left: 14pt;text-indent: 0pt;line-height: 8pt;text-align: left;">  <span class="s32">If no FNA then Monitor at 12-24 months</span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:67.5822pt" cellspacing="0"><tr style="height:10pt"><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E7E7E7"><p class="s32" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Monitor at 12-24 months              Monitor at 12 months</p></td></tr><tr style="height:28pt"><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E7E7E7"><p class="s32" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Either                        Recommend FN</p><p class="s33" style="padding-left: 14pt;text-indent: 0pt;text-align: left;">  <span class="s32">Consider FNA</span></p><p class="s33" style="padding-left: 14pt;text-indent: 0pt;line-height: 8pt;text-align: left;">  <span class="s32">If no FNA then Monitor at 12 months</span></p></td></tr><tr style="height:10pt"><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E7E7E7"><p class="s32" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Recommend FNA                  Recommend FN</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:67.5822pt" cellspacing="0"><tr style="height:28pt"><td style="width:368pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E7E7E7"><p class="s32" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Either                        Either</p><p class="s33" style="padding-left: 14pt;text-indent: 0pt;text-align: left;">  <span class="s32">Consider FNA</span>                 <span class="s32">Consider FN</span></p><p class="s33" style="padding-left: 14pt;text-indent: 0pt;line-height: 8pt;text-align: left;">  <span class="s32">If no FNA then Monitor at 12 months     If no FNA then Monitor at 12 months</span></p></td></tr><tr style="height:10pt"><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E7E7E7"><p class="s32" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Recommend FNA                  Recommend FN</p></td></tr><tr style="height:10pt"><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E7E7E7"><p class="s32" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Recommend FNA                  Recommend FN</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:67.5822pt" cellspacing="0"><tr style="height:10pt"><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E7E7E7"><p class="s32" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Recommend FNA                  Recommend FN</p></td></tr><tr style="height:10pt"><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E7E7E7"><p class="s32" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Recommend FNA                  Recommend FN</p></td></tr><tr style="height:10pt"><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E7E7E7"><p class="s32" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Recommend FNA                  Recommend FNA</p></td></tr></table><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_116.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="572" height="138" alt="3 ultrasound images of the thyroid nodules display, a. a cyst with the border, b. cystic nodule, and c. isoechoic spongiform nodule with a branch-like structure." title="3 ultrasound images of the thyroid nodules display, a. a cyst with the border, b. cystic nodule, and c. isoechoic spongiform nodule with a branch-like structure." src="Image_117.gif"/></span></p><p class="s21" style="text-indent: 0pt;text-align: left;">a</p><p style="text-indent: 0pt;text-align: left;"/><p class="s21" style="text-indent: 0pt;text-align: left;">c</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 5pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">berating artifacts (<b>b</b>), isoechoic spongiform nodule (</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="572" height="329" alt="4 ultrasound images of the thyroid display, a. the colored spots representing nodules, b. elevated stiffness on elastography with 2 highlighted spots. c. a nodule with a border, and d. a cluster of spots." title="4 ultrasound images of the thyroid display, a. the colored spots representing nodules, b. elevated stiffness on elastography with 2 highlighted spots. c. a nodule with a border, and d. a cluster of spots." src="Image_118.jpg"/></span></p><p class="s21" style="text-indent: 0pt;text-align: left;">a</p><p style="text-indent: 0pt;text-align: left;"/><p class="s21" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s21" style="text-indent: 0pt;text-align: left;">c</p><p style="text-indent: 0pt;text-align: left;"/><p class="s21" style="text-indent: 0pt;text-align: left;">d</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><span class="s17">Fig. 2.3  </span>US 2 (Intermediate-risk) features: Isoechoic nodules with: central vascularity* (<b>a</b>), elevated stiffness on elastography (</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">(<b>c</b>), and indeterminate hyperechoic spots (<b>d</b>). *Not assigned a score</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 19pt;text-align: left;">TNAPP provides guidance in the initial evaluation of ambula tory patients with thyroid nodules that are not extremely likely to be malignant. Thus, nodules in those who presented with elevated calcitonin levels, multiple endocrine neoplasia type 2 syndromes, previously documented thyroid cancer, and suspicious lymphade nopathy were excluded.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Clinical factors (Table <span style=" color: #0000F9;">2.1</span>) were comprised of features in favor of performing FNA, termed Clinical 2, and those with</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_119.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="257" alt="6 ultrasound images labeled a to f, display a thyroid nodule with marked hypoechogenicity, margins, extracapsular growth, calcification, and a region around the nodule highlighted with colored spots." title="6 ultrasound images labeled a to f, display a thyroid nodule with marked hypoechogenicity, margins, extracapsular growth, calcification, and a region around the nodule highlighted with colored spots." src="Image_120.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><span class="s17">Fig. 2.4 </span>US 3 (High-risk) features: Marked hypoechogenicity ( (spiculated) margins (<b>b</b>), extracapsular growth (<b>c</b></p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">taller than wide shape (<b>e</b>), and a suspicious regional lymph node (</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">features against performing FNA, termed Clinical 1. When fac tors for and against doing an FNA are present, clinical judg ment  becomes  the  default  decision-making  factor  (e.g., consideration of other medical conditions that take precedence at the time).</p><p style="padding-left: 25pt;text-indent: 0pt;text-align: left;">Management recommendations are informed by nodule size,</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">US, and clinical characteristics (Table <span style=" color: #0000F9;">2.3</span></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">these guidelines, nodules with a major diameter &lt;5 mm should only be monitored with US if they have high-risk ultrasound fea tures (US 3). Nodules with a major diameter 5–10 mm with inter mediate- or high-risk ultrasound features (US 2/US 3) can either be monitored or aspirated. All nodules with a major diameter</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">&gt;10 mm require monitoring or FNA regardless of ultrasound characterization (US 1/US 2/US 3).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-top: 14pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a22">American Thyroid Association (ATA)</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">The 2015 ATA guidelines (update is in progress) categorize nodules based on ultrasound features into 5 categories: benign, very low, low, intermediate, or high suspicion (Table <span style=" color: #0000F9;">2.4</span></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">are informed by nodule size and ultrasound characteristics.</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_121.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:10.332pt" cellspacing="0"><tr style="height:18pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" colspan="3" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:47pt"><td style="width:209pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:92pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:130pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:46pt"><td style="width:209pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:92pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:130pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:90pt"><td style="width:209pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s34" style="padding-left: 4pt;padding-right: 35pt;text-indent: 0pt;text-align: left;">Very low suspicion <span class="s24">Spongiform or partially cystic nodules </span>without <span class="s24">any of the</span></p><p class="s24" style="padding-left: 4pt;padding-right: 11pt;text-indent: 0pt;text-align: left;">sonographic features described in low, intermediate, or high suspicion patterns</p></td><td style="width:92pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:130pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:119pt"><td style="width:209pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s34" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Low suspicion</p><p class="s24" style="padding-left: 4pt;padding-right: 11pt;text-indent: 0pt;text-align: left;">Isoechoic or hyperechoic solid nodule, or partially cystic nodule with eccentric solid areas, <i>without</i>:</p><ul id="l16"><li data-list-text="•"><p class="s24" style="padding-left: 12pt;text-indent: -8pt;line-height: 14pt;text-align: left;">Microcalcification</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;text-indent: -8pt;text-align: left;">Irregular margin</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;text-indent: -8pt;text-align: left;">Extrathyroidal extension (ETE)</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;text-indent: -8pt;text-align: left;">Taller than wide shape</p></li></ul></td><td style="width:92pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">5–10</p></td><td style="width:130pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:90pt"><td style="width:209pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s34" style="padding-left: 4pt;padding-right: 35pt;text-indent: 0pt;text-align: left;">Intermediate suspicion <span class="s24">Hypoechoic solid nodule with smooth margins </span>without:</p><ul id="l17"><li data-list-text="•"><p class="s24" style="padding-left: 12pt;text-indent: -8pt;line-height: 14pt;text-align: left;">Microcalcifications</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;text-indent: -8pt;text-align: left;">Extrathyroidal extension (ETE)</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;text-indent: -8pt;text-align: left;">Taller than wide shape</p></li></ul></td><td style="width:92pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">10–20</p></td><td style="width:130pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:193pt"><td style="width:209pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s34" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">High suspicion</p><p class="s24" style="padding-left: 4pt;padding-right: 11pt;text-indent: 0pt;text-align: left;">Solid hypoechoic nodule or solid hypoechoic component of a partially cystic nodule <i>with 1 or more </i>of the following features:</p><ul id="l18"><li data-list-text="•"><p class="s24" style="padding-left: 12pt;padding-right: 28pt;text-indent: -8pt;text-align: left;">Irregular margins (infiltrative, microlobulated).</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;text-indent: -8pt;line-height: 14pt;text-align: left;">Microcalcifications.</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;text-indent: -8pt;text-align: left;">Taller than wide shape.</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;padding-right: 15pt;text-indent: -8pt;text-align: left;">Rim calcifications with small extrusive soft tissue component.</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;padding-right: 45pt;text-indent: -8pt;text-align: left;">Evidence of extrathyroidal extension (ETE).</p></li></ul></td><td style="width:92pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">&gt;70–90</p></td><td style="width:130pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_122.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">which evaluated a total of 3422 nodules concluded that the aggre gate risk levels for TR1, TR2, TR3, TR4, and TR5 nodules were 0.3%, 1.5%, 4.8%, 9.1%, and 35.0%, respectively.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Assessing a nodule with TI-RADS involves evaluation of its composition, echogenicity, shape, margin, and echogenic foci. Points are assigned to each US feature, with higher values indicat ing greater degrees of suspicion (Fig. <span style=" color: #0000F9;">2.5</span>). Recommendations for FNA or ultrasound follow-up are based on a nodule’s ACR TI- RADS level and its maximum diameter.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Overall, TI-RADS has a higher size threshold for recommend ing biopsy compared with other systems. In a study of 2847 patients with biopsy results proven by pathology data, ACR TI- RADS classification had a specificity of 98.8% for diagnosing benign nodules at the cost of missing a small number of papillary cancers in TR2 and TR3 nodules that were smaller than 2.5 cm (i.e., lower sensitivity for nodules &lt;2.5 cm).</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: justify;">More recently, artificial intelligence (AI) has been used to update ACR TI-RADS, though its use is not yet as widespread as ACR-TIRADS. AI TI-RADS assigned new point values for eight ACR TI-RADS features (Fig. <span style=" color: #0000F9;">2.6</span>). The five imaging characteristic categories were maintained with the following changes in each:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l19"><li data-list-text="•"><p class="s8" style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Composition—only solid nodules receive points</p><ul id="l20"><li data-list-text="–"><p style="padding-left: 45pt;text-indent: -19pt;text-align: left;">Mixed cystic/solid nodules receive 0 points instead of 1 point</p></li><li data-list-text="–"><p style="padding-left: 45pt;text-indent: -19pt;line-height: 110%;text-align: left;">Solid or near-completely solid nodules receive 3 points instead of 2 points</p></li><li data-list-text="–"><p style="padding-left: 45pt;text-indent: -19pt;line-height: 110%;text-align: left;">Nodules that cannot be classified receive 0 points instead of 2 points</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:17.0053pt" cellspacing="0"><tr style="height:8pt"><td style="width:84pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#C2CDDF"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#C2CDDF"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#C2CDDF"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:84pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#C2CDDF"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" bgcolor="#C2CDDF"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:26pt"><td style="width:84pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p class="s35" style="padding-top: 2pt;padding-left: 3pt;padding-right: 18pt;text-indent: 0pt;line-height: 109%;text-align: left;">Spongiform: <span class="s36">Composed predomi- nantly (&gt;50%) of small cystic spaces. Do not add further points for other categories.</span></p></td><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p class="s35" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;line-height: 109%;text-align: left;">Anechoic: <span class="s36">Applies to cystic or almost completely cystic nodules.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s35" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Hyperechoic/isoechoic/hypoechoic:</p><p class="s36" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Compared to adjacent parenchyma.</p></td><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p class="s35" style="padding-top: 2pt;padding-left: 2pt;padding-right: 9pt;text-indent: 0pt;line-height: 4pt;text-align: left;">Taller-than-wide: <span class="s36">Should be assessed on a transverse image with measure- ments parallel to sound beam for height and perpendicular to sound beam for width.</span></p></td><td style="width:84pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p class="s35" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Lobulated:</p><p class="s36" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">tissue.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s35" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Irregular:</p><p class="s36" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">angles.</p></td><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="3"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:14pt"><td style="width:84pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p class="s35" style="padding-left: 3pt;padding-right: 18pt;text-indent: 0pt;line-height: 4pt;text-align: left;">Mixed cystic and solid: <span class="s36">Assign points for predominant solid component.</span></p></td><td style="width:83pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p class="s35" style="padding-top: 1pt;padding-left: 2pt;padding-right: 12pt;text-indent: 0pt;line-height: 109%;text-align: left;">Very hypoechoic: <span class="s36">More hypoechoic than strap muscles.</span></p></td><td style="width:82pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s36" style="padding-left: 2pt;padding-right: 12pt;text-indent: 0pt;line-height: 4pt;text-align: left;">This can usually be assessed by visual inspection.</p></td><td style="width:84pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p class="s35" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Extrathyroidal extension:</p><p class="s36" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">invasion = malignanc</p></td></tr><tr style="height:22pt"><td style="width:84pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s36" style="padding-left: 3pt;padding-right: 18pt;text-indent: 0pt;line-height: 109%;text-align: left;">Assign 2 points if composition cannot be determined because of calicification.</p></td><td style="width:83pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p class="s36" style="padding-left: 2pt;padding-right: 12pt;text-indent: 0pt;line-height: 109%;text-align: left;">Assign 1 point if echogenicity cannot be determined</p></td><td style="width:82pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:84pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p class="s36" style="padding-left: 3pt;padding-right: 14pt;text-indent: 0pt;line-height: 109%;text-align: left;">Assign 0 points if margin cannot be determined</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="681" height="623" src="Image_123.png"/></span></p><p class="s37" style="text-indent: 0pt;text-align: center;">COMPOSITION</p><p class="s38" style="text-indent: 0pt;text-align: center;">(Choose 1)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s39" style="text-indent: 0pt;line-height: 111%;text-align: left;">Cystic or almost completely cystic*</p><p class="s39" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Spongiform*</p><p class="s39" style="padding-top: 3pt;text-indent: 0pt;text-align: left;">Mixed cystic/solid</p><p class="s39" style="padding-top: 2pt;text-indent: 0pt;line-height: 111%;text-align: left;">Solid or almost completely solid</p><p class="s39" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Can’t classify</p><p style="text-indent: 0pt;text-align: left;"/><p class="s39" style="text-indent: 0pt;text-align: left;">0</p><p class="s39" style="padding-top: 5pt;text-indent: 0pt;text-align: left;">0</p><p class="s39" style="padding-top: 3pt;text-indent: 0pt;text-align: left;">0</p><p class="s39" style="padding-top: 6pt;text-indent: 0pt;text-align: left;">3</p><p style="text-indent: 0pt;text-align: left;"/><p class="s39" style="text-indent: 0pt;text-align: left;">0</p><p style="text-indent: 0pt;text-align: left;"/><p class="s37" style="padding-left: 22pt;text-indent: 0pt;text-align: left;">SHAPE</p><p class="s38" style="padding-left: 17pt;text-indent: 0pt;text-align: left;">(Choose 1)</p><p class="s39" style="padding-top: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Wider-than-tall Taller-than-wide</p><p style="text-indent: 0pt;text-align: left;"/><p class="s39" style="text-indent: 0pt;text-align: left;">0</p><p class="s39" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">1</p><p style="text-indent: 0pt;text-align: left;"/><p class="s39" style="padding-left: 1pt;text-indent: 0pt;text-align: left;">Smoot</p><p class="s39" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">III-defined</p><p class="s39" style="padding-top: 4pt;text-indent: 0pt;line-height: 115%;text-align: left;">Lo irregular Extra-th ex</p><p class="s39" style="text-indent: 0pt;text-align: left;">Can’t classify</p><p style="text-indent: 0pt;text-align: left;"/><p class="s39" style="text-indent: 0pt;text-align: left;">0</p><p style="text-indent: 0pt;text-align: left;"/><p class="s40" style="text-indent: 0pt;text-align: left;">*Refer to discussion fo papillary microcarcinomas for 5-9 mm TR% nodules.</p><p style="text-indent: 0pt;text-align: left;"/><p class="s41" style="text-indent: 0pt;text-align: left;">AI TI-RADS</p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s39" style="text-indent: 0pt;text-align: right;">0</p><p style="text-indent: 0pt;text-align: left;"/><p class="s37" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: center;">ECHOGENICITY</p><p class="s38" style="padding-left: 5pt;text-indent: 0pt;text-align: center;">(Choose 1)</p><p class="s39" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: center;">Anechoic    0</p><p class="s39" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: center;">Hyperechoic   0</p><p class="s39" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: center;">Isoechoic    0</p><p class="s39" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: center;">Hypoechoic   2</p><p class="s39" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: center;">Very hypoechoic  3</p><p class="s39" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: center;">Can’t classify   0</p><p style="text-indent: 0pt;text-align: left;"/><p class="s42" style="padding-top: 5pt;padding-left: 127pt;text-indent: 0pt;text-align: left;">Add Points From All Categories to Determine TI-RADS Level</p><p class="s39" style="padding-left: 69pt;text-indent: 0pt;text-align: left;">*Cystic and spongiform nodules receive 0 points in total without adding furt</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-left: 17pt;text-indent: 0pt;text-align: left;">			<span><img width="89" height="78" src="Image_124.png"/></span><span class="s44">	</span><span><img width="88" height="78" src="Image_125.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="89" height="78" src="Image_126.png"/></span></p><p class="s45" style="text-indent: 0pt;text-align: left;">1 Point or Less</p><p style="text-indent: 0pt;text-align: left;"/><p class="s46" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">TR1</p><p class="s45" style="text-indent: 0pt;text-align: left;">Benign</p><p class="s47" style="text-indent: 0pt;text-align: left;">No FNA</p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><img width="88" height="78" src="Image_127.png"/></span></p><p class="s45" style="text-indent: 0pt;text-align: left;">2 Points</p><p style="text-indent: 0pt;text-align: left;"/><p class="s46" style="text-indent: 0pt;text-align: center;">TR2</p><p class="s45" style="text-indent: 0pt;text-align: center;">Not Suspicious</p><p class="s47" style="text-indent: 0pt;text-align: center;">No FNA</p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><img width="89" height="78" src="Image_128.png"/></span></p><p class="s45" style="text-indent: 0pt;text-align: left;">3 Points</p><p style="text-indent: 0pt;text-align: left;"/><p class="s46" style="text-indent: 0pt;text-align: center;">TR3</p><p class="s47" style="text-indent: 0pt;line-height: 108%;text-align: center;"><b>Mildly Suspicious </b>FNA if <span class="s48"></span><span class="s49"> </span>2.5 cm Follow if <span class="s48"></span><span class="s49"> </span>1.5 cm</p><p style="text-indent: 0pt;text-align: left;"/><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Fig. 2.5  <span class="s12">Scoring systems: ACR Thyroid Imaging, Reporting and Data Sys tem (TI-RADS) lexicon, TR levels, and criteria for fine-needle aspiration or follow-up ultrasound and Artificial Intelligence-optimized Thyroid Imag ing, Reporting and Data System (AI TIRADS). Adapted from ACR: TI- RADS: White paper of the ACR TI-RADS committee by Franklin N Tessler et al., 2017</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_129.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:31.8988pt" cellspacing="0"><tr style="height:88pt"><td style="width:79pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s50" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">0</p></td><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s50" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">0</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="576" height="1" src="Image_130.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:31.8988pt" cellspacing="0"><tr style="height:52pt"><td style="width:79pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" colspan="2"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#E22D2C;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="2"><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 64pt;text-indent: 0pt;text-align: left;"><span><img width="16" height="25" src="Image_131.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 64pt;text-indent: 0pt;text-align: left;"><span><img width="16" height="18" src="Image_132.png"/></span></p></td><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="2"><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 64pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><span><img width="17" height="15" src="Image_133.png"/></span></p></td><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="2"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s50" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">0</p></td><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#2B2A29;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:1pt;border-right-color:#2B2A29" rowspan="2"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s50" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">0</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 63pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><span><img width="17" height="15" src="Image_134.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:35pt"><td style="width:66pt;border-left-style:solid;border-left-width:1pt;border-left-color:#2B2A29;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#2B2A29;border-right-style:solid;border-right-width:2pt;border-right-color:#E22D2C"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s50" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Can’t classify</p></td><td style="width:13pt;border-top-style:solid;border-top-width:2pt;border-top-color:#E22D2C;border-left-style:solid;border-left-width:2pt;border-left-color:#E22D2C;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#E22D2C;border-right-style:solid;border-right-width:1pt;border-right-color:#E22D2C"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s50" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">0</p></td></tr></table><p class="s39" style="padding-top: 1pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">* Could not be evaluated due to small sample size. Points adapted from ACR TI-RADS.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Fig. 2.6 <span class="s12">Comparison of ACR TI-RADS and AI TI-RADS</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li></ul></li><li data-list-text="•"><p class="s8" style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Echogenicity—only hypoechoic nodules receive points</p><ul id="l21"><li data-list-text="–"><p style="padding-top: 1pt;padding-left: 45pt;text-indent: -19pt;line-height: 110%;text-align: left;">Iso/hyperechoic and nodules that cannot be classified receive 0 points instead of 1 point</p></li></ul></li><li data-list-text="•"><p class="s8" style="padding-left: 25pt;text-indent: -19pt;line-height: 17pt;text-align: left;">Shape</p><ul id="l22"><li data-list-text="–"><p style="padding-top: 1pt;padding-left: 45pt;text-indent: -19pt;line-height: 110%;text-align: left;">Taller than wide nodules receive only 1 point instead of 3 points</p></li></ul></li><li data-list-text="•"><p class="s8" style="padding-left: 25pt;text-indent: -19pt;line-height: 17pt;text-align: left;">Margins</p><ul id="l23"><li data-list-text="–"><p style="padding-top: 1pt;padding-left: 45pt;text-indent: -19pt;text-align: left;">No change</p></li></ul></li><li data-list-text="•"><p class="s8" style="padding-top: 1pt;padding-left: 25pt;text-indent: -19pt;text-align: left;">Echogenic foci</p><ul id="l24"><li data-list-text="–"><p style="padding-top: 1pt;padding-left: 45pt;text-indent: -19pt;text-align: left;">Macrocalcifications receive 0 points instead of 1 point</p></li></ul></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a23">EU-TIRADS</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">The European Thyroid Association (ETA), namely EU-TIRADS, categorizes nodules into five classes from TR1 (no nodules) to TR5, which is the highest risk level (Table <span style=" color: #0000F9;">2.5</span></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">risk stratification system that considers tumor composition, echo genicity, and suspicious US features with recommendations for FNA informed by size cut-offs.</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_135.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:10.3325pt" cellspacing="0"><tr style="height:18pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" colspan="5" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:47pt"><td style="width:61pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:121pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:77pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:61pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:121pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:77pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:46pt"><td style="width:61pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:121pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:77pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:61pt"><td style="width:61pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">TR3</p></td><td style="width:121pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">Ovoid, smooth, iso/ hyperechoic</p><p class="s24" style="padding-left: 4pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">No features of high suspicion</p></td><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Low-risk</p></td><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">&gt;2.0 cm</p></td><td style="width:77pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:61pt"><td style="width:61pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">TR4</p></td><td style="width:121pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">Ovoid, smooth, mildly hypoechoic No features of high suspicion</p></td><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Intermediate- risk</p></td><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">&gt;1.5 cm</p></td><td style="width:77pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:149pt"><td style="width:61pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">TR5</p></td><td style="width:121pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">At least 1 of the following features of high suspicion:</p><ul id="l25"><li data-list-text="•"><p class="s24" style="padding-left: 12pt;text-indent: -8pt;line-height: 14pt;text-align: left;">Irregular shape</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;text-indent: -8pt;text-align: left;">Irregular margins</p></li><li data-list-text="•"><p class="s24" style="padding-left: 4pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">Microcalcifications</p></li><li data-list-text="•"><p class="s24" style="padding-left: 12pt;padding-right: 8pt;text-indent: -8pt;text-align: left;">Marked hypoechogenicity (and solid)</p></li></ul></td><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">High-risk</p></td><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">&gt;1.0 cm</p></td><td style="width:77pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a24">K-TIRADS</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">The  Korean  Thyroid  Imaging  Reporting  and  Data  System (K-TIRADS) is an ultrasound-based risk stratification system for thyroid nodules that was endorsed by the Korean Society of Thyroid Radiology (KSThR) and Korean Thyroid Association (KTA) in 2016. Risk stratification is based on tumor composition, echogenicity, and suspicious US features with FNA informed by size cut-offs (Table <span style=" color: #0000F9;">2.6</span>).</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_136.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.64678pt" cellspacing="0"><tr style="height:18pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" colspan="4" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:61pt"><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:66pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:77pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:75pt"><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-top: 10pt;padding-left: 4pt;text-indent: 0pt;text-align: left;">(3) Pure cyst</p></td><td style="width:66pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:77pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:46pt"><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">Low suspicion (K-TIRADS 3)</p></td><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">Partially cystic or iso/ hyperechoic nodule without any of three suspicious US features</p></td><td style="width:66pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:77pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:149pt"><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">Intermediate suspicion</p><p class="s24" style="padding-left: 4pt;text-indent: 0pt;line-height: 14pt;text-align: left;">(K-TIRADS 4)</p></td><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 24pt;padding-right: 9pt;text-indent: -19pt;line-height: 15pt;text-align: left;">(1) Solid hypoechoic nodule without any of three suspicious US features (<i>microcalcification, nonparallel orientation, spiculated/microlobulated margin</i>) or (2) partially cystic or isohyperechoic nodule with any of three suspicious US features</p></td><td style="width:66pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:77pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:47pt"><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">High suspicion (K-TIRADS 5)</p></td><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">Solid hypoechoic nodule with any of three suspicious US features</p></td><td style="width:66pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:77pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p class="s51" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">a<span class="s52">Not routinely indicated, but may be selectively considered for a spongiform nodule when the nodule size is ≥2 cm and indicated for the therapeutic drain age of the cystic content as well as for diagnosis prior to ablation therapy</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a25">C-TIRADS</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">The Chinese Thyroid Imaging Reporting and Data System (C-TIRADS) is an ultrasound-based risk stratification system for thyroid nodules that was developed by the Superficial Organ and Vascular Ultrasound Group of the Society of Ultrasound in Medi</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_137.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Multiple studies have been done to compare various risk stratifi cation tools, with no one system being demonstrated consistently superior to the others, which may be due to different inclusion criteria, patient populations, and analytic methods.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">In a study that looked at a total of 2000 consecutive thyroid nodules (≥1 cm) in 1802 patients, comparing seven society guide lines, ACR TI-RADS recommended the fewest “unnecessary” (benign) thyroid nodule FNAs at 25.3%, followed by the 2016 AACE/ACE/AME  guidelines  (32.5%),  ATA  (51.7%),  and</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">K-TIRADS (56.9%). K-TIRADS (94.5%) and ATA (89.6%)</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">guidelines were more sensitive than those of the AACE/ACE/ AME (80.4%) and ACR (74.7%), while the latter guidelines were more specific (ACR 67.3%, AACE/ACE/AME 58%, and ATA 33.2%). Table <span style=" color: #0000F9;">2.7 </span>summarizes 2 meta-analyses comparing vari ous risk stratification systems (RSS).</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">An important question that remains is: What is an acceptable rate of missing or postponing the diagnosis of relatively small thyroid cancers between 10 and 15 mm in size? ACR TI-RADS does not recommend FNA for TR4 nodules between 10 and 15 mm. For example, in one study, 17% of nodules with histol ogy proven cancer of size &gt;10 mm, FNA was not recommended by ACR TI-RADS.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_138.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.64668pt" cellspacing="0"><tr style="height:18pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" colspan="4" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:61pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" colspan="4" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:47pt"><td style="width:118pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:121pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:112pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:118pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:121pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:112pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:118pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:121pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:112pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:118pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">AACE/ACE-AME</p></td><td style="width:121pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">17% (4–30)</p></td><td style="width:112pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">93% (87–98)</p></td><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:118pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">EU TI-RADS</p></td><td style="width:121pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">29% (7–52)</p></td><td style="width:112pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">81% (60–100)</p></td><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:118pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">K TI-RADS</p></td><td style="width:121pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">25% (12–39)</p></td><td style="width:112pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">87% (75–99)</p></td><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:105pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" colspan="4" bgcolor="#E2E7F5"><p class="s34" style="padding-left: 4pt;padding-right: 13pt;text-indent: 0pt;text-align: left;">Comments<span class="s24">: 5 head-to-head studies: ACR TI-RADS had higher relative diagnostic odds ratio (DOR) than ATA</span></p><p class="s24" style="padding-left: 4pt;padding-right: 13pt;text-indent: 0pt;text-align: left;">To avoid the bias that arises from the different methodologies of the published reports in a meta-analysis, summary operating measures assumed to be independent of the disease prevalence were used such as DOR, which is the odds of a positive test in those with disease relative to the odds of a positive test in those without disease</p></td></tr><tr style="height:6pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" colspan="4"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:61pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" colspan="4" bgcolor="#C4D0EC"><p class="s24" style="padding-left: 4pt;padding-right: 35pt;text-indent: 0pt;text-align: left;">29 studies; 33,748 nodules with pathological or imaging follow-up Kim PH., et al., <i>Diagnostic performance of four ultrasound risk stratification systems: a systematic review and meta-analysis</i></p><p class="s24" style="padding-left: 4pt;text-indent: 0pt;line-height: 14pt;text-align: left;">2020 Aug;30(8):1159–1168</p></td></tr><tr style="height:32pt"><td style="width:105pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">RSS</p></td><td style="width:185pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" colspan="2" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Median unnecessary FNA (%)</p></td><td style="width:141pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:105pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">ACR TI-RADS</p></td><td style="width:185pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" colspan="2" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">25</p></td><td style="width:141pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:105pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">ATA</p></td><td style="width:185pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" colspan="2" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">52</p></td><td style="width:141pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:105pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">EU TI-RADS</p></td><td style="width:185pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" colspan="2" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">39</p></td><td style="width:141pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:105pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">K TI-RADS</p></td><td style="width:185pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" colspan="2" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">59</p></td><td style="width:141pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:47pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" colspan="4" bgcolor="#E2E7F5"><p class="s34" style="padding-left: 4pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Comments<span class="s24">: When high-risk categories (categories 4–5) were evaluated, no difference was found between RSS. Unnecessary FNA was defined as biopsy-proven benign nodules</span></p></td></tr></table><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_139.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">RADS category along with recommendations for FNA.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: justify;"><a href="https://deckard.duhs.duke.edu/%7Eai-ti-rads/index.html" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 14.5pt;" target="_blank">The  Artificial  Intelligence-optimized  Thyroid  Imaging Reporting and Data System (AI TI-RADS) was developed in 2019    (</a><a href="https://deckard.duhs.duke.edu/%7Eai-ti-rads/index.html" class="s23" target="_blank">https://deckard.duhs.duke.edu/~ai-</a></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">using a data set of 1425 thyroid nodules. This revised AI TI-RADS assigned new point values for eight features, including a simpli fied scheme for some categories (Fig. <span style=" color: #0000F9;">2.6</span>). AI TI-RADS resulted in slightly higher specificity for identifying malignant nodules and recommending fine-needle aspiration (mean increase of 7.6% across eight radiologist readers; <i>P </i>&lt; 0.001).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-left: 10pt;text-indent: 0pt;line-height: 90%;text-align: left;"><a name="a26">Malignancy Risk Estimation of Lesions with AUS/ FLUS</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s10" style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><a href="http://www.gap.kr/thyroidnodule_b3.php" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 14.5pt;" target="_blank">A web-based malignancy risk stratification system using a combi nation of ultrasound characteristics and subcategorized biopsy results for Bethesda III, atypia of undetermined significance/fol licular lesion of undetermined significance (AUS/FLUS) thyroid nodules was developed in 2018 (</a><a href="http://www.gap.kr/thyroidnodule_b3.php" class="s23" target="_blank">http://www.gap.kr/thyroidnod </a>ule_b3.php<span style=" color: #2B2A29;">). This was based on patients enrolled in the Korean Thyroid Study Group multicenter retrospective study and on the cytology reporting system developed by the Korean Endocrine Pathology Thyroid Core Needle Biopsy Study Group. US images from 672 thyroid nodules and biopsy results according to nuclear atypia and architectural atypia were analyzed and a 13-point risk scoring system was developed.</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_140.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">malignancy were demonstrated for patient age &lt;52 years, male sex, nodule size, cystic content (lower odds ratio with higher cystic content), and the presence of additional nodules</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">The tool is easy-to-use and reproducible; however, the only US characteristics it employs are size and composition. Thus, it is best for assigning risk to patient populations rather than indi viduals.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-top: 14pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a27">Thyroid Nodule Malignancy Risk Calculator: Spain</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s10" style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><a href="https://obgynreference.shinyapps.io/calccdt/" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 14.5pt;" target="_blank">A predictive model for the individual risk of malignancy of thy roid nodules was developed and validated using clinical, analyti cal, and ultrasound variables in 2020 (</a><a href="https://obgynreference.shinyapps.io/calccdt/" class="s23" target="_blank">https://obgynreference. </a>shinyapps.io/calccdt/<span style=" color: #2B2A29;">). A retrospective case-control study was carried out in 542 patients with thyroid nodules that underwent thyroidectomy and a predictive model for thyroid cancer risk was devised. In the final model, the independent predictors of risk of malignancy were: male gender, very young or old age, a family history of thyroid cancer, TSH level &gt;4.7 mcU/L, presence of autoimmune thyroiditis, solid composition, hypoechogenicity, irregular or microlobed borders, taller than wide shape, microcal cifications, and suspicious adenopathy. This tool requires exten sive  data  input  and  employs  features  such  as  anti-thyroid antibodies which are not always available nor required when eval uating nodules.</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_141.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 19pt;text-align: left;">Clinical records of all patients with thyroid nodules who underwent ultrasound-guided FNA and operative resection at Cleveland Clinic during 2007–2008 were analyzed. The eight variables with the greatest predictive value were biochemical (thyroid-stimulating hormone), ultrasonographic (shape, echotex ture, and vascularity), and cytologic (nuclear grooves, pseudo- inclusions, cellularity, and presence of colloid). The tool employs vascularity as one of its inputs which is no longer generally used for nodule risk stratification.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a28">The Thyroid Nodule App: TNAPP</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s10" style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><a href="https://aace-thyroid.deontics.com/dwe/int/public/welcome.jsp" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 14.5pt;" target="_blank">TNAPP was developed in 2021 and is an update of the 2016 AACE/AME   guidelines   (</a><a href="https://aace-thyroid.deontics.com/dwe/int/public/welcome.jsp" class="s23" target="_blank">https://aace- </a>dwe/int/public/welcome.jsp<span style=" color: #2B2A29;">). It is a novel interactive web-based tool based on a comprehensive narrative clinical practice guide line that uses clinical, imaging, cytologic, and molecular marker data to guide </span><span class="s8">sequential clinical decision-making</span></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">and  manage  thyroid  nodules.  Simultaneously,  it  calculates malignancy probability ranges based on published data, as well as ACR TI-RADS risk category, when sufficient data is pro vided.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_142.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 45pt;text-indent: 0pt;text-align: left;">Recommending surgery</p><ul id="l26"><li data-list-text="–"><p style="padding-top: 1pt;padding-left: 45pt;text-indent: -19pt;text-align: left;">Considering the use of molecular markers</p></li><li data-list-text="–"><p style="padding-top: 1pt;padding-left: 45pt;text-indent: -19pt;text-align: left;">Repeating FNA</p></li><li data-list-text="–"><p style="padding-left: 45pt;text-indent: -19pt;text-align: left;">Duration of follow-up, if any</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">The inputs used in this tool are: clinical features (a total of 26 clinical features, optional); US features (a total of 36 fea tures). Size, composition, and echogenicity are the only data that must be provided for TNAPP to categorize the US as US 1 [low-risk], US 2 [intermediate-risk], or US 3 [high risk]); cytol ogy features (a combined total of 45 options from which to select). These are comprised of required Bethesda categories (I-VI) (6), optional subcategories (33), or a combination of a main category and a subcategory (6) and molecular marker data can be used.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Table <span style=" color: #0000F9;">2.8 </span>summarizes the features of the risk calculators dis cussed  above,  along  with  delineating  their  strengths  and weaknesses. Apart from the BWH thyroid nodule risk estima tor, which does not utilize cytology data, other calculators are subject to the variability in interpretation of US or cytologic features.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="2" height="575" src="Image_143.png"/></span></p><h4 style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Table 2.8 <span class="s53">Thyroid nodule risk calculators</span></h4><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.46365pt" cellspacing="0"><tr style="height:20pt"><td style="width:203pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s54" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Inputs</p></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s54" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Outputs</p></td><td style="width:109pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s54" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Link</p></td><td style="width:220pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s54" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Comments</p></td></tr><tr style="height:118pt"><td style="width:203pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s55" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">ACR TI-RADS and AI TI-RADS<span class="s54">:</span></p><ul id="l27"><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Composition</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Echogenicity</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Shape</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Margin</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Echogenic foci</p></li></ul></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><ul id="l28"><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Total points</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">TI-RADS score</p></li><li data-list-text="•"><p class="s54" style="padding-left: 16pt;padding-right: 15pt;text-indent: 0pt;text-align: left;">Recommendation for FNA</p></li></ul></td><td style="width:109pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="padding-left: 3pt;padding-right: 25pt;text-indent: 0pt;text-align: left;"><a href="https://tiradscalculator.com/" class="s56" target="_blank">https:// tiradscalculator. </a><a href="https://deckard.duhs.duke.edu/%7Eai-ti-rads/index.html" class="s56" target="_blank">com/ https://deckard. duhs.duke. edu/~ai-ti-rads/</a></p><p style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;"><a href="https://deckard.duhs.duke.edu/%7Eai-ti-rads/index.html" class="s56">index.html</a></p></td><td style="width:220pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Most widely used US risk calculator, particularly among radiologists</p><p class="s54" style="padding-left: 3pt;padding-right: 20pt;text-indent: 0pt;text-align: left;">Is restricted to thyroid US features and size (does not consider clinical factors)</p></td></tr><tr style="height:168pt"><td style="width:203pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s55" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Malignancy risk estimation of lesions with AUS/FLUS<span class="s54">:</span></p><ul id="l29"><li data-list-text="•"><p class="s54" style="padding-left: 16pt;padding-right: 49pt;text-indent: 0pt;text-align: left;">Biopsy results (nuclear vs architectural atypia)</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;line-height: 16pt;text-align: left;">Diameter</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Internal content</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Shape</p></li></ul></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><ul id="l30"><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Total score</p></li><li data-list-text="•"><p class="s54" style="padding-left: 16pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">Estimated malignancy risk in %</p></li></ul></td><td style="width:109pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="padding-left: 3pt;text-indent: 0pt;text-align: left;"><a href="http://www.gap.kr/thyroidnodule_b3.php" class="s56" target="_blank">http://www.gap.kr/ thyroidnodule_ b3.php</a></p></td><td style="width:220pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">It is restricted to nodules with AUS/FLUS It provides statistics about the risk of malignancy but not guidance about whether to perform FNA</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="2" height="575" src="Image_144.png"/></span></p><h4 style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Table 2.8 <span class="s53">(continued)</span></h4><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.52803pt" cellspacing="0"><tr style="height:20pt"><td style="width:203pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s54" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Inputs</p></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s54" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Outputs</p></td><td style="width:109pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s54" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Link</p></td><td style="width:220pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s54" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Comments</p></td></tr><tr style="height:201pt"><td style="width:203pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s55" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">The BWH thyroid nodule risk estimator<span class="s54">:</span></p><ul id="l31"><li data-list-text="•"><p class="s54" style="padding-left: 28pt;text-indent: -12pt;line-height: 16pt;text-align: left;">Age at time of diagnosis</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Sex</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Largest diameter</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Cystic content</p></li><li data-list-text="•"><p class="s54" style="padding-left: 22pt;text-indent: -6pt;text-align: left;">Additional nodules (≥1 cm)</p></li></ul></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Risk of malignancy in</p><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">%</p></td><td style="width:109pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><a href="https://thyroidcancerrisk.brighamandwomens.org/" class="s56" target="_blank">https:// thyroidcancerrisk. brighamandwomens. org/</a></p></td><td style="width:220pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Strengths:</p><p class="s54" style="padding-left: 3pt;padding-right: 21pt;text-indent: 0pt;text-align: justify;">Simple, reproducible (due to relatively objective data used as inputs), and best suited for populations</p><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">Weaknesses:</p><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">By only employing a limited amount of reproducible data, it is best suited for evaluating risk of malignancy in populations rather than individual patients</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse" cellspacing="0"><tr style="height:35pt"><td style="width:203pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" colspan="2" bgcolor="#E2E7F5"><p class="s55" style="padding-left: 3pt;padding-right: 33pt;text-indent: 0pt;text-align: left;">Thethyroidnodulemalignancyrisk calculator—Spain</p></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" rowspan="2" bgcolor="#E2E7F5"><ul id="l32"><li data-list-text="•"><p class="s54" style="padding-left: 16pt;padding-right: 15pt;text-indent: 0pt;text-align: left;">Riskofmalignancy in%</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;line-height: 16pt;text-align: left;">FNA</p></li></ul><p class="s54" style="padding-left: 16pt;text-indent: 0pt;text-align: left;">recommendations</p></td><td style="width:109pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" rowspan="2" bgcolor="#E2E7F5"><p style="padding-left: 3pt;padding-right: 23pt;text-indent: 0pt;text-align: left;"><a href="https://obgynreference.shinyapps.io/calccdt/" class="s56" target="_blank">https:// obgynreference. shinyapps.io/ calccdt/</a></p></td><td style="width:220pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" rowspan="2" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Requires data such as anti-thyroid antibodies which are not routinely performed in the evaluation of thyroid nodules</p></td></tr><tr style="height:234pt"><td style="width:101pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s55" style="padding-left: 3pt;padding-right: 18pt;text-indent: 0pt;text-align: left;">Patient characteristics<span class="s54">:</span></p><ul id="l33"><li data-list-text="•"><p class="s54" style="padding-left: 22pt;text-indent: -6pt;line-height: 16pt;text-align: left;">Age</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Sex</p></li><li data-list-text="•"><p class="s54" style="padding-left: 16pt;padding-right: 3pt;text-indent: 0pt;text-align: left;">Family history of thyroid cancer (first degree relatives)</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;line-height: 16pt;text-align: left;">TSH</p></li></ul></td><td style="width:102pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s55" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Nodule characteristics<span class="s54">:</span></p><ul id="l34"><li data-list-text="•"><p class="s54" style="padding-left: 16pt;padding-right: 25pt;text-indent: 0pt;text-align: left;">Maximum diameter</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;line-height: 16pt;text-align: left;">Content</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Echogenicity</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Margins</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Calcifications</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Shape</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Suspicious</p></li></ul></td></tr></table><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><span style=" color: black; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; vertical-align: 78pt;">	</span><span><img width="2" height="563" src="Image_145.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="2" height="575" src="Image_146.png"/></span></p><table style="border-collapse:collapse" cellspacing="0"><tr style="height:20pt"><td style="width:203pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" colspan="2" bgcolor="#C4D0EC"><p class="s54" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Inputs</p></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s54" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Outputs</p></td><td style="width:109pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s54" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Link</p></td><td style="width:220pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s54" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Comments</p></td></tr><tr style="height:19pt"><td style="width:203pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" colspan="2" bgcolor="#E2E7F5"><p class="s55" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Cleveland Clinic calculat<span class="s54">:</span>or</p></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" rowspan="2" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Probability of thyroid cancer (%)</p></td><td style="width:109pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" rowspan="2" bgcolor="#E2E7F5"><p style="padding-left: 3pt;padding-right: 8pt;text-indent: 0pt;text-align: left;"><a href="https://riskcalc.org/ThyroidCancer/" class="s56" target="_blank">https://riskcalc.org/ ThyroidCancer/</a></p></td><td style="width:220pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" rowspan="2" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Employs vascularity, which is no long recognized as a key determinant of thyroid malignancy</p></td></tr><tr style="height:201pt"><td style="width:101pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><ol id="l35"><li data-list-text="(a)"><p class="s54" style="padding-left: 26pt;text-indent: -22pt;text-align: left;">FNA—No:</p><ul id="l36"><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Shape</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -6pt;text-align: left;">Vascularity</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">TSH</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Echo texture</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -6pt;text-align: left;">Age</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Margin</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Tumor size</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Calcification</p></li></ul></li></ol></td><td style="width:102pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><ol id="l37"><li data-list-text="b)"><p class="s54" style="padding-left: 17pt;text-indent: -13pt;text-align: left;">FNA—Yes:</p><ul id="l38"><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Shape</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -6pt;text-align: left;">Vascularity</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">TSH</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Echo texture</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Calcification</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;text-align: left;">Grooves</p></li><li data-list-text="•"><p class="s54" style="padding-left: 16pt;padding-right: 34pt;text-indent: 0pt;text-align: left;">Pseudo- inclusions</p></li><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;line-height: 16pt;text-align: left;">Cellularity</p></li></ul></li></ol></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><h4 style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Table 2.8 <span class="s53">(continued)</span></h4><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s53" style="padding-top: 10pt;text-indent: 0pt;text-align: right;">er</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse" cellspacing="0"><tr style="height:18pt"><td style="width:203pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s55" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">TNAPP<span class="s54">:</span></p></td><td style="width:128pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><ul id="l39"><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;line-height: 16pt;text-align: left;">Eligibility for using</p></li></ul></td><td style="width:109pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;"><a href="https://aace-thyroid.deontics.com/dwe/int/public/welcome.jsp" class="s56">https://aace-thyroid.</a></p></td><td style="width:220pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">Strengths:</p></td></tr><tr style="height:17pt"><td style="width:203pt;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">(a) Clinical features</p></td><td style="width:128pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 16pt;text-indent: 0pt;line-height: 16pt;text-align: left;">TNAPP</p></td><td style="width:109pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;"><a href="https://aace-thyroid.deontics.com/dwe/int/public/welcome.jsp" class="s56">deontics.com/dwe/</a></p></td><td style="width:220pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">Interactive, comprehensive, paralleling</p></td></tr><tr style="height:17pt"><td style="width:203pt;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">(b) US features</p></td><td style="width:128pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><ul id="l40"><li data-list-text="•"><p class="s54" style="padding-left: 22pt;text-indent: -6pt;line-height: 16pt;text-align: left;">AACE US category</p></li></ul></td><td style="width:109pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;"><a href="https://aace-thyroid.deontics.com/dwe/int/public/welcome.jsp" class="s56">int/public/welcome.</a></p></td><td style="width:220pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">CPG guidance</p></td></tr><tr style="height:17pt"><td style="width:203pt;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">(c) Cytology features</p></td><td style="width:128pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><ul id="l41"><li data-list-text="•"><p class="s54" style="padding-left: 22pt;text-indent: -6pt;line-height: 16pt;text-align: left;">AACE clinical</p></li></ul></td><td style="width:109pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;"><a href="https://aace-thyroid.deontics.com/dwe/int/public/welcome.jsp" class="s56">jsp</a></p></td><td style="width:220pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">Integrates clinical, sonographic, and</p></td></tr><tr style="height:17pt"><td style="width:203pt;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:128pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 16pt;text-indent: 0pt;line-height: 16pt;text-align: left;">category</p></td><td style="width:109pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:220pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">cytologic variables together to assess risk</p></td></tr><tr style="height:17pt"><td style="width:203pt;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:128pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><ul id="l42"><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;line-height: 16pt;text-align: left;">FNA</p></li></ul></td><td style="width:109pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:220pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">Limited data required for each</p></td></tr><tr style="height:17pt"><td style="width:203pt;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:128pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 16pt;text-indent: 0pt;line-height: 16pt;text-align: left;">recommendations</p></td><td style="width:109pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:220pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">recommendation</p></td></tr><tr style="height:17pt"><td style="width:203pt;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:128pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><ul id="l43"><li data-list-text="•"><p class="s54" style="padding-left: 22pt;text-indent: -6pt;line-height: 16pt;text-align: left;">ACR TI-RADS risk</p></li></ul></td><td style="width:109pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:220pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">Guides the clinician at various stages:</p></td></tr><tr style="height:17pt"><td style="width:203pt;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:128pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 16pt;text-indent: 0pt;line-height: 16pt;text-align: left;">category</p></td><td style="width:109pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:220pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">Eligibility to use the application, FNA and</p></td></tr><tr style="height:17pt"><td style="width:203pt;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:128pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><ul id="l44"><li data-list-text="•"><p class="s54" style="padding-left: 22pt;text-indent: -6pt;line-height: 16pt;text-align: left;">ACR TI-RADS</p></li></ul></td><td style="width:109pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:220pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">follow-up advice, post-FNA advice</p></td></tr><tr style="height:17pt"><td style="width:203pt;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:128pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 16pt;text-indent: 0pt;line-height: 16pt;text-align: left;">biopsy advice</p></td><td style="width:109pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:220pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">Modifies recommendations as more</p></td></tr><tr style="height:17pt"><td style="width:203pt;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:128pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><ul id="l45"><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;line-height: 16pt;text-align: left;">Probability of</p></li></ul></td><td style="width:109pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:220pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">information is provided</p></td></tr><tr style="height:17pt"><td style="width:203pt;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:128pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 16pt;text-indent: 0pt;line-height: 16pt;text-align: left;">cancer (%)</p></td><td style="width:109pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:220pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">Weaknesses:</p></td></tr><tr style="height:17pt"><td style="width:203pt;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:128pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><ul id="l46"><li data-list-text="•"><p class="s54" style="padding-left: 23pt;text-indent: -7pt;line-height: 16pt;text-align: left;">If FNA available,</p></li></ul></td><td style="width:109pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:220pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">Requires familiarity with the user</p></td></tr><tr style="height:17pt"><td style="width:203pt;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:128pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 16pt;text-indent: 0pt;line-height: 16pt;text-align: left;">recommendations on</p></td><td style="width:109pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:220pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">interface</p></td></tr><tr style="height:17pt"><td style="width:203pt;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:128pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 16pt;text-indent: 0pt;line-height: 16pt;text-align: left;">molecular testing,</p></td><td style="width:109pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:220pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">Creation of an account login is necessary</p></td></tr><tr style="height:19pt"><td style="width:203pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:128pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 16pt;text-indent: 0pt;line-height: 16pt;text-align: left;">surgery, follow-up</p></td><td style="width:109pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:220pt;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 16pt;text-align: left;">but is easy to do</p></td></tr></table><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><span style=" color: black; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; vertical-align: 137pt;">	</span><span><img width="2" height="563" src="Image_147.png"/></span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_148.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.64678pt" cellspacing="0"><tr style="height:18pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:177pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:174pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:61pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:177pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:174pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:18pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:177pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:174pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:76pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:177pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-top: 10pt;padding-left: 4pt;text-indent: 0pt;text-align: left;">highly suspicious</p></td><td style="width:174pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-top: 11pt;padding-left: 4pt;text-indent: 0pt;text-align: left;">(as it is</p></td></tr><tr style="height:76pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">AI</p><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">TI-RADS</p></td><td style="width:177pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;padding-right: 28pt;text-indent: 0pt;text-align: left;">Score 7 (3 for composition + 2 for</p><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">echogenicity + 2 for borders); highly suspicious</p></td><td style="width:174pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-top: 1pt;padding-left: 4pt;text-indent: 0pt;text-align: left;">No FNA (as it is</p><p class="s24" style="padding-left: 4pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">consider FNA after shared decision-making; if no FNA, follow annually for 5 years (as it is</p></td></tr><tr style="height:32pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">EU</p><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">TI-RADS</p></td><td style="width:177pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">TR 5; high risk</p></td><td style="width:174pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Consider FNA or active surveillance</p></td></tr><tr style="height:32pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">K TI-RADS</p></td><td style="width:177pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">K TI-RADS 5; high</p><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">suspicion</p></td><td style="width:174pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-top: 1pt;padding-left: 4pt;text-indent: 0pt;text-align: left;">No FNA (as it is</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-top: 11pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a29">Case Conclusion:</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">FNA of the patient’s 0.9 × 0.7 × 0.9 cm posterior right mid- nodule was performed, and cytology was consistent with papillary thyroid carcinoma (Bethesda category VI). She then underwent right hemithyroidectomy and pathology showed a 1.2 cm, unifocal, conventional papillary thyroid carcinoma with focal lymphovascu lar invasion and positive BRAF-V600E mutation.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">This case highlights the discrepancy between recommenda tions, based on inclusion or exclusion of clinical features and vari ability in US size cut-offs informing guidance regarding FNA (Table <span style=" color: #0000F9;">2.9</span>).</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_149.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 10pt;padding-left: 30pt;text-indent: 0pt;text-align: justify;">RG, Tessler FN, Mazurowski MA. Using artificial intelligence to revise ACR TI-RADS risk stratification of thyroid nodules: diagnostic accuracy and utility. Radiology. 2019;292(1):112–9. PMID: 31112088.</p><p style="padding-left: 385pt;text-indent: 0pt;text-align: left;"><span><a href="http://crossmark.crossref.org/dialog/?doi=10.1007/978-3-031-18448-2_3&amp;domain=pdf"><img width="69" height="61" src="Image_150.png"/></a></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s11" style="padding-left: 19pt;text-indent: 0pt;text-align: left;">Key Points</p><ul id="l47"><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Biopsy of neck masses is safe, can be done on an outpa tient basis, and provides valuable diagnostic informa tion.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Thyroid FNA is best performed with 25G or 27G needles using capillary action, rather than active aspiration. Aspiration is only necessary when limited specimens are obtained with the capillary technique.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">In a heterogeneous thyroid nodule, aspirates should be obtained from different regions. In particular, hypoechoic areas should be specifically targeted.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Core biopsies may be necessary for indeterminate lymph nodes, or unusual head, neck, and salivary gland masses.</p></li></ul><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="226" height="1" src="Image_151.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_152.png"/></span></p><p class="s12" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">B. Sacks (<span class="s13">*</span>)</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Department of Radiology, Beth Israel Deaconess Medical Center,</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Boston, MA, USA</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><a href="mailto:bsacks@bidmc.harvard.edu" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">e-mail: </a><a href="mailto:bsacks@bidmc.harvard.edu" target="_blank">bsacks@bidmc.harvard.edu</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">© The Author(s), under exclusive license to Springer Nature Switzerland AG 2023</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">L. S. Eldeiry et al. (eds.), <i>Handbook of Thyroid and Neck Ultrasonography</i><a href="https://doi.org/10.1007/978-3-031-18448-2_3" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">, Contemporary Endocrinology, </a><a href="https://doi.org/10.1007/978-3-031-18448-2_3" target="_blank">https://doi.org/10.1007/978-3-031-18448-2_3</a></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_153.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><span><img width="575" height="177" src="Image_154.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_155.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a30">Introduction</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">This chapter discusses the practical aspects of fine needle aspira tion (FNA) and core biopsies of a spectrum of neck lesions, including thyroid nodules, technical suggestions to obtain optimal samples, and several miscellaneous tips. A successful FNA alone will frequently establish the diagnosis in the majority of cervical lesions, is simple and safe to perform. For some lesions, perform ing both FNA and core biopsy at the initial procedure provides the most expeditious diagnosis and management.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Recommendations in the following sections dealing with spe cific organs or disease processes will include:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l48"><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">When to pursue FNA alone versus when core biopsies are war ranted.</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">The number and type of specimens to be collected based on the potential diagnoses.</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">The various media or fluids in which specimens should be sub mitted.</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Biopsy pitfalls and complications.</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a31">Case Presentation</a></h3><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">A 52-year-old woman underwent total thyroidectomy for multifo cal, bilateral papillary thyroid carcinoma (PTC), and parathyroid exploration for primary hyperparathyroidism. Four glands were</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_156.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">showed normal thyroid tissue. The PTH level was 4270 pg/mL from the left thyroid bed lesion. This confirmed a diagnosis of right thyroid remnant and a left-sided parathyroid adenoma. She</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="156" alt="Two scanned images illustrate the locations of parathyroid adenoma on both the left and right sides of the thyroid. It is confirmed through the 4 D C T Technique. " title="Two scanned images illustrate the locations of parathyroid adenoma on both the left and right sides of the thyroid. It is confirmed through the 4 D C T Technique. " src="Image_157.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 3.1  <span class="s12">4DCT demonstrating 2 enhancing lesions, one on each side (arrows), possibly representing 2 parathyroid adenomas</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="144" alt="Two ultrasound for the presence of two areas of enhancement in the left thyroid bed and in the right thyroid bed. The labels in the ultrasounds are Carotid and Trachea." title="Two ultrasound for the presence of two areas of enhancement in the left thyroid bed and in the right thyroid bed. The labels in the ultrasounds are Carotid and Trachea." src="Image_158.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;"><span class="s17">Fig. 3.2  </span>Ultrasound confirmed the lesions: The left-sided lesion was well- defined, hypoechoic and vascular, consistent with a parathyroid adenoma (right panel, arrow). The right-sided lesion was less well-defined and had low-level internal echoes (left panel, arrow), but also vascular, consistent with either a parathyroid adenoma or thyroid remnant. The differential diagnosis of these lesions is indicated in Table <span style=" color: #00F;">3.1</span>. FNA of both lesions was performed</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_159.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="71" src="Image_160.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="156" alt="Two scanned images represent the needle shaft in the left and right-sided lesion with arrows. Carotid is marked on the scans." title="Two scanned images represent the needle shaft in the left and right-sided lesion with arrows. Carotid is marked on the scans." src="Image_161.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Fig. 3.3 <span class="s12">Arrows indicating needle shaft in the right-sided lesion (right panel) and left-sided lesion (right panel)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="198" alt="Two images of the parathyroid adenoma on the left and a magnified version of the cells and adipocytes on the right." title="Two images of the parathyroid adenoma on the left and a magnified version of the cells and adipocytes on the right." src="Image_162.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Fig. 3.4  <span class="s12">Left panel: Parathyroid adenoma. There is a well-circumscribed lesion comprised predominantly of chief cells and oxyphilic cells with reduced stromal adipocytes (H&amp;E, 4×). Right panel: Higher magnification of chief cells and scattered adipocytes at one of the edges of the adenoma (H&amp;E, 10×)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">underwent a unilateral neck exploration and successful left para thyroidectomy (Fig. <span style=" color: #00F;">3.4</span>), which cured the hyperparathyroidism. She continues routine ultrasound (US) follow-up for the papillary thyroid cancer.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_163.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">able that allow single handed aspiration (Fig.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="437" height="409" src="Image_164.png"/></span></p><p class="s59" style="text-indent: 0pt;text-align: left;">a</p><p style="text-indent: 0pt;text-align: left;"/><p class="s59" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s17" style="padding-top: 4pt;padding-left: 7pt;text-indent: 0pt;text-align: justify;">Fig. 3.5 <span class="s12">Example of an aspiration device used single handed. (</span></p><p class="s12" style="padding-left: 7pt;text-indent: 0pt;text-align: justify;">placed in device, in neutral position. Needle attached and introduced into lesion. (<b>b</b>) By pulling on the trigger, the plunger is withdrawn, creating suction. Device/syringe removed and specimen expressed into Cytolyt or a smear made</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_165.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s60" style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><span><img width="185" height="134" alt="A 3-part illustration of different types of core biopsy needles and their operations. Photos of four core biopsy needles are exhibited on the left. The illustration in the middle exhibits the notch in the inner core and the outer spring-loaded metallic sheath. The illustration on the right exhibit two core biopsy needles advancing into the lesion." title="A 3-part illustration of different types of core biopsy needles and their operations. Photos of four core biopsy needles are exhibited on the left. The illustration in the middle exhibits the notch in the inner core and the outer spring-loaded metallic sheath. The illustration on the right exhibit two core biopsy needles advancing into the lesion." src="Image_166.jpg"/></span> <span><img width="382" height="136" alt="A 3-part illustration of different types of core biopsy needles and their operations. Photos of four core biopsy needles are exhibited on the left. The illustration in the middle exhibits the notch in the inner core and the outer spring-loaded metallic sheath. The illustration on the right exhibit two core biopsy needles advancing into the lesion." title="A 3-part illustration of different types of core biopsy needles and their operations. Photos of four core biopsy needles are exhibited on the left. The illustration in the middle exhibits the notch in the inner core and the outer spring-loaded metallic sheath. The illustration on the right exhibit two core biopsy needles advancing into the lesion." src="Image_167.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">outer metallic sheath is fired, slicing off the specimen (red arrows). The nee dles vary in caliber (13G–21G) and the notch varies from 11 to 22 mm in length. As expected, the larger the needle and the longer the notch, the larger the specimen</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 19pt;text-align: left;">Multiple companies supply core biopsy devices with needle gauges from 11G to 21G. For neck lesions, 18G-21G needles are adequate. Most core biopsy devices have 2 important compo nents: a sharp inner core containing a notch and a spring-loaded outer sleeve. The inner core is initially advanced into the lesion (manually or automatically). The tissue specimen prolapses into the notch. The outer core is then fired, slicing off the specimen. The notch size varies in depth and length. There are several designs (Fig. <span style=" color: #00F;">3.6</span>).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_168.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a32">Solutions and Media</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">The FNA and core biopsy specimens are submitted in different solutions and media for optimal specimen preservation (Fig.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_169.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="259" alt="A photograph of some F N A and core biopsy specimens solutions." title="A photograph of some F N A and core biopsy specimens solutions." src="Image_170.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 3.7 <span class="s12">Standard solutions for FNA and core biopsy specimens</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_171.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a33">Thyroid Nodule Biopsy</a></h1><ul id="l49"><li data-list-text="•"><p style="padding-top: 17pt;padding-left: 25pt;text-indent: -19pt;text-align: left;">FNA specimens are submitted in Cytolyt solution (methanol- based solution, Cytyc Corporation). If separate smears are made, the slides are placed in 95% alcohol for PAP stain or are air-dried for Wright-Giemsa stain. When molecular markers are needed, the specimen is submitted in a special medium provided by the company (ThyroSeq, Afirma, etc.). Core biop sies are infrequently indicated.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_172.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a34">Lymph Node</a></h1></li><li data-list-text="•"><p style="padding-top: 17pt;padding-left: 25pt;text-indent: -19pt;text-align: justify;">Specimens required will depend on lymph node location and suspected pathology.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">For thyroid cancer: Cytology is collected in CytoLyt solution, and needle washings in 1 cc (mL) of normal saline (N/S) are sent for Thyroglobulin measurement.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">For head and neck tumor: Cytology is collected in CytoLyt solution; core biopsy specimen in 10% buffered formalin may be necessary.</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_173.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="142" alt="Two scanned images of the sagittal view of the left thyroid lobe and the performance of F N A lesion. The first scan represents the thyroid nodule and intra-thyroidal parathyroid upper pole on the left. The second scan exhibit Trans isthmic F N A for P T H and cytology." title="Two scanned images of the sagittal view of the left thyroid lobe and the performance of F N A lesion. The first scan represents the thyroid nodule and intra-thyroidal parathyroid upper pole on the left. The second scan exhibit Trans isthmic F N A for P T H and cytology." src="Image_174.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="•"><p style="padding-top: 4pt;padding-left: 30pt;text-indent: -19pt;text-align: left;">Suspected lymphoma: Cytology is collected in CytoLyt solu tion and flow cytometry in RPMI medium (Roswell Park Memorial Institute).</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">If core biopsies are obtained (18G or larger), specimens are collected in 10% buffered formalin for pathology and addi tional samples in RPMI for cytogenetics.</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;line-height: 107%;text-align: justify;">For suspected parathyroid adenoma: PTH sample is collected in ½ to 1 cc N/S. If the lesion is intrathyroidal, add cytology in Cytolyt solution (in case the PTH is negative, cytology will establish the nature of the intrathyroidal nodule) (Fig.</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_175.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a35">Biopsy Techniques</a></h1><h2 style="padding-top: 15pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a36">Preparation</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Protocols vary from institution to institution and between inpa tient and outpatient sites. Teaching institutions usually require gown, mask, gloves, and the transducer in a sterile sheath. However, for outpatient sites, simple protocols may be more prac tical. After standard skin preparation with a sterile solution, the ultrasound probe is wiped with absolute alcohol to prevent infec tion. This measure has been proven safe and effective.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_176.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">lesions, particularly core biopsies, standard local anesthesia is generously used.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-top: 13pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a37">US Guidance Techniques (Fig. </a><span class="s19">3.9</span>)</h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="572" height="132" alt="A group of 3 illustrations and a photo exhibit the ultrasound guidance techniques." title="A group of 3 illustrations and a photo exhibit the ultrasound guidance techniques." src="Image_177.jpg"/></span></p><p class="s59" style="text-indent: 0pt;text-align: left;">a</p><p style="text-indent: 0pt;text-align: left;"/><p class="s59" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s59" style="text-indent: 0pt;text-align: left;">c</p><p style="text-indent: 0pt;text-align: left;"/><p class="s59" style="text-indent: 0pt;text-align: left;">d</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;"><span class="s17">Fig. 3.9  </span>The  diagrams  above  demonstrate  two  optional  approaches  to ultrasound-guided FNA. (<b>a</b>) Demonstrates the needle approach from the side of the transducer, allowing continuous visualization of the needle from skin, through the subcutaneous tissue, and into the nodule (US field between the two thin vertical lines). This also allows accurate targeting of specific areas within the nodule. (<b>b</b>) Demonstrates the puncture from a site in the middle of the transducer. (<b>c</b>) Is a view from the narrow side, also demonstrated in image</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">(<b>d</b>) With this approach, the needle cannot be seen until the tip enters the ultra sound beam path within the target, usually as a single high reflective echo. Many clinicians prefer this approach but its main value is in ultrasound- guided vascular access</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_178.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">bruising.</p><ul id="l50"><li data-list-text="•"><p style="padding-top: 1pt;padding-left: 30pt;text-indent: -19pt;line-height: 110%;text-align: justify;">Sometimes the lateral approach is necessary, particularly when the target nodule is in the posterior and medial aspect of the lobe, limiting adequate access from the opposite side.</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 18pt;text-indent: 0pt;text-align: left;"><span><img width="551" height="134" alt="Three scanned images of the thyroid nodule and performance of the trans-isthmic F N A. The first scan is labeled Transverse left mid-pole. The second scan is labeled Doppler with a few parts highlighted. The third scan is labeled F N A and has three arrows." title="Three scanned images of the thyroid nodule and performance of the trans-isthmic F N A. The first scan is labeled Transverse left mid-pole. The second scan is labeled Doppler with a few parts highlighted. The third scan is labeled F N A and has three arrows." src="Image_179.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Fig. 3.10  <span class="s12">Left, middle panels: Large, hypoechoic and hypervascular left thy roid nodule. Right: Trans-isthmic FNA performed, with the entire length of the needle visible (arrows)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="570" height="113" src="Image_180.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Fig. 3.11  <span class="s12">Left and middle panels: Suspicious lesion in the right thyroid lobe, taller than wide (arrow, left), with microcalcifications. Trans-isthmic FNA was performed. Right panel: Posterior lesion on the left thyroid. FNA access is better from a lateral approach</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_181.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s16" style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="194" src="Image_182.png"/></span>	<span><img width="242" height="186" src="Image_183.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">plunger is reintroduced (A2) and the specimen is ejected onto a slide or into CytoLyt solution. Standard aspiration technique. B1: The needle, attached to a syringe, is advanced into the lesion, suction is applied during a forward and back movement. B2: The specimen is then ejected onto a slide or irrigated into CytoLyt solution</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="583" height="139" alt="Three scanned images of the intrathyroidal nodule and the F N A done with the specimens. The first scan is labeled Transverse right mid to lower pole. The second scan is labeled sagittal right lobe. The third scan has an arrow pointing to a dark area, labeled F N A." title="Three scanned images of the intrathyroidal nodule and the F N A done with the specimens. The first scan is labeled Transverse right mid to lower pole. The second scan is labeled sagittal right lobe. The third scan has an arrow pointing to a dark area, labeled F N A." src="Image_184.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 3.13  <span class="s12">Left, middle panels: Patient with hyperparathyroidism and a suspi cious intrathyroidal nodule that may represent either thyroid vs parathyroid. Right panel: FNA (arrow) done with specimens sent for cytology and PTH. The PTH was &gt;5000 pg/mL (measurement of thyroglobulin is not help ful in this case because the needle has to pass through thyroid tissue to access the lesion)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l51"><li data-list-text="•"><p style="padding-top: 11pt;padding-left: 25pt;text-indent: -19pt;text-align: left;">It is advisable to obtain 3–4 separate samples for thyroid FNA using new 25G needles for each pass and to target different regions within the same nodule. Sampling the most heteroge neous and/or hypoechoic area is advised, as it is likely to be the most de-differentiated.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Capillary action vs active aspiration: For the capillary tech nique, the syringe plunger is removed and a 25G needle is attached only to the syringe barrel. On entering the nodule, the</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_185.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="132" alt="Four scanned images. The first 2 images is of the neck and a small focus. The third and fourth images exhibit the presence of the lesion and its F N A." title="Four scanned images. The first 2 images is of the neck and a small focus. The third and fourth images exhibit the presence of the lesion and its F N A." src="Image_186.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Right panel: FNA of the lesion (arrow) with PTH measurement demonstrated marked PTH elevation, confirming a parathyroid adenoma</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">needle/syringe barrel combination is moved back and forth a few times, then removed. The plunger is reinserted and the specimen is either smeared on a slide or irrigated into ThinPrep CytoLyt solution. In active aspiration compared to capillary action, the likelihood of a moderately bloody specimen is increased, diluting the cellular component. Aspiration is neces sary when the initial passes yield limited material.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_187.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a38">FNA Specimens</a></h1><ul id="l52"><li data-list-text="•"><p style="padding-top: 17pt;padding-left: 30pt;text-indent: -19pt;text-align: left;">Some institutions have the benefit of having a cytologist on hand to immediately prepare and review the adequacy of the specimen. At most non-academic sites, this service is not avail able and samples need to be transported to the laboratory. As a result, excellent technique and specimen handling are impera tive to getting a diagnostic specimen.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_188.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a39">Molecular Markers</a></h1></li><li data-list-text="•"><p style="padding-top: 17pt;padding-left: 30pt;text-indent: -19pt;text-align: left;">When the cytology is indeterminate, repeat FNA for molecular markers may be performed (see indications in the chapter ded icated to this topic).</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_189.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 25pt;text-indent: 0pt;text-align: left;">FNA will miss the targeted area.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_190.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a40">Thyroid Cyst Aspiration and Sclerosis</a></h1></li></ul></li><li data-list-text="•"><p style="padding-top: 17pt;padding-left: 25pt;text-indent: -19pt;text-align: left;">Patients with large thyroid cysts may require aspiration to relieve pressure symptoms or treat a prominent visible nodule. The cysts may be simple or complex (solid and cystic). The cystic component often originates from spontaneous (often painless) hemorrhage into a spongiform nodule, with the fluid containing low-level echoes on US or dependent echogenic material (usu ally due to debris, proteinaceous or blood). The reason for spon giform lesions spontaneously bleeding is still unclear.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: left;">The presence of a solid component requires FNA for cytologic evaluation before contemplating sclerosis of the cyst.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Recurrence rates after cyst aspiration alone are about 70%.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">Lastly, if acute or subacute hemorrhage is detected, aspiration/ sclerosis should be delayed for 6–12 weeks to allow the original bleeding site to heal. Premature aspiration often results in re-bleeding and re-accumulation into the cyst.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_191.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a41">Procedure</a></h1><p style="padding-top: 17pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Aspiration: The initial setup is identical to thyroid nodule FNA. Following administration of local anesthesia, a 21G needle is advanced into the cyst and aspiration is performed. If the fluid is too viscous, a larger (18G) needle may be required. If the fluid is still too viscous, gentle repeated irrigation with small volumes</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_192.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">that a repeat procedure may be required.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_193.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a42">Lymph Node Aspiration</a></h1><ul id="l53"><li data-list-text="•"><p style="padding-top: 17pt;padding-left: 30pt;text-indent: -19pt;text-align: left;">FNA/biopsy technique for lymph nodes is strongly influenced by the patient’s clinical presentation. If there is a known his tory of or current thyroid malignancy, nodal FNA is done to exclude metastatic disease, or during pre-operative assess ment, to guide the surgical approach.</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Confirmed pathologic lateral neck lymph nodes warrant a lat eral neck dissection, in addition to total thyroidectomy. Elevated thyroglobulin post-thyroidectomy demands a careful search for nodal metastases.</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Lymph node biopsy involves 25–27G US-guided active FNA (1–2 passes), with samples submitted for cytology and thyro globulin washout (needle irrigated into 1–2 cc saline and sub mitted in a red top tube).</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Suspicious nodes in the absence of a thyroid cancer history are submitted for cytology (to exclude thyroid or other neck malig nancy), thyroglobulin, and flow cytometry (in RPMI solution), to exclude lymphoma.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_194.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a43">FNA vs Core Biopsy</a></h1></li><li data-list-text="•"><p style="padding-top: 17pt;padding-left: 30pt;text-indent: -19pt;text-align: left;">In general, in most neck lesions, FNA alone is performed as the first step, with the decision to perform core biopsy depend ing on cytology results.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_195.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="130" src="Image_196.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li></ul></li><li data-list-text="•"><p style="padding-top: 4pt;padding-left: 25pt;text-indent: -19pt;text-align: justify;">If lymphoma is suspected based on initial cytology and flow cytometry results, core biopsies will be needed for pathology and cytogenetics, to more accurately characterize the lesion for treatment purposes.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">Surgical excision may occasionally be required to obtain ade quate tissue for more sophisticated molecular studies.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;line-height: 110%;text-align: left;">For salivary gland masses, both FNA and core biopsies can be performed at the initial biopsy procedure. An acceptable alter native would be to perform the FNA for cytology and follow- up  core  only  if  indicated  based  on  the  cytology result (Fig. <span style=" color: #00F;">3.15</span>).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_197.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a44">Parathyroid Adenomas</a></h1></li><li data-list-text="•"><p style="padding-top: 17pt;padding-left: 25pt;text-indent: -19pt;text-align: left;">The combination of ultrasound and 4DCT can diagnose and localize a single parathyroid adenoma or multi-gland disease in the vast majority of patients with hyperparathyroidism, whether the glands are in an orthotopic (eutopic) or ectopic location. As a result, the need for parathyroid FNA for parathy roid hormone (PTH) is limited to complex cases, including postoperative recurrent or persistent disease that remains unre solved  after  performing  the  usual  imaging techniques. Additional  examples  include  intrathyroidal parathyroid (Fig.  <span style=" color: #00F;">3.8</span>),  or  patients  with  hyperparathyroidism and Hashimoto’s thyroiditis, in whom the presence of reactive lymph nodes near the thyroid gland makes it difficult to dif ferentiate lymph nodes from parathyroid.</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_198.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="575" height="2" src="Image_199.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="•"><p style="padding-top: 13pt;padding-left: 30pt;text-indent: -19pt;text-align: left;">The biopsy approach to these lesions will vary depending on the specific circumstances. In some situations, FNA may ade quately establish the diagnosis, while in others it may be nec essary to obtain a larger core biopsy specimen for pathology (or consider core biopsy if the initial cytology is indeterminate or warrants a larger specimen for diagnosis).</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_200.png"/></span></p><h1 style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a45">Further Reading</a></h1><p class="s12" style="padding-top: 17pt;padding-left: 30pt;text-indent: -19pt;text-align: justify;">Chen C-N, Yang T-L. Review Article: Application of ultrasound-guided core biop head and neck. J Med Ultras. 2014;22(3):133–9.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: justify;">Haugen BR, et al. The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1– 133.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Learned KO, Lev-Toaff AS, Brake BJ, Wu RI, Langer JE, Loevner LA. US- guided biopsy of neck lesions: the head and neck neuroradiologist’s per spective. Radiographics. 2016;36(1):226–43.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: justify;">Pynnonen  MA,  Gillespie  MB,  Roman  B,  Rosenfeld  RM, Tunkel  DE, Bontempo L, et al. Clinical practice guideline: evaluation of the neck mass  in  adults  executive  summary.  Otolaryngol  Head  Neck  Surg. 2017;157(3):355–71.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Singh Nanda KD, Mehta A, Nanda J. Fine-needle aspiration cytology: a reli able tool in the diagnosis of salivary gland lesions. J Oral Pathol Med. 2012;41(1):106–12.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: justify;">Tessler FN, et al. ACR thyroid imaging, reporting and data system (TI- RADS): white paper of the ACR TIRADS committee. J Am Coll Radiol. 2017;14(5):587–95.</p><p style="padding-left: 385pt;text-indent: 0pt;text-align: left;"><span><a href="http://crossmark.crossref.org/dialog/?doi=10.1007/978-3-031-18448-2_4&amp;domain=pdf"><img width="69" height="61" src="Image_201.png"/></a></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s11" style="padding-left: 19pt;text-indent: 0pt;text-align: left;">Key Points</p><ul id="l54"><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: left;">Fine needle aspiration (FNA) is the most valuable screen ing and diagnostic test for thyroid nodules and plays a crucial role in managing patients with thyroid cancer.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">The Bethesda System for Reporting Thyroid Cytopathology classifies aspirates of thyroid nodules into six diagnostic categories.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Each diagnostic category is associated with an evidence- based cancer risk and clinical management guidelines, which are endorsed by the American Thyroid Association.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: left;">Incorporating the clinical and radiologic findings, thy roid FNA allows for a standardized, team-based approach to managing patients with thyroid nodules.</p></li></ul><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="226" height="1" src="Image_202.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_203.png"/></span></p><p class="s12" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">T. H. Kim · J. F. Krane (<span class="s13">*</span>)</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA</p><p class="s58" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;"><a href="mailto:TeresaKim@mednet.ucla.edu" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">e-mail: </a>TeresaKim@mednet.ucla.edu<a href="mailto:jkrane@mednet.ucla.edu" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">; </a><a href="mailto:jkrane@mednet.ucla.edu" target="_blank">jkrane@mednet.ucla.edu</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">© The Author(s), under exclusive license to Springer Nature Switzerland AG 2023</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">L. S. Eldeiry et al. (eds.), <i>Handbook of Thyroid and Neck Ultrasonography</i><a href="https://doi.org/10.1007/978-3-031-18448-2_4" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">, Contemporary Endocrinology, </a><a href="https://doi.org/10.1007/978-3-031-18448-2_4" target="_blank">https://doi.org/10.1007/978-3-031-18448-2_4</a></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_204.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">duction, FNA has become the most valuable screening and diag nostic test for thyroid nodules. Many are now performed under ultrasound guidance, with optional rapid on-site evaluation to ensure proper placement of the needle, which improves accuracy and decreases the number of nondiagnostic specimens. The results are then reported using The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC).</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: justify;">TBSRTC is the most widely used standardized system for reporting thyroid fine needle aspiration biopsy results. TBSRTC is a six-tiered scheme with evidence-based anticipated risk of malignancy (ROM) and standard treatment approaches associated with each diagnostic category.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Since its introduction, TBSRTC has been widely adopted worldwide and endorsed by the American Thyroid Association. It outlines six distinct diagnostic categories and provides a standard ized, well-defined approach to reporting thyroid cytopathology. Each category is associated with an anticipated risk of malignancy (ROM) and linked to evidence-based clinical management guide lines (Table <span style=" color: #00F;">4.1</span>). As a result, TBSRTC not only allows for improved communication within a healthcare team, but also pro vides guidance for appropriate clinical management. A brief dis cussion of each diagnostic category within TBSRTC follows.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_205.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.64678pt" cellspacing="0"><tr style="height:76pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:98pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:107pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:46pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:98pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:107pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:46pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:98pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:107pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:90pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;padding-right: 1pt;text-indent: 0pt;text-align: left;">Atypia of undetermined significance or follicular lesion of undetermined significance</p></td><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">6–18</p></td><td style="width:98pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">~10–30</p></td><td style="width:107pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:46pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;padding-right: 1pt;text-indent: 0pt;text-align: left;">Follicular neoplasm or suspicious for a follicular neoplasm</p></td><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">10–40</p></td><td style="width:98pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">25–40</p></td><td style="width:107pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:46pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;padding-right: 1pt;text-indent: 0pt;text-align: left;">Suspicious for malignancy</p></td><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">45–60</p></td><td style="width:98pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">50–75</p></td><td style="width:107pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:47pt"><td style="width:127pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Malignant</p></td><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">94–96</p></td><td style="width:98pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">97–99</p></td><td style="width:107pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p class="s14" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">NIFTP <span class="s12">noninvasive follicular thyroid neoplasm with papillary-like nuclear features</span></p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Table adapted from: Cibas ES, Ali SZ. The 2017 Bethesda System for Report ing Thyroid Cytopathology. Thyroid. 2017;27(11):1341–1346. doi:10.1089/ thy.2017.0500</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="575" height="2" src="Image_206.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a46">Discussion</a></h1><h2 style="padding-top: 15pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a47">Nondiagnostic</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">This category includes specimens that are unsatisfactory for inter pretation due to scant cellularity or are compromised by obscur ing blood, air-drying artifact, or overly thick smears (Fig.</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_207.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="572" height="197" alt="Two histological scans labeled a and b. a has a chunk of solid cellular structure. An arrow in b points to a cluster of tiny seed-like cell structures in the center." title="Two histological scans labeled a and b. a has a chunk of solid cellular structure. An arrow in b points to a cluster of tiny seed-like cell structures in the center." src="Image_208.jpg"/></span></p><p class="s59" style="text-indent: 0pt;text-align: left;">a</p><p style="text-indent: 0pt;text-align: left;"/><p class="s59" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">the follicular cells and distorts architecture, precluding evaluation. (</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">ules with cystic degeneration often contain abundant hemosiderin-laden mac rophages and cyst lining cells (arrow). If insufficient follicular cells are present, cystic aspirates are classified as nondiagnostic</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 8pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Normal thyroid aspirates consist of follicular cells and colloid. A thyroid FNA requires six or more groups of well-visualized fol licular cells, with at least ten cells in each group, to be considered adequate for evaluation. Specimens that fail to meet the criteria for adequacy, including cystic lesions (Fig.</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">nondiagnostic.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">The three exceptions to this rule include cases with any atypia, abundant colloid indicative of a benign colloid nodule, or specific diagnostic conditions such as chronic lymphocytic (Hashimoto) thyroiditis. The precise ROM for nondiagnostic nodules varies but is estimated as 5–10%. Nondiagnostic nodules are generally man aged with a repeat FNA under ultrasound guidance with rapid on- site evaluation. In up to 60% of cases, a subsequent FNA results in a diagnostic interpretation, with a majority proving to be benign. However, FNAs that are repeatedly nondiagnostic may require surgery depending on other clinical and radiologic factors.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a48">Benign</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Since most thyroid nodules are benign, the most common FNA interpretation is a benign result. This category comprises approxi mately 60–70% of all cases and may be subclassified further into</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_209.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="572" height="197" alt="Two histological scans of benign follicular nodules labeled a and b. a has a giant cluster of tiny seed-like structures in the center. b has clusters of thread-like structures with filled granule-like designs." title="Two histological scans of benign follicular nodules labeled a and b. a has a giant cluster of tiny seed-like structures in the center. b has clusters of thread-like structures with filled granule-like designs." src="Image_210.jpg"/></span></p><p class="s59" style="text-indent: 0pt;text-align: left;">a</p><p style="text-indent: 0pt;text-align: left;"/><p class="s59" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">appear as flat, monolayered sheets of evenly spaced follicular cells on cyto logic preparations. Benign follicular cells have round to oval nuclei, finely granular chromatin, smooth nuclear contours, inconspicuous nucleoli, and scant amounts of delicate cytoplasm. (<b>b</b>) Colloid may have a watery or dense appearance staining pink or green-blue on alcohol-fixed Papanicolaou-stained slides. Abundant colloid favors a benign process and, if sufficiently plentiful, may be called benign even if follicular cells are absent</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">specific entities. A diagnosis of “benign follicular nodule” on cytology encompasses a group of histologic entities with identical cytologic features, including nodular hyperplasia in multinodular goiter, adenomatoid nodules, and colloid nodules. These are all predominantly composed of macrofollicles that once aspirated rupture to release luminal colloid and appear as flat sheets of unremarkable follicular cells (Fig. <span style=" color: #00F;">4.2</span>).</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Benign follicular cells have small and round nuclei, smooth nuclear contours, uniformly granular chromatin, and scant to moderate amounts of delicate cytoplasm. Mild nuclear size varia tion and oncocytic (Hürthle cell) or cystic degenerative changes with hemosiderin-laden macrophages are acceptable. A colloid nodule may be sparsely cellular, but is considered benign as it also consists of macrofollicles with abundant colloid.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Hashimoto thyroiditis aspirates are characterized by numerous lymphoid cells admixed with normal follicular cells and occa sional Hürthle cells (Fig. <span style=" color: #00F;">4.3</span>). Although generally straight for ward on cytology, the diagnosis should be confirmed clinically by serologic tests. Examples of other less common benign conditions</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_211.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="382" alt="A histological scan of chronic lymphocytic thyroiditis. An arrow on the top-right points to a cluster of tiny seed-like cell structures. The entire surface of the scan is spread with similar structures." title="A histological scan of chronic lymphocytic thyroiditis. An arrow on the top-right points to a cluster of tiny seed-like cell structures. The entire surface of the scan is spread with similar structures." src="Image_212.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Fig. 4.3  <span class="s12">Chronic lymphocytic (Hashimoto) thyroiditis. A group of Hürthle cells (arrow) with abundant granular cytoplasm is present in a background of abundant polymorphous lymphocytes</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">encountered in FNA specimens include subacute (de Quervain) thyroiditis, amyloid goiter, and black or pigmented thyroid.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: justify;">A benign interpretation is associated with a very low ROM (&lt;3%). These patients are managed conservatively, and follow-up intervals are determined by risk stratification algorithms based on ultrasound patterns.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-left: 10pt;text-indent: 0pt;line-height: 90%;text-align: left;"><a name="a49">Atypia of Undetermined Significance (AUS)/ Follicular Lesion of Undetermined Significance (FLUS)</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">This category encompasses a heterogeneous group of aspirates demonstrating a degree of atypia that is greater than normally attributable to benign, reactive changes, but insufficient for a malignant or suspicious diagnosis. Since “AUS” and “FLUS” are synonymous, one term should be selected for use by a laboratory</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_213.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">cinoma (PTC) (Fig.   ). In contrast,</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;"><b>atypia </b>may be appropriate when the possibility of a follicular neoplasm cannot be ruled out, due to the diffuse presence of microfollicles (defined as 6 to 15 follicular cells arranged in a circular pattern around a central portion of colloid) in a scantly cellular specimen (Fig. <span style=" color: #00F;">4.4b</span>).</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: justify;">A combination of both <b>cytologic and architectural atypia </b>can be observed in the same specimen as these patterns are not mutually exclusive. Scantly cellular specimens may contain a pure population of Hürthle cells (<b>AUS, Hürthle cell type</b></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">ing it impossible to rule out the chance of a Hürthle cell neoplasm. Hürthle cells refer to oncocytic cells with enlarged, often eccentri</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="572" height="192" alt="Two histological scans of A U S and F L U S follicular nodules labeled a and b. a has a cluster of tiny seed-like cell structures. b has a magnified view of such clusters divided into groups." title="Two histological scans of A U S and F L U S follicular nodules labeled a and b. a has a cluster of tiny seed-like cell structures. b has a magnified view of such clusters divided into groups." src="Image_214.jpg"/></span></p><p class="s59" style="text-indent: 0pt;text-align: left;">a</p><p style="text-indent: 0pt;text-align: left;"/><p class="s59" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><span class="s17">Fig. 4.4  </span>AUS/FLUS. (<b>a</b>) Follicular cells show mild cytologic atypia associ ated with Hürthle cell change. Nuclear enlargement, pallor, pinpoint nucleoli, and occasional nuclear grooves (arrow) are seen. Intranuclear pseudoinclu sions are absent. (<b>b</b>) High power image of a microfollicle. When predominant in a modestly cellular specimen, a diagnosis of AUS/FLUS with architectural atypia is warranted</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_215.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 19pt;text-align: left;">Molecular testing helps triage patients with AUS/FLUS or FN/ SFN results and is recognized by TBSRTC and the ATA as a valid approach to further inform clinical management. Most classic and tall cell variants of PTC harbor a <i>BRAF </i>V600E mutation, while many follicular variants of PTC and follicular neoplasms have <i>RAS </i>or <i>RAS-</i>like mutations. Enhanced understanding of the genetic alterations underlying thyroid tumorigenesis has created a potential role for the routine use of commercially available molec ular tests, such as the Afirma Genomic Sequencing Classifier and ThyroSeq v.3. The high negative predictive values of the most recent iterations of these tests make it appropriate to triage patients with negative results to conservative management.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-left: 10pt;text-indent: 0pt;line-height: 90%;text-align: left;"><a name="a50">Follicular Neoplasm (FN)/Suspicious for a Follicular Neoplasm (SFN) (Specify if Oncocytic/Hürthle Cell Type)</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">The FN/SFN category identifies nodules with significant architec tural abnormalities that raise the possibility of a follicular carci noma.  On  histologic  evaluation,  follicular  carcinoma  is distinguished from an adenoma by the presence of capsular and/ or vascular invasion. However, these criteria cannot be reliably assessed on cytology. Therefore, FNA of follicular neoplasms is considered a screening, rather than a diagnostic test.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: justify;">In contrast to benign follicular nodules that are comprised of predominantly macrofollicles with abundant colloid, FN/SFN lesions demonstrate follicular cells arranged in crowded, overlap</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_216.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="400" alt="A histological scan of F N and S F N lesion follicular cells. The scan surface has tiny granule-like structures spread all over. In between such structures are clusters of tiny seed-like cells." title="A histological scan of F N and S F N lesion follicular cells. The scan surface has tiny granule-like structures spread all over. In between such structures are clusters of tiny seed-like cells." src="Image_217.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 4.5  <span class="s12">FN/SFN. This cellular aspirate shows crowded, uniform follicular cells predominantly in microfollicular arrangements</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">ping groups, microfollicles, or trabeculae, with scant to absent colloid (Fig. <span style=" color: #00F;">4.5</span>).</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Most cases diagnosed as FN/SFN are ultimately benign, but 25–40% of cases prove to be malignant. As a result, the differen tial diagnosis includes benign follicular nodules, a subset of which can have prominent microfollicles without clinical significance, as well as other follicular-patterned lesions, such as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Strict histologic criteria preclude a definitive diagnosis of NIFTP on FNA, but cytologic preparations often show a pre dominance of microfollicles in addition to mild nuclear changes that are abnormal enough to fall within the indeterminate catego ries (Fig. <span style=" color: #00F;">4.6</span>).</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: justify;">These lesions are classified as FN/SFN when nuclear changes are mild and intranuclear pseudoinclusions, papillae, or psammoma bodies are absent. When nuclear changes are more pronounced and these suspicious features are present, a diagnosis of at least suspi</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_218.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="197" alt="Two histological scans of N I F T P cells labeled a and b. a has small and large clusters of tiny cells spread all over. b has the magnified view of such clusters. It consists of tiny seed-like structures." title="Two histological scans of N I F T P cells labeled a and b. a has small and large clusters of tiny cells spread all over. b has the magnified view of such clusters. It consists of tiny seed-like structures." src="Image_219.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">and enlargement. (<b>b</b>) At high power, powdery chromatin and nuclear grooves are seen. The diagnosis of NIFTP requires histologic examination, but FNA specimens are usually classified as AUS/FLUS, FN/SFN, or suspicious for PTC. An explanatory note suggesting the possibility of NIFTP is recom mended when the diagnosis is suspected</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">cious for malignancy is warranted. If NIFTP is suspected on FNA, TBSRTC suggests adding an explanatory note to encourage limited surgical management (typically diagnostic lobectomy).</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">The interpretation “suspicious for a follicular neoplasm/ fol licular neoplasm, Hürthle cell type (FNHCT/SFNHCT)” refers to a subset of aspirates within the FN/SFN category that consists (almost) exclusively of Hürthle cells and raises the possibility of a Hürthle cell carcinoma (Fig. <span style=" color: #00F;">4.7</span>).</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">As with its conventional follicular counterpart, it is impossible to identify the presence of invasion to confirm malignancy on cytology. However, the mere presence of Hürthle cells is not diag nostic of FNHCT/SFNHCT. For example, Hashimoto thyroiditis often shows Hürthle cells admixed with numerous lymphoid cells. Similarly, Hürthle cell change is a common focal finding in benign follicular nodules. In addition to extensive Hürthle cell change, the most concerning lesions in the FNHCT/SFNHCT category also show the following worrisome cytologic or architectural fea tures: small cell or large cell dysplasia, dyscohesion (loosened inter-cellular connections), or crowding. The background con tains little to no colloid and transgressing blood vessels may also be seen.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_220.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="400" alt="A histological scan of F N H C T and S F N H C T cells. The scan surface is spread with tiny granule-like cells. In the center of such cells are a cluster of tiny seed-like structures. The cluster forms a radial arrangement with an empty center." title="A histological scan of F N H C T and S F N H C T cells. The scan surface is spread with tiny granule-like cells. In the center of such cells are a cluster of tiny seed-like structures. The cluster forms a radial arrangement with an empty center." src="Image_221.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Fig. 4.7  <span class="s12">FNHCT/SFNHCT. Cellular smears show a pure population of Hürthle cells arranged in loosely cohesive groups. Colloid and lymphocytes are absent from the background</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">As a minority of FN/SFN cases are malignant, they are typi cally managed conservatively with diagnostic lobectomy or molecular testing with the potential to avoid surgery.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-top: 14pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;"><a name="a51">Suspicious for Malignancy (SFM)</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">“Suspicious for malignancy” (SFM) is the last indeterminate cat egory in TBSRTC and is indicated for cases with cytomorpho logic features that are strongly suspicious for malignancy but are quantitatively and/or qualitatively insufficient for a conclusive diagnosis. SFM includes a variety of potential malignancies, although most cases are suspicious for PTC (Fig.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">As with AUS/FLUS, this interpretation should be used judi ciously to ensure that patients are managed appropriately. Often the sample may lack cellularity or the characteristic features are</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_222.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="400" alt="A histological scan of sheets of follicular cells in papillary thyroid carcinoma. It has a cluster of tiny disk-shaped seed-like cells. Arrows point to these individual disk-shaped cells." title="A histological scan of sheets of follicular cells in papillary thyroid carcinoma. It has a cluster of tiny disk-shaped seed-like cells. Arrows point to these individual disk-shaped cells." src="Image_223.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Fig. 4.8  <span class="s12">Suspicious for papillary thyroid carcinoma. Sheets of follicular cells demonstrate nuclear enlargement, crowding, powdery chromatin, and nuclear grooves (arrows). Intranuclear pseudoinclusions, psammoma bodies, and papillary architecture are absent</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 9pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">patchy and incomplete. A SFM interpretation still conveys a degree of uncertainty but suggests that malignancy is considered more likely than not. Given the relatively high ROM (50–75%), ancillary molecular studies are not utilized for risk stratification. Instead, these cases are managed surgically, and the clinical and radiologic findings are crucial for determining the extent of surgery.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a52">Malignant</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">PTC is the most common cancer of the thyroid, accounting for approximately 85% of malignancies. Its characteristic nuclear features are readily identified on cytology, making FNA biopsy an ideal diagnostic test for PTC (Fig. <span style=" color: #00F;">4.9</span>). Common features are</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_224.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="197" alt="Two histological scans of the cell surface of the papillary thyroid carcinoma labeled a and b. An arrow in a points to cracks in the surface caused by clusters of foreign cells. Arrowheads in b point to the magnified disk-shaped foreign cell structures." title="Two histological scans of the cell surface of the papillary thyroid carcinoma labeled a and b. An arrow in a points to cracks in the surface caused by clusters of foreign cells. Arrowheads in b point to the magnified disk-shaped foreign cell structures." src="Image_225.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">of malignant cells with a syncytial-like appearance. At low power, nuclear enlargement, pallor, and crowding are appreciated. A papillary structure with a fibrovascular core is present (arrow). (<b>b</b>) At high power, the nuclear features of papillary thyroid carcinoma, including nuclear membrane irregularities, grooves, and numerous pseudoinclusions (highlighted with arrows), are read ily identified</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">nuclear grooves and pseudoinclusions, membrane irregularities, chromatin pallor, crowding, or overlapping. Classical PTC is the most common type and has papillary architecture, which is appreciable on FNA as fibrovascular cores lined by malignant cells. Other helpful features include psammomatous calcifica tions and multinucleated giant cells. In most cases, it is difficult and unnecessary to identify the specific subtype of PTC. However, some variants can demonstrate more focal or subtle nuclear changes. Patients with low-risk PTC up to 4 cm in size may be treated with lobectomy, according to current ATA guidelines, otherwise with near-total thyroidectomy, and prognosis is excel lent overall.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Poorly differentiated (insular) thyroid carcinoma has an inter mediate degree of cytomorphologic atypia and clinical behavior between a well-differentiated and an undifferentiated thyroid car cinoma. The diagnosis is difficult to make on FNA and rests on histologic evaluation. However, cytologic preparations are usu ally hypercellular and demonstrate nuclear overlapping, with nested, trabecular, or solid architectural patterns (Fig.</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Tumor cells are typically uniform, but more pronounced atypia may also be appreciated. The presence of increased mitotic activ</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_226.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="572" height="197" alt="Two histological scans of thyroid carcinoma cell structures labeled a and b. a has a cell surface with cracks caused by foreign cell clusters. b has the magnified view of the tiny seed-like cell structures in between the regular cell surface." title="Two histological scans of thyroid carcinoma cell structures labeled a and b. a has a cell surface with cracks caused by foreign cell clusters. b has the magnified view of the tiny seed-like cell structures in between the regular cell surface." src="Image_227.jpg"/></span></p><p class="s59" style="text-indent: 0pt;text-align: left;">a</p><p style="text-indent: 0pt;text-align: left;"/><p class="s59" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">image shows abundant groups of monotonous follicular cells arranged in crowded insulae. (<b>b</b>) Tumor cells show mild nuclear atypia with granular chromatin and overlapping nuclei. Scattered isolated tumor cells are present in the background</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">ity, apoptosis, and necrosis further suggests the diagnosis. Poorly differentiated thyroid carcinoma can resemble other entities, such as follicular neoplasms, medullary thyroid carcinoma, or anaplas tic carcinoma. Immunohistochemical stains may help with the distinction on FNA, but surgical pathology evaluation is often necessary for definitive classification.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Undifferentiated (anaplastic) thyroid carcinoma is even more unfavorable than poorly differentiated thyroid carcinoma. This disease behaves aggressively and clinically presents as a rapidly enlarging mass, which has often already spread to adjacent struc tures or distant sites. The cytologic appearance is variable, com prised of large, markedly pleomorphic tumor cells that can demonstrate epithelioid, spindled, rhabdoid, or giant-cell mor phology (Fig. <span style=" color: #00F;">4.11</span>). The nuclear features are undoubtedly malig nant, and necrosis and abundant mitoses are also present. A proportion of cases focally demonstrate features of a well-differ entiated precursor lesion, either PTC or follicular carcinoma. Prognosis is extremely poor, and the diagnosis relies on clinical and radiologic correlation.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">In contrast to the previously described thyroid neoplasms which are derived from follicular cells, medullary thyroid carci noma (MTC) arises from the parafollicular (C) cells of the thy roid. MTC is rare, accounting for 1–2% of all thyroid carcinomas.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_228.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="572" height="197" alt="Two histological scans of anaplastic thyroid carcinoma cell structures labeled a and b. a has a surface filled with tiny granule-like cells pointed by arrows. An arrow in b points to a big sphere-shaped cell structure." title="Two histological scans of anaplastic thyroid carcinoma cell structures labeled a and b. a has a surface filled with tiny granule-like cells pointed by arrows. An arrow in b points to a big sphere-shaped cell structure." src="Image_229.jpg"/></span></p><p class="s59" style="text-indent: 0pt;text-align: left;">a</p><p style="text-indent: 0pt;text-align: left;"/><p class="s59" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">abundant tumor necrosis (left portion of image) with well-preserved, malig nant cells (highlighted with arrows in right portion of image). ( pleomorphism is seen with enlarged, eccentrically located nuclei, irregular nuclear contours, coarse chromatin, prominent nucleoli, and abundant dense cytoplasm. Increased mitotic activity is present (arrow)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="572" height="197" alt="Two histological scans of medullary thyroid carcinoma cell structures labeled a and b. Arrowheads in a point to small lump-like cells in between seed-like cell structures. b has a surface with dispersed patches of cell structures." title="Two histological scans of medullary thyroid carcinoma cell structures labeled a and b. Arrowheads in a point to small lump-like cells in between seed-like cell structures. b has a surface with dispersed patches of cell structures." src="Image_230.jpg"/></span></p><p class="s59" style="text-indent: 0pt;text-align: left;">a</p><p style="text-indent: 0pt;text-align: left;"/><p class="s59" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><span class="s17">Fig. 4.12  </span>Medullary thyroid carcinoma. (<b>a</b>) Hypercellular preparations are composed of abundant, loosely cohesive, and variably shaped (epithelioid, plasmacytoid, and spindled) cells. The background contains scattered amor phous material, consistent with amyloid (arrows). The malignant cells show stippled “salt and pepper” chromatin, anisonucleosis, small nucleoli, and scant to abundant amounts of delicate to granular cytoplasm. (</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">preparations show tumor cells that are immunoreactive for calcitonin (brown cytoplasmic staining)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">They are often sporadic in adults but may be associated with germline <i>RET </i>mutations and multiple endocrine neoplasia (MEN) syndromes. Aspirates show loose aggregates or singly dispersed cells with coarsely granular, “salt and pepper” chromatin, typical of neuroendocrine tumors (Fig. <span style=" color: #00F;">4.12a</span>). The cells are plasmacytoid</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_231.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">is diagnostic of MTC and measurement of this marker generally plays a first line role in confirmation of the diagnosis, particularly when immunohistochemical stains, which are not universally available, cannot be performed. MTC is usually treated with total thyroidectomy and regional lymphadenectomy.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Primary thyroid lymphomas are rare, comprising 1–5% of all thyroid malignancies, with up to 5% reported at some referral centers. These tumors usually occur in older-aged females with a longstanding history of Hashimoto thyroiditis. Patients present with an enlarging thyroid mass, often accompanied by compres sive  symptoms  and  involvement  of  cervical  lymph  nodes. Aspirates are highly cellular and consist of isolated lymphoid cells (Fig. <span style=" color: #00F;">4.13</span>). A majority are B-cell lymphomas, most com monly extranodal marginal zone B-cell lymphoma of mucosa-</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="572" height="197" alt="Two histological scans of lymphoma cell structures labeled a and b. The surface in a is filled with clusters and lone pairs of tiny granule-like cells. b has a magnified view of such clusters attached with fine hair-like cell structures." title="Two histological scans of lymphoma cell structures labeled a and b. The surface in a is filled with clusters and lone pairs of tiny granule-like cells. b has a magnified view of such clusters attached with fine hair-like cell structures." src="Image_232.jpg"/></span></p><p class="s59" style="text-indent: 0pt;text-align: left;">a</p><p style="text-indent: 0pt;text-align: left;"/><p class="s59" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><span class="s17">Fig. 4.13  </span>Lymphoma. (<b>a</b>) MALT lymphoma of the thyroid showing a monotonous population of intermediate-sized lymphoid cells. (</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">large B-cell lymphoma (DLBCL) of the thyroid with large, atypical lymphoid cells with nuclear enlargement and prominent nucleoli</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_233.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="575" height="2" src="Image_234.png"/></span></p><h1 style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a53">Further Reading</a></h1><p class="s12" style="padding-top: 17pt;padding-left: 25pt;text-indent: -19pt;text-align: left;">Ali SZ, Cibas ES, editors. The Bethesda system for reporting thyroid cytopa thology. Definitions, criteria, and explanatory notes. 2nd ed. New York: Wiley; 2017.</p><p class="s12" style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Haugen  BR, Alexander  EK,  Bible  KC,  et  al.  2015 American Thyroid Association Management guidelines for adult patients with thyroid nod ules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.</p><p class="s12" style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">Krane JF, Alexander EK, Cibas ES, Barletta JA. Coming to terms with NIFTP:  a  provisional  approach  for  cytologists.  Cancer  Cytopathol. 2016;124:767–72.</p><p class="s12" style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">Patel KN, Angell TE, Babiarz J, et al. Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules. JAMA Surg. 2018;153(9):817–24.</p><p class="s12" style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">Steward DL, Carty SE, Sippel RS, et al. Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study [published correction appears in JAMA Oncol. 2019 Feb 1;5(2):271]. JAMA Oncol. 2019;5(2):204–12.</p><p style="padding-left: 385pt;text-indent: 0pt;text-align: left;"><span><a href="http://crossmark.crossref.org/dialog/?doi=10.1007/978-3-031-18448-2_5&amp;domain=pdf"><img width="69" height="61" src="Image_235.png"/></a></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s11" style="padding-left: 19pt;text-indent: 0pt;text-align: left;">Key Points</p><ul id="l55"><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">The malignant potential of thyroid nodules is determined through consideration of clinical risk, clinical findings, ultrasonographic features, and cytopathologic results, as classified by the Bethesda System of Reporting Thyroid Cytopathology.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Cytologically indeterminate lesions yield a wide range of malignant outcomes on histopathology, which can be more precisely predicted using molecular information obtained by FNA.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: left;">Clinically available methods of assessing the genetic profile of indeterminate thyroid nodules have been devel oped and include immunochemical staining for markers of thyroid cancer, identification of specific molecular</p></li></ul><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="226" height="1" src="Image_236.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_237.png"/></span></p><p class="s12" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">J. V. Hennessey (<span class="s13">*</span>)</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Harvard Medical School, Beth Israel Deaconess Medical Center,</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Boston, MA, USA</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><a href="mailto:jhenness@bidmc.harvard.edu" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">e-mail: </a><a href="mailto:jhenness@bidmc.harvard.edu" class="s20" target="_blank">jhenness@bidmc.harvard.edu</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">© The Author(s), under exclusive license to Springer Nature Switzerland AG 2023</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">L. S. Eldeiry et al. (eds.), <i>Handbook of Thyroid and Neck Ultrasonography</i><a href="https://doi.org/10.1007/978-3-031-18448-2_5" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">, Contemporary Endocrinology, </a><a href="https://doi.org/10.1007/978-3-031-18448-2_5" class="s20" target="_blank">https://doi.org/10.1007/978-3-031-18448-2_5</a></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_238.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 39pt;text-indent: 0pt;text-align: justify;">The identification of benign pathology among BSRTC indeterminate nodules is accomplished through a system which provides a high level of accuracy to rule out malignancy, avoiding the need for surgery, while the ability to predict the presence of malignancy is more modest.</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_239.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a54">Introduction</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Fine needle aspiration (FNA) findings are interpreted considering the pretest probability of malignancy. The Bethesda System of Reporting Thyroid Cytopathology (BSRTC [Bethesda will be referred to as B in this chapter]) was introduced to standardize reporting of results and associate an evidence-based risk of malig nancy (ROM) for each category. Clinical action is taken based on ROM projections in 70–80% of BSRTC results. Surgical inter vention is indicated for B VI lesions and follow-up is generally suggested for B II nodules; however, management is less certain for the 20–30% of cases that are B III (atypia of unknown signifi cance [AUS] or follicular lesion of unknown significance [FLUS], with an estimated ROM 5–47%) and B IV lesions (follicular/ Hürthle cell neoplasm [FN] or suspicious for follicular/Hürthle cell neoplasm [SFN], with an estimated ROM of 15–40%). Surgery has usually been carried out in B V lesions (suspicious for malignancy), due to the high ROM (60–75%). When originally</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_240.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_241.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 13pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">The pretest probably of malignancy is established by considering individual clinical risk factors, ultrasound and cytology findings (which may lead to adjustment of pretest malignancy risk rates from those originally reported in the BSRTC). To better define the ROM posed by a cytologically indeterminate thyroid nodule, a good test should be accurate, accessible, affordable, and have impact on patient management to “rule out” or “rule in” the pres ence of thyroid malignancy. A useful additional investigation would then predict the ROM to below 5% or well above the 30 + % range represented by the B III or B IV finding when risk factors are otherwise reassuring. In this context, a “rule-in” test would provide a positive predictive value (PPV) similar to a B VI diagnosis (<span class="s61">≅ </span>96%) and an ideal “rule-out” test would generate a negative predictive value (NPV) of about 3–5%. The American Thyroid Association (ATA) recommends that patients be coun seled regarding the potential benefits and limitations of molecular marker testing (no test will be 100%). Current ATA guidelines also recommend that these tests be performed in established, CLIA-certified molecular laboratories for the most consistent clinical reliability.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Several approaches have been investigated to further define the ROM of indeterminate nodules. One technique has used immuno chemistry staining of prepared cytopathology specimens using markers of thyroid malignancy (“rule-in” tests with high PPV) such as galectin-3, cytokeratin-19, Hector Battifora mesothelial- 1(HBME1), and trophoblast cell surface antigen 2 (TROP2).</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_242.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s61" style="padding-top: 4pt;padding-left: 50pt;text-indent: 0pt;text-align: left;">γ<span class="p">).</span></p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">An alternative approach uses molecular techniques designed to identify benign thyroid tissue and provides a high NPV. Such a technique analyzes the mRNA expression of 167 genes in a gene expression classifier (GEC) and its current form, the gene sequenc ing classifier (GSC).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_243.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a55">Immunohistochemical Staining</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Immunohistochemical stains for galectin-3 and HBME-1 done on cell block specimens from material obtained by FNA using vari ous methodologies have been reported. Using reverse transcriptase- PCR (RT-PCR), a small study of FNA samples classified as indeterminate was analyzed for the expression of galectin-3 and/ or CD44v6 and resulted in a 100% sensitivity and 60% specificity for thyroid cancer. While potentially representing a good “rule- out test,” the low specificity, technical difficulty in performing these tests, lack of widespread availability, and small series repre sent limitations of the clinical utility of this type of testing. Cytokeratin-19 and HBME1 (usually negative in normal thyroid cells) were assessed in a series of 150 FNAs from indeterminate nodules and were reported to be 100% sensitive and 85% specific for the presence of thyroid cancer. Overall, the accuracy of immu nohistochemical staining has been limited in follicular cell lesions, particularly for distinguishing benign follicular adenomas from follicular thyroid cancer (FTC) and the follicular variant of papillary thyroid cancer (FVPTC).</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_244.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">past, BRAF positivity was viewed as an indication to perform a total thyroidectomy, as it confirms the presence of PTC. This mutation is not or is infrequently found in FTC, FVPTC, and Hürthle cell carcinoma (HCC). The prevalence of this mutation in cytologically indeterminate cases ranges from 0 to 48% (lower rates in Western countries). The MAPK pathway drives several human cancers and is strongly activated by the B-type RAF kinase (BRAF). The sensitivity of the BRAFV600E point mutation is too low, however, to reliably exclude the presence of thyroid malig nancy in the assessment of indeterminate thyroid nodules.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Retrovirus-associated DNA sequences (RAS) point mutations constitute the second most frequently encountered (0–36%) find ing  in  thyroid  malignancy  discovered  among  indeterminate BSRTC results. The 3 RAS subtypes are associated with follicular- patterned  histology  such  as  follicular  adenoma  (FA),  FTC, FVPTC,  and  non-invasive  follicular  thyroid  neoplasm  with papillary-like nuclear features (NIFTP). Gene mutations identi fied in the oncogenic Harvey rat sarcoma (HRAS) predict the presence of malignancy in 56% of cases, while mutations of the Kirsten murine sarcoma virus (KRAS) and neuroblastoma cells (NRAS) have been reported to be 100% and 74% predictive, respectively. Each encodes for RAS proteins that are involved in signaling in the MAPK/ERK pathway. Mutations in the RAS genes result in overactive RAS signaling, inducing malignant growth. In general, the presence of RAS mutations predicts thy roid cancer in more than 80% of cases, though generally with favorable clinical features, such as encapsulation and a paucity of lymph node metastases, for which hemithyroidectomy may be</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_245.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_246.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a56">Genetic Translocations</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Genetic translocation products, such as the Ret proto-oncogene rearrangements (RET/PTC), activate the MAPK and PI3K/AKT pathways through BRAF signaling, resulting in malignant trans formation. Of the 12+ fusion variants identified, RET/PTC1 and RET/PTC3 are the most common. RET/PTC3 occurs in PTC in children and those exposed to irradiation and is associated with lymph node metastases. Benign adenomas that are positive for RET/PTC  and  occur  after  irradiation  are  considered  pre- cancerous. RET/PTC rearrangements are seldom reported in most series of indeterminate nodules; however, one Italian series reported a 36% incidence in this setting. As such RET/PTC has low utility as a stand-alone test, but is most useful when included in a panel of molecular tests.</p><p style="padding-left: 30pt;text-indent: 0pt;text-align: left;">Rearrangements of the PAX8 and PPAR</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">genetic material have been detected in up to 45% of FTC, 33% of FA’s, and up to 38% of FVPTC, but have not been routinely observed in Hürthle cell lesions. Some have reported that the presence of this fusion is associated with malignancy. In general, the PAX8/PPAR<span class="s61">γ </span>fusion predicts encapsulated, indolent lesions and does not activate the MAPK pathway. PAX8/PPAR</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">occur  frequently  in  cytologically  indeterminate  nodules. Approximately 2/3 of PAX8/PPAR<span class="s61">γ</span>-positive nodules are malig nant (FVPTC, FTC). Benign lesions known to be PAX8/PPAR positive are also considered pre-malignant.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_247.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">more aggressive variants of thyroid cancer, such as poorly differ entiated and anaplastic (70%) cancers. The presence of the TERT promoter mutation is highly correlated with mortality in differen tiated thyroid cancer, especially when present in conjunction with BRAFV600E. TERT is potentially useful in the preoperative identification  of  differentiated  thyroid  cancer  (DTC),  with reported sensitivity and specificity rates of 57–88% and 75–85%, respectively.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Other genetic alterations observed in thyroid cancers include the eukaryotic translation initiation factor 1A, X chromosomal (EIF1AX), found in low percentages of PTC and FTC. The pres ence of this mutation in poorly differentiated thyroid cancers, however, is associated with poorer clinical outcomes. A gene nor mally encoding endoribonucleases (DICER1) has been found to be mutated in germline and somatic pediatric thyroid cancers (FTC and PTC). This mutation is usually reported in the context of a hereditary pediatric cancer predisposition syndrome, which includes pleuro-pulmonary blastoma, ovarian sex cord-stromal tumors, lung cysts, cystic nephroma, renal sarcoma and Wilms’ tumor, and other lesions. In adults, the presence of a germline DICER1 mutation seems to be a risk factor for renal sarcoma, Wilms tumor, and other lesions and is associated with having had a thyroidectomy for reasons other than thyroid cancer or goiter.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: justify;">Alterations in a gene encoding adenylate cyclase-stimulating G <span class="s61">α</span>-protein at codon 201 (GNAS) may result in activation of the cyclic AMP process affecting cell proliferation and function. GNAS alterations are more frequently found in hyperfunctioning adenomas of the thyroid, but may also be present in FTC. Long</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_248.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_249.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s61" style="padding-top: 4pt;padding-left: 10pt;text-indent: 75pt;text-align: left;">γ <span class="p">gene rearrangements, is designed to assess the malignant potential of indeterminate nodules more comprehen sively (including newly described pre-malignant lesions such as NIFTP [see below]). This approach enhances the power of detec tion, given that these mutations are generally mutually exclusive. Usually, the presence of one characteristic mutation among those in the panel is a significant indicator of malignancy. In B III cases that are positive for BRAF, RET/PTC, or PAX8/PPAR</span></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">nancy has been reported in all cases, while some RAS mutations may point to cancer in 84% of cases in this same series. In studies of B IV lesions, where a 15–30% risk of malignancy is assumed to exist, this seven-gene mutational panel was demonstrated to have a 57–75% sensitivity for malignancy, a specificity of 97–100%, PPV of 87–100% (highlighting its usefulness as a “rule-in” test), and a NPV of 79–86%. However, nodules lacking all 7 of these markers still harbored a significant risk of malig nancy, limiting its utility as a “rule-out” test. In one study of these panels, only 1 of 18 nodules with Hürthle cell cytology tested positive, likely providing early evidence that the genetic basis of Hürthle  cell  lesions  differs  from  that  of  other  types  of DTC. Additionally, the PPV of these panels is unlikely to ever exceed 90%, as RAS mutations trigger positive results and the prevalence  of  malignancy  of  populations  studied  has  been 15–40%. A limitation to the accuracy of PPV and NPV calcula tions is the fact that histology data is not available for all nodules characterized as “not malignant” in these panels, rendering a pre cise calculation of false negatives impossible. Extending a 7-gene panel to include additional markers observed in thyroid cancer</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_250.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">v3 was assessed in a multi-institutional study of 286 indetermi nate nodules: 72% were classified as benign, and a total of 28% (including NIFTP: 14% of the total, which likely impacted clini cal management and calculation of PPV) were classified as malig nant. A sensitivity of 94%, specificity of 82%, and NPV of 97% were observed, while the PPV for malignancy was 66%. ROM of positive tests ranged from 50 to 100% depending on the pattern of genetic abnormalities identified. An independent assessment of ThyroSeq v3 performance in 415 B III and B IV qualifying nod ules resulted in a total of 121 positive (29%) and 294 negative (71%) results. Of ThyroSeq v3-positive cases with histopatho</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 12pt;padding-left: 7pt;text-indent: 0pt;text-align: left;">Table 5.1 <span class="s12">Methods employed in molecular testing of indeterminate thyroid nodules</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:7.9888pt" cellspacing="0"><tr style="height:18pt"><td style="width:150pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Method</p></td><td style="width:123pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Diagnostic utility</p></td><td style="width:158pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Markers of malignancy</p></td></tr><tr style="height:46pt"><td style="width:150pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Immunocytochemistry</p></td><td style="width:123pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">“Rule-in” tests with high PPV</p></td><td style="width:158pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:90pt"><td style="width:150pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Molecular marker (mutation panel) testing</p></td><td style="width:123pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;padding-right: 5pt;text-indent: 0pt;text-align: justify;">“Rule-in” tests with high PPV and in the absence of markers, good NPV</p></td><td style="width:158pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Mutations—BRAF, EIF1AX, DICER1,</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">proto-oncogene, hTERT</p></td></tr><tr style="height:47pt"><td style="width:150pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">GEC (no longer available), GSC</p></td><td style="width:123pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">Identification of benign thyroid tissue</p></td><td style="width:158pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">rearrangment expression</p></td></tr></table><p class="s12" style="padding-top: 3pt;padding-left: 7pt;text-indent: 0pt;text-align: left;">See text for detail. <i>NPV </i>negative predictive value,</p><p class="s12" style="padding-left: 7pt;text-indent: 0pt;text-align: left;">value, <i>GEC </i>gene expression classifier, <i>GSC </i>gene sequencing classifier</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_251.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">&gt;4 cm: PPV 50%; NPV 89%).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_252.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a57">MicroRNA (miRNA) Analysis</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">MicroRNA (miRNA) markers have been evaluated in nodules with indeterminate cytology. MicroRNAs are small, endogenous non-coding RNAs about 22 nucleotides in length that play a role in the regulation of posttranscriptional protein synthesis. Human cancers are associated with dysregulation of miRNA expression and these miRNAs appear as a pre-malignant event before dereg ulating tumor suppressor and oncogenes. These miRNAs are more stable than mRNA, may be detected in the circulation, and maintain their expression in formalin-fixed tissue and FNA sam ples, making retrieval from cytopathology slides possible. Studies have found that different miRNAs and levels of expression are of clinical utility in the identification of malignancy. For example, in PTC, there is a reported up-regulation of miR-146b, miR-221, miR-222, and miR-187 and a down-regulation of miR-1 and miR-</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">138. Additionally, FTC, poorly differentiated, and anaplastic thy roid cancers are also associated with up-regulation of miR-221, miR-222, and miR-187. The degree of overexpression may also be of utility, as FVPTC appears to have twice the expression of miR-221 and miR-222 than PTC and FTC. Based on these and further characteristic variances in expression, diagnostic panels of miRNAs have been combined to evaluate the malignant potential of thyroid nodules with variable degrees of success. A commer cial product evaluating 24 up- and down-regulated miRNAs</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_253.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_254.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">promising results for both “rule in” and “rule out” purposes. A commercial  product  combining  the  sequencing  of  8  genes (ThyGenX<span class="s62">®</span>) and 10 miRNAs (ThyraMIR<span class="s62">®</span></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">of 94%, specificity of 85%, PPV of 68%, and a NPV of 97% in B III lesions. The most recent configuration includes an expanded gene panel (ThyGeNEXT<span class="s62">®</span>) with the ThyraMIR panel and has been reported to have a PPV of 75% and NPV of 97%.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_255.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;"><a name="a58">Identification of Benign Nodule Characteristics</a></h1><p style="padding-top: 17pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">When first introduced, the 167 Afirma<span class="s62">® </span>gene expression classifier (GEC [a historical term, as this version is no longer in clinical use]) used quantification of messenger RNA (mRNA) run through a proprietary algorithm to differentiate benign from potentially malignant (“suspicious”) thyroid nodules. The GEC was processed on material obtained by 2 additional FNA passes and was intro duced as a “rule-out” test based on an initial reported 92% sensitiv ity and NPV of 93%. In one study, this resulted in a reduction of malignancy risk from 24% in AUS/FLUS lesions to 5%. In cases where surgical pathology was available, the relatively low specific ity for predicting the presence of malignancy in indeterminate nod ules (48–53%), however, was acknowledged to be a limitation to use as a “rule-in” test. The reporting protocol indicated that the results were either “likely benign,” as reflected by the high NPV or designated as “suspicious.” Some misinterpreted these reports to equate to the 7-gene mutation panel reporting nomenclature, which was reported as “positive” (for malignancy), an indication for total</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_256.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">sequencing, and genomic copy number analysis. This version is designated as the gene sequencing classifier (GSC) and incorpo rates BRAFV600E, RET/PTC fusion, parathyroid tissue, and med ullary thyroid cancer (MCT) markers. The GSC was validated on a subset of the original pivotal GEC data set and demonstrated a sensitivity of 91% and specificity of 68% in a population with a 24% cancer prevalence. The NPV was 96% and PPV was 47%. Independent, real world evaluation from several institutions com paring the GSC performance with that of the original GEC con figuration has led to a decrease in suspicious results by 21–54%, classification of more Hürthle cell lesions as benign, and a higher PPV of 57.1–61.5% (with a higher PPV in B IV vs. B III). Currently, the Afirma<span class="s62">® </span>system also offers optional testing for a lim ited number of specific driver mutations (as included in the muta tion panels described above) when overall results are designated as suspicious. Use of this optional marker panel has enhanced preop erative PPV and surgical planning when specific markers are pres ent. Meta-analysis of 4 independent studies evaluating the clinical performance of the GSC indicates an overall sensitivity of 95%, specificity of 51%, PPV of 60%, and NPV of 91%.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_257.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a59">Genetic Testing and NIFTP Lesions</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">The performance of genetic testing in the identification of lesions diagnosed as NIFTP, an entity considered to have low malignant potential, is limited. Although the initial series of 109 cases of NIFTP reported no adverse clinical outcomes, subsequent studies have</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_258.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">a false positive. Although surgical removal of NIFTP lesions is appro priate due to NIFTP’s potential pre-malignant nature, some have (ret rospectively) opined that surgery may be overly aggressive for this final diagnosis. In the past, a total rather than limited (hemi) thyroid ectomy was recommended for confirmed malignancy. Currently, as aggressive surgery or I-131 therapy is not indicated for NIFTP, exces sive surgical intervention is generally to be avoided, though given the limitations of preoperative diagnosis and some challenges in making this pathology diagnosis, for example, in the distinction from FVPTC, an individualized management approach is needed, particularly in the case of larger nodules (&gt;4 cm).</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Genetic alterations detected in the evaluation of the indetermi nate thyroid nodule differ depending on the approach taken. The presence of BRAF or RET/PTC would not generally support the diagnosis of NIFTP preoperatively (in fact the presence of BRAFV600E mutation is an exclusion criterion for the diagnosis of NIFTP). Other “positive” indicators of cancer, such as RAS mutations, occur more frequently in NIFTP. In addition, PAX8- PPAR<span class="s61">γ</span>, THADA fusions and EIF1AX mutations may be found in NIFTP. In a similar way, a proportion of indeterminate nodules labeled as “suspicious” in the Afirma<span class="s62">® </span>GEC as well as GSC sys tem have been found to be NIFTP.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Given these findings, repeat FNA of cytologically indetermi nate nodules prior to molecular testing and following a conserva tive pathway to initial surgical intervention or, alternatively, clinical observation, seems prudent.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Table <span style=" color: #0000F9;">5.2 </span>summarizes the currently available commercial pan els, their performance and method of collection.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="2" height="575" src="Image_259.png"/></span></p><h4 style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Table 5.2 <span class="s53">Comparison of commercial panels, their performance and the method of collection</span></h4><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.49583pt" cellspacing="0"><tr style="height:20pt"><td style="width:183pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s54" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Commercial panel</p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s54" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Sensitivity</p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s54" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Specificity</p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s54" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">PPV</p></td><td style="width:53pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p class="s54" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">NPV</p></td><td style="width:90pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#C4D0EC"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:35pt"><td style="width:183pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s63" style="padding-left: 3pt;padding-right: 2pt;text-indent: 0pt;text-align: left;">ThyroSeq v3<span class="s64">™ </span><span class="s65">(genomic classifier)</span></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">94%</p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">82%</p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">66%</p></td><td style="width:53pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">97%</p></td><td style="width:90pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:19pt"><td style="width:183pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">NGS, 112 genes, point mutations</p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">93%</p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">90%</p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">68%</p></td><td style="width:53pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">98%</p></td><td style="width:90pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:19pt"><td style="width:183pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Gene fusions, copy # alterations</p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">99%</p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">64%</p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">78%</p></td><td style="width:53pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">96%</p></td><td style="width:90pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:19pt"><td style="width:183pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Gene expression alterations</p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:53pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:90pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:35pt"><td style="width:183pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s66" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">ThyGenX/ThyraMIR<span class="s64">®</span></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">57%</p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">92%</p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">74%</p></td><td style="width:53pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">94%</p></td><td style="width:90pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:68pt"><td style="width:183pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">NGS, 7 gene mutations</p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">Due to limited data no</p><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">meta-analysis estimation</p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:53pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:90pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:19pt"><td style="width:183pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">3 Gene fusions and 10 miRNAs</p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:53pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:90pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:19pt"><td style="width:183pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:53pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:90pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:19pt"><td style="width:183pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:53pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:90pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:19pt"><td style="width:183pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:53pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:90pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:19pt"><td style="width:183pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:53pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:90pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF;border-right-style:solid;border-right-width:1pt;border-right-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-left-style:solid;border-left-width:1pt;border-left-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="2" height="575" src="Image_260.png"/></span></p><ol id="l56"><li data-list-text="[3]"><p class="s53" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Silaghi CA, Lozovanu V, Silaghi H, Georgescu RD, Pop C, Dobrean A, et al. The Prognostic value of microRNAs in thyroid cancers—a systematic review and meta-analysis. Cancers (Basel). 2020;12(9).</p></li><li data-list-text="[4]"><p class="s53" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Ullmann TM, Gray KD, Moore MD, Zarnegar R, Fahey TJ 3rd. Current controversies and future directions in the diagnosis and management of differentiated thyroid cancers. Gland Surg. 2018;7(5):473–86.</p></li><li data-list-text="[5]"><p class="s53" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">de Koster EJ, de Geus-Oei LF, Dekkers OM, van Engen-van Grunsven I, Hamming J, Corssmit EPM, et al. Diagnostic utility of molecular and imaging biomarkers in cytological indeterminate thyroid nodules. Endocr Rev 2018;39(2):154–191.</p></li><li data-list-text="[6]"><p class="s53" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Patel KN, Angell TE, Babiarz J, Barth NM, Blevins T, Duh QY, et al. Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules. JAMA Surg. 2018;153(9):817–24.</p></li><li data-list-text="[7]"><p class="s53" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Endo M, Nabhan F, Porter K, Roll K, Shirley LA, Azaryan I, et al. Afirma gene sequencing classifier compared with gene expres sion classifier in indeterminate thyroid nodules. Thyroid. 2019;29(8):1115–24.</p></li><li data-list-text="[8]"><p class="s53" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Gortakowski M, Feghali K, Osakwe IN. Single institution experience with Afirma and Thyroseq testing in indeterminate thyroid nodules. Thyroid. 2021;31:1376.</p></li></ol><p class="s67" style="padding-left: 5pt;text-indent: 0pt;line-height: 16pt;text-align: left;">a<span class="s68">Real world confirmation</span></p><p class="s67" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">b<span class="s68">Meta-analysis</span></p><p class="s69" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">NGS <span class="s53">next generation sequencing, </span>GSC <span class="s53">gene sequencing classifier</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_261.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">than 4 cm with no clinical or ultrasound evidence of local invasion or metastases that are suspected of being malignant. This is based on the observation that specific tumor types (including minimally invasive FTC, FVPTC, and NIFTP, which may be molecularly identified as positive by these methods) have an observed clinical course that does not justify aggressive surgery and post-operative 131-I ablation, given a less favorable risk-benefit profile for total thyroidectomy. Any decision to recommend surgery, including hemithyroidectomy, however, is not without long-term conse quences, as up to 43% of patients may develop hypothyroidism post-operatively. Ongoing investigation into how molecular infor mation may guide preoperative planning and modify the subse quent clinical course of DTC is expected to further enhance the management of patients with indeterminate thyroid nodules (with the potential exception of finding a clinically unexpected medul lary thyroid cancer). Figure <span style=" color: #0000F9;">5.1 </span>shows a suggested management approach for the incorporation of molecular testing in the evalua tion of indeterminate thyroid nodules.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_262.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="574" height="353" src="Image_263.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="7" height="32" src="Image_264.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="7" height="32" src="Image_265.png"/></span></p><p class="s70" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Surgical interven on: Hemithyroidectomy if clinically uncomplicated (no clinical or US evidence of local invasion or metastases)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Clinical observa on with appropriate follow up</p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s70" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">associated muta on = high NPV</p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s70" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">a thyroid cancer = high PPV</p><p style="text-indent: 0pt;text-align: left;"/><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 5.1 <span class="s12">Molecular testing of the indeterminate thyroid nodule</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_266.png"/></span></p><h1 style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a60">Further Reading</a></h1><p class="s12" style="padding-top: 17pt;padding-left: 25pt;text-indent: -19pt;text-align: left;">de Koster EJ, de Geus-Oei LF, Dekkers OM, van Grunsven IVE, Hamming J, Corssmit EPM, et al. Diagnostic utility of molecular and imaging bio markers  in  cytological  indeterminate  thyroid  nodules.  Endocr  Rev. 2018;39(2):154–91.</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: right;">Desai D, Lepe M, Baloch ZW, Mandel SJ. ThyroSeq v3 for Bethesda III and IV: an institutional experience. Cancer Cytopathol. 2021;129(2):164–70. Endo M, Nabhan F, Porter K, Roll K, Shirley LA, Azaryan I, et al. Afirma gene sequencing classifier compared with gene expression classifier in</p><p class="s12" style="padding-left: 25pt;text-indent: 0pt;line-height: 14pt;text-align: justify;">indeterminate thyroid nodules. Thyroid. 2019;29(8):1115–24.</p><p class="s12" style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">Gortakowski M, Feghali K, Osakwe IN. Single institution experience with Afirma and Thyroseq testing in indeterminate thyroid nodules. Thyroid. 2021;31:1376.</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_267.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">nodules:  a  systematic  review  and  meta-analysis.  Front  Endocrinol. 2021;12(649522):19.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: justify;">Steward DL, Carty SE, Sippel RS, Yang SP, Sosa JA, Sipos JA, et al. Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study. JAMA Oncol. 2019;5(2):204–12.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: justify;">Ullmann TM, Gray KD, Moore MD, Zarnegar R, Fahey TJ 3rd. Current con troversies and future directions in the diagnosis and management of dif ferentiated thyroid cancers. Gland Surg. 2018;7(5):473–86.</p><p style="padding-left: 385pt;text-indent: 0pt;text-align: left;"><span><a href="http://crossmark.crossref.org/dialog/?doi=10.1007/978-3-031-18448-2_6&amp;domain=pdf"><img width="69" height="61" src="Image_268.png"/></a></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_269.png"/></span></p><p class="s71" style="padding-top: 11pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">and Karen C. McCowen</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s11" style="padding-left: 19pt;text-indent: 0pt;text-align: left;">Key Points</p><ul id="l57"><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Hashimotos’ and Graves’ disease glands exhibit hypoechogenicity on ultrasound (US).</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">“Thyroid inferno” has a high positive predictive value (PPV) for diagnosing and monitoring relapse of Graves’ disease.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Hashimoto’s glands are characterized by hypoecho genicity, micronodules, “white knight” and “giraffe pat</p></li></ul><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="226" height="1" src="Image_270.png"/></span></p><p class="s12" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">P. S. Ekanayake (<span class="s13">*</span>) · K. C. McCowen</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Division of Endocrinology, Diabetes and Metabolism, University of California, San Diego, San Diego, CA, USA</p><p class="s58" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;"><a href="mailto:pekanayake@health.ucsd.edu" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">e-mail: </a>pekanayake@health.ucsd.edu<a href="mailto:kmccowen@ucsd.edu" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">; </a><a href="mailto:kmccowen@ucsd.edu" target="_blank">kmccowen@ucsd.edu</a></p><p class="s12" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">O. Aisagbonhi</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Department of Pathology, University of California, San Diego,</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">San Diego, CA, USA</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><a href="mailto:oaisagbonhi@health.ucsd.edu" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">e-mail: </a><a href="mailto:oaisagbonhi@health.ucsd.edu" target="_blank">oaisagbonhi@health.ucsd.edu</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">© The Author(s), under exclusive license to Springer Nature Switzerland AG 2023</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">L. S. Eldeiry et al. (eds.), <i>Handbook of Thyroid and Neck Ultrasonography</i><a href="https://doi.org/10.1007/978-3-031-18448-2_6" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">, Contemporary Endocrinology, </a><a href="https://doi.org/10.1007/978-3-031-18448-2_6" target="_blank">https://doi.org/10.1007/978-3-031-18448-2_6</a></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_271.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><span><img width="575" height="200" src="Image_272.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_273.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a61">Introduction</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Apart from history, physical examination, and laboratory work- up, ultrasound (US) characteristics may be useful in distinguish ing  between  various  diffuse  thyroid  conditions  such  as Hashimoto’s thyroiditis, Graves’ disease, acute/subacute thy roiditis, and toxic multinodular goiter (TMNG). For example, the gland usually appears heterogeneous, enlarged, and hypervascu lar in Graves’ disease, whereas a heterogeneous, hypoechoic thy roid with pseudonodules is suggestive of Hashimoto’s. Thyroiditis can be characterized by early reduced vascularity followed by a hypervascular phase as the thyroid recovers. The diagnosis of TMNG often requires additional imaging such as a radioactive iodine uptake and scan.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a62">Case Presentation 1</a></h3><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">A 29-year-old woman was referred for abnormal lab tests and a several month history of severe fatigue, worsening depression, menorrhagia, and weight gain of 30 lbs. There was a strong family history of hypothyroidism. Physical exam was pertinent for an enlarged thyroid without any palpable nodules. Neck ultrasound was performed (see Image <span style=" color: #00F;">6.1</span>). Table <span style=" color: #00F;">6.1 </span>shows the potential dif ferential diagnosis for this ultrasound image.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_274.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="295" alt="An ultrasound image of the left lobe with thyroid parenchyma. The enlarged view of the gland is displayed in light and dark shades. " title="An ultrasound image of the left lobe with thyroid parenchyma. The enlarged view of the gland is displayed in light and dark shades. " src="Image_275.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 6.1  <span class="s12">Sagittal view of the left lobe. Thyroid parenchyma is hypoechoic with a heterogeneous echotexture. There are micronodules with internal col loid and irregular “puff pastry” or “honeycomb” appearance, with thin sur rounding echogenic walls. The gland is also enlarged</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse" cellspacing="0"><tr style="height:17pt"><td style="width:240pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">1. Hashimoto’s thyroiditis</p></td></tr><tr style="height:17pt"><td style="width:240pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">2. Subacute thyroiditis</p></td></tr><tr style="height:17pt"><td style="width:240pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">3. Graves’ disease</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><p class="s17" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Table 6.1 <span class="s12">Differential diagnosis of ultrasound</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Laboratory  tests  showed  significantly  elevated  TSH  of 296 uIU/L (ref 0.49–4.67), undetectable free T4 &lt; 0.25 ng/dL (ref 0.7–1.9), and total T3 &lt; 20 ng/dL (60–181). Thyroid peroxidase (TPO) antibody titer was elevated at 420 U/mL (ref &lt;60), con firming the diagnosis of Hashimoto’s thyroiditis with severe hypothyroidism. While the ultrasound was consistent with this diagnosis, it is worth noting that appearance on sonography is variable and in no way predicts the severity of thyroid dysfunc tion. The gland may vary from greatly enlarged to atrophic. She was treated with thyroid hormone replacement and subsequently had shrinkage of the goiter, although ultrasound was not repeated. Additional imaging as well as pathology examples of Hashimoto’s thyroiditis are seen on Images <span style=" color: #00F;">6.2</span>, <span style=" color: #00F;">6.3</span>, <span style=" color: #00F;">6.4</span></p><p class="s15" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">6.9<span style=" color: #2B2A29;">.</span></p><h3 style="padding-left: 25pt;text-indent: 0pt;text-align: left;"><a name="a63">Additional Imaging Examples of Hashimoto’s Thyroiditis</a></h3><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_276.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="314" alt="An ultrasound image of Hashimoto&#39;s thyroiditis with a hypoechoic, very heterogeneous thyroid lobe. It appears in dark and light shades. Borders of the gland are marked with a plus sign." title="An ultrasound image of Hashimoto&#39;s thyroiditis with a hypoechoic, very heterogeneous thyroid lobe. It appears in dark and light shades. Borders of the gland are marked with a plus sign." src="Image_277.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 6.2  <span class="s12">Sagittal view of the left lobe shows a hypoechoic, very heteroge neous thyroid lobe. Borders of the gland have a lobular and irregular contour.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="573" height="182" alt="Two ultrasound images of Hashimoto&#39;s giraffe hide pattern with globular hyperechogenic areas that appear bright. It is surrounded by linear, thin hypoechoic areas that appear dark." title="Two ultrasound images of Hashimoto&#39;s giraffe hide pattern with globular hyperechogenic areas that appear bright. It is surrounded by linear, thin hypoechoic areas that appear dark." src="Image_278.gif"/></span></p><p class="s59" style="text-indent: 0pt;text-align: left;">a</p><p style="text-indent: 0pt;text-align: left;"/><p class="s59" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><span class="s17">Image 6.3 </span>Transverse (<b>a</b>) and sagittal (<b>b</b>) views showing a “giraffe hide” pat tern of Hashimoto’s, which is characterized by globular hyperechogenic (bright) areas surrounded by linear, thin hypoechoic (dark) areas similar to the two-color patterns seen on a giraffe. Margins of the Hashimoto’s gland are also lobulated</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a64">Case Presentation 2</a></h3><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">A 26-year-old female with a history of refractory acute lympho cytic leukemia and allogenic stem cell transplant was referred to endocrinology for weight loss, palpitations, proximal muscle weakness, tremors, and dry eyes. Physical exam was notable for sinus tachycardia, proptosis, and a firm, diffusely enlarged thyroid without palpable nodules.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_279.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="421" src="Image_280.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 6.4  <span class="s12">The classic “white knight” (arrow), which is a well-demarcated, hyperechoic nodule with a dark/hypoechoic halo. This is sometimes referred to as “nodular Hashimoto’s.” These lesions are composed of hyperplastic islands surrounded by hypoechoic tissue. Some patients with long-standing Hashimoto’s have sonographic findings of a “hypoechoic triangle” (HET) sign, which is a 10 mm triangular hypoechoic region between the lateral wall of the atrophic thyroid lobe and the medial wall of the carotid (not shown)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 25pt;text-indent: 0pt;text-align: left;">Her mother had hypothyroidism. Images</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">her initial ultrasonography. Table <span style=" color: #00F;">6.2 </span>shows the correct differen tial diagnosis based on this ultrasonography pattern.</p><p style="padding-left: 25pt;text-indent: 0pt;text-align: left;">Bloodwork revealed a suppressed TSH of &lt;0.01 uIU/mL (ref</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">&lt;0.3 uIU/mL), elevated free T4 of 4.15 ng/dL (ref 0.9-2.3 ng/dL) and total T3 of 3.5 ng/mL (ref 0.8-2 ng/mL). Thyroid stimulating immunoglobulins (TSI) were elevated at 5.49 IU/L (ref &lt;0.54) and TSH receptor antibodies (TRAB) were 8.61 IU/L (ref &lt;1.75). She was diagnosed with Graves’ disease and started on methima zole 10 mg twice a day. After two doses, she had a severe anaphy lactic reaction requiring epinephrine. Given the severity of the thyrotoxicosis and inability to tolerate thionamides, she under</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_281.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="273" src="Image_282.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 6.5  <span class="s12">The thyroid parenchyma can have increased vascularity in the early stages of Hashimoto’s (sagittal image above shows slight textural patch iness; color Doppler below). In later, atrophic stages, thyroid vascularity can be decreased, due to extensive fibrosis. The hypervascularity of Hashimoto’s is not as impressive as that in Graves’ disease</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="406" src="Image_283.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Image 6.6  <span class="s12">Chronic lymphocytic thyroiditis (Hashimoto’s) classically shows diffuse involvement of the thyroid gland by a prominent lymphoid infiltrate with associated germinal centers (arrows) (×4 H&amp;E)</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_284.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 17pt;text-indent: 0pt;text-align: left;"><span><img width="545" height="328" src="Image_285.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 6.7  <span class="s12">Hashimoto’s may be associated with reactive adenopathy (arrow) that is especially common around the inferior thyroid lobes</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="570" height="163" alt="Two ultrasound images of Hashimotoђs Delphian lymph nodes. The nodes pointed out by arrows look like thick drops with granules of tiny dots." title="Two ultrasound images of Hashimotoђs Delphian lymph nodes. The nodes pointed out by arrows look like thick drops with granules of tiny dots." src="Image_286.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 6.8  <span class="s12">Occasionally noted in cases of Hashimoto’s are Delphian lymph nodes, located superior to the isthmus, giving the appearance of one or two “eyes” (arrows)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="160" src="Image_287.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 6.9  <span class="s12">Since the echotexture can be so heterogeneous, identification of papillary thyroid carcinoma (arrow) in a Hashimoto’s gland may be difficult and delayed. In this case, a nodule with irregular margins and microcalcifica tions can be seen in sagittal (left panel) and transverse views (right panel)</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_288.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="153" alt="Two ultrasound images. The first highlights a heterogeneous, hypoechoic thyroid parenchyma with a coarse echotexture, and the second highlights smooth borders and a hypoechogenic with coarse parenchyma." title="Two ultrasound images. The first highlights a heterogeneous, hypoechoic thyroid parenchyma with a coarse echotexture, and the second highlights smooth borders and a hypoechogenic with coarse parenchyma." src="Image_289.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">of Hashimoto’s) and a hypoechogenic, coarse parenchyma</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s16" style="padding-left: 15pt;text-indent: 0pt;text-align: left;"><span><img width="298" height="149" alt="Two color flow doppler images of the thyroid parenchyma are highlighted. The image on the left has a horizontal black shade at the center with color spots around it. The image on the right has its full area covered by colorful spots." title="Two color flow doppler images of the thyroid parenchyma are highlighted. The image on the left has a horizontal black shade at the center with color spots around it. The image on the right has its full area covered by colorful spots." src="Image_290.jpg"/></span> <span><img width="258" height="149" alt="Two color flow doppler images of the thyroid parenchyma are highlighted. The image on the left has a horizontal black shade at the center with color spots around it. The image on the right has its full area covered by colorful spots." title="Two color flow doppler images of the thyroid parenchyma are highlighted. The image on the left has a horizontal black shade at the center with color spots around it. The image on the right has its full area covered by colorful spots." src="Image_291.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 6.11 <span class="s12">The thyroid parenchyma is markedly hypervascular on color flow Doppler</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse" cellspacing="0"><tr style="height:17pt"><td style="width:245pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">1. Graves’ disease</p></td></tr><tr style="height:17pt"><td style="width:245pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">2. Hashimoto’s thyroiditis</p></td></tr><tr style="height:17pt"><td style="width:245pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">3. Silent thyroiditis</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><p class="s17" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Table 6.2 <span class="s12">Differential diagnosis of the Ultra- sound Image </span><span class="s58">6.10</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">went total thyroidectomy. Image <span style=" color: #00F;">6.12a, b </span>shows the pathology of the resected thyroid. Images <span style=" color: #00F;">6.13 </span>and <span style=" color: #00F;">6.14</span></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">logical images for Graves’ disease.</p><h3 style="padding-left: 30pt;text-indent: 0pt;text-align: left;"><a name="a65">Additional Imaging Examples of Graves’ Disease</a></h3><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">In qualitative color flow Doppler (CFD), pattern 0 is blood flow limited to the peripheral thyroid arteries, while parenchymal flow is absent (i.e., normal thyroid); pattern I is mildly increased parenchymal flow; pattern II is clearly increased flow with a dif fuse distribution; and pattern III is markedly increased color flow with a homogenous distribution. The cutoff for the quantitative</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_292.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="200" alt="Two ultrasound images of the thyroid gland. A structure like branching lines appears at a distance in a and closer in b. An asterisk is marked on clustered granules on a and two asterisks are marked on two nodes on b." title="Two ultrasound images of the thyroid gland. A structure like branching lines appears at a distance in a and closer in b. An asterisk is marked on clustered granules on a and two asterisks are marked on two nodes on b." src="Image_293.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">hyperplasia with reduced colloid and follicles that exhibit non-branching pap illary projections (asterisk*) into the lumen (<b>a</b>; ×20 H&amp;E). Treated Graves may exhibit some colloid; thyroid follicles have papillary projections (aster isks*) that are often associated with prominent colloid scalloping (</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">H&amp;E)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="295" alt="A radiological image for gravesђ disease with the thyroid blood flow measured qualitatively by color flow Doppler. The colors are in clusters on the mid-point left." title="A radiological image for gravesђ disease with the thyroid blood flow measured qualitatively by color flow Doppler. The colors are in clusters on the mid-point left." src="Image_294.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 6.13  <span class="s12">A different example of “thyroid inferno” sign, which is a marked increase in parenchymal thyroid blood flow, pathognomonic of untreated and/or uncontrolled Graves’ disease. The thyroid blood flow can be measured qualitatively by color flow Doppler (CFD) (as above), or quantita tively by peak systolic velocity (PSV) at the inferior thyroid artery (not shown). Graves’ disease patients who become euthyroid have low or normal CFD and PSV compared to uncontrolled Graves’ patients. Therefore, an increase in CFD can be an early marker for identifying a euthyroid patient that is progressing to hyperthyroidism during a thionamide hiatus</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_295.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="394" src="Image_296.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><span class="s17">Image 6.14  </span>The patient in Image <span style=" color: #00F;">6.13 </span>had an I-123 radioiodine uptake and scan. Uptake at 6 h was 46.1% (normal, 5–15%) and at 24 h was 67.6% (nor mal, 15–35%). There are also multiple, bilateral small cold nodules (arrows demonstrate darker areas within the thyroid). The cold nodules were biopsied and showed benign (Bethesda II) cytology</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">measurement, the PSV, differentiating Graves’ disease from thy roiditis is ~40 to 50 cm/s. Image <span style=" color: #00F;">6.13 </span>shows pattern III CFD.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a66">Case Presentation 3</a></h3><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">A 59-year-old woman with a history of atrial fibrillation presented with worsening palpitations, dyspnea on exertion, peripheral edema, and tremor. She was treated with amiodarone for many years. She denied neck pain, but reported new anterior neck full ness. On physical examination, she was in no apparent distress, but had signs of congestive heart failure, including tachycardia, peripheral edema, and jugular venous distension. Thyroid gland had an irregular texture and was marginally enlarged. Laboratory values showed a suppressed TSH of &lt;0.01 uIU/mL (ref &lt;0.3 uIU/ mL), high free T4 of &gt;7.77 ng/dL (ref 0.9-2.3 ng/dL), and total T3 of 3.1 ng/mL (0.8-2 ng/mL). Images <span style=" color: #00F;">6.15</span></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">tial ultrasound. Table <span style=" color: #00F;">6.3 </span>shows the differential diagnosis based on image findings.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_297.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="158" alt="Two ultrasound images of thyroid parenchyma highlight mildly hypoechogenic with coarse echotexture on the bright and darker region enlarged lobes." title="Two ultrasound images of thyroid parenchyma highlight mildly hypoechogenic with coarse echotexture on the bright and darker region enlarged lobes." src="Image_298.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 12pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">there are no nodules</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="268" alt="An ultrasound image of the right lobe with several bright and dark spots. The left side of the image has a large bright patch of approximately 6 centimeters per second." title="An ultrasound image of the right lobe with several bright and dark spots. The left side of the image has a large bright patch of approximately 6 centimeters per second." src="Image_299.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 6.16 <span class="s12">Sagittal view of the right lobe shows very low parenchymal vascularity</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse" cellspacing="0"><tr style="height:17pt"><td style="width:216pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">1. Hashimoto’s thyroiditis</p></td></tr><tr style="height:17pt"><td style="width:216pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">2. Subacute thyroiditis</p></td></tr><tr style="height:17pt"><td style="width:216pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">3. Graves’ disease</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><p class="s17" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Table 6.3 <span class="s12">Differential diagnosis of the ultrasound</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_300.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 19pt;text-align: left;">Destructive thyroiditis may respond well to glucocorticoids. This patient was started on high doses of prednisone, but due to worsening heart failure and inability to effectively control the thy rotoxicosis, she required thyroidectomy. The resected thyroid appeared edematous and enlarged, due to acute inflammation. Image <span style=" color: #00F;">6.17 </span>shows a pathology slide of the patient’s resected thy</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="573" height="406" src="Image_301.png"/></span></p><p class="s72" style="text-indent: 0pt;text-align: left;">*</p><p style="text-indent: 0pt;text-align: left;"/><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 6.17  <span class="s12">Light microscopy of the above patient’s resected thyroid with thyroiditis. The thyroid has colloid-rich, denuded thyroid follicles, and vacu olated cytoplasm (white arrow) with surrounding areas infiltrated by foamy histiocytes (black asterisk). (×10 H&amp;E)</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_302.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 12pt;text-indent: 0pt;text-align: left;"><span><img width="570" height="237" alt="Two I-123 uptake scans of destructive thyroiditis highlight granules of tiny dots circumscribed within two circular structures." title="Two I-123 uptake scans of destructive thyroiditis highlight granules of tiny dots circumscribed within two circular structures." src="Image_303.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 6.18  <span class="s12">I-123 uptake and scan of another patient with destructive thy roiditis. Uptake at 6 h is 0.8% and at 24 h is 0.4%, which is very low</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 11pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">roid. Image <span style=" color: #00F;">6.18 </span>shows I-123 uptake and scan of a different patient with destructive thyroiditis.</p><h3 style="padding-left: 5pt;text-indent: 19pt;text-align: justify;"><a name="a67">Additional  Imaging  Examples  of  Non-Autoimmune, Destructive Thyroiditis:</a></h3><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Case Presentation 4</h3><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">A 70-year-old female smoker with atrial fibrillation, osteoporosis, and a goiter presented with long-standing fatigue, weight loss, proximal muscle weakness, palpitations, and tremors. She denied a family history of thyroid disease. Exam was notable for a visible goiter with bilateral thyroid nodules, an irregularly irregular heart rhythm, and fine hand tremor. Lab work demonstrated a sup pressed TSH of &lt;0.16 uIU/mL (ref &lt;0.3 uIU/mL) and normal free T4 of 1.4 ng/dL (ref 0.9-2.3 ng/dL). Images</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">her initial ultrasound. Table <span style=" color: #00F;">6.4 </span>shows the differential diagnosis in this case based on the image findings.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: justify;">Thyroid autoantibodies were negative. Given the patient’s age and comorbidities, methimazole was prescribed for subclinical hyperthyroidism. Subsequent I-123 uptake and scan showed both “hot” and “cold” nodules. Diagnosis of TMNG was made, based on the presence of palpable and sonographically localized thyroid nodules, increased radioiodine uptake in the nodules with a low uptake in surrounding thyroid tissue, and excess thyroid hormone</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_304.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="574" height="283" src="Image_305.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 6.19  <span class="s12">Multiple nodules were demonstrated bilaterally. The nodule in the right inferior lobe is solid and hypoechoic, with peripheral rim calcifica tions (arrow)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="309" alt="An ultrasound image of the superior lobe nodules highlights glands with multiple overlapping or confluent nodules. It appears in dark and light shades." title="An ultrasound image of the superior lobe nodules highlights glands with multiple overlapping or confluent nodules. It appears in dark and light shades." src="Image_306.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 6.20  <span class="s12">In contrast to the inferior lobe nodules, the superior lobe nod ules are solid and hyperechoic. Glands with multiple overlapping or confluent nodules/lobules should be distinguished from those with distinct nodules, as often in the former case, biopsy is not required and observation is sufficient</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_307.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 210pt;text-indent: 0pt;text-align: left;"><span><img width="304" height="48" src="Image_308.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="568" height="78" alt="Four I-123 uptake scans of a patient with toxic multinodular goiter with hot and cold nodules. Two arrows point at high radioiodine uptake in the superior right lobe and an arrow points at low radioiodine uptake in the right inferior lobe." title="Four I-123 uptake scans of a patient with toxic multinodular goiter with hot and cold nodules. Two arrows point at high radioiodine uptake in the superior right lobe and an arrow points at low radioiodine uptake in the right inferior lobe." src="Image_309.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 12pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">(darker areas) are in the right inferior lobe (left panel, bottom arrow)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 8pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">production leading to TSH suppression. TMNG results from autonomously functioning thyrocytes.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">On ultrasound, “hot” (autonomous) nodules may appear hyper echoic compared to “cold” nodules. But a hyperechoic nodule on US does not exclude the presence of thyroid cancer since follicu lar thyroid cancer may present this way. I-123 scan with increased iodine uptake corresponding to the hyperechoic nodules generally excludes thyroid cancer within these nodules. “Cold” nodules (with reduced iodine uptake) meeting fine needle aspiration (FNA) size criteria should be biopsied. This patient had FNAs of the cold nodules, which showed benign cytology. Images</p><p class="s15" style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">6.22 <span style=" color: #2B2A29;">show two different patients with toxic multinodular goiter with hot and cold nodules. Image </span>6.23 <span style=" color: #2B2A29;">is the pathology slide of the resected thyroid of the patient on image </span>6.22</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">pressive multinodular goiter.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Other Imaging Examples of Diffuse Thyroid Disease: <span class="p">Subacute Thyroiditis Sonography of subacute (also known as painful or granulomatous) thyroiditis can be misleading when nodular areas are evident. In this condition, thyroid parenchyma can be patchy, with hypoechoic, focal areas. Vascularity is gener ally decreased. Over time, these abnormalities resolve, thus care</span></h3><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_310.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="239" src="Image_311.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><span class="s17">Image 6.22  </span>A severe case of TMNG with a suppressed TSH of 0.015, nega tive  thyroid  autoantibodies,  and  symptoms  of  compression.  Contrast- enhanced coronal (<b>a</b>) and axial (<b>b</b>) CT images of the neck show a large, exophytic mass (arrows) projecting along the inferior aspect of the left thy roid gland, measuring approximately 5 × 4.4 × 4.6 cm, compressing the esophagus, and deviating the trachea. Note: iodinated contrast commonly used in radiologic examinations and interventional procedures results in a huge iodide exposure to the thyroid, which, in individucals with pre-existing thyroid disease, can result in thyrotoxicosis</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="406" src="Image_312.png"/></span></p><p class="s17" style="padding-top: 8pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Image 6.23  <span class="s12">The  above  patient  with TMNG  had  a  thyroidectomy  for mechanical compression symptoms. Histologic sections show adenomatoid nodules that are circumscribed, unencapsulated nodules (arrow) comprised of benign thyroid follicles benign thyroid follicles (×4 H&amp;E)</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_313.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="573" height="195" src="Image_314.png"/></span></p><p class="s21" style="text-indent: 0pt;text-align: left;">a</p><p style="text-indent: 0pt;text-align: left;"/><p class="s21" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">with subacute thyroiditis. Irregular echotexture is common and hypoechoic areas can sometimes resemble nodules (arrow)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">ful consideration should be given before pursuing fine needle aspiration<b>. </b>Image <span style=" color: #00F;">6.24 </span>shows this additional example.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_315.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a68">Discussion</a></h1><p style="padding-top: 17pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">In general, ultrasonography is not a major component of the diag nosis of autoimmune thyroid disease (AITD), which is primarily driven by clinical and biochemical findings. However, due to the finding of thyromegaly on physical exam, ultrasound is often per formed to rule out the presence of nodules that may require biopsy.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Hashimoto’s and Graves’ disease, as well as non-immune thy roid diseases (such as destructive thyroiditis and TMNG) have some defining characteristics on US. Reduced thyroid echo genicity is a strong predictor of AITD. This finding can occur early in the disease course, even before the onset of thyroid dys function. Although the sensitivity of this finding is high, hypoecho genicity is not specific to AITD, as thyroiditis can also present with this feature. However, micronodularity has a positive predic tive value (PPV) of 95% for Hashimoto’s thyroiditis. Large pseudonodules (which often appear as nodular regions surrounded by white, fibrous bands) are relatively common in Hashimoto’s and a less experienced operator may not recognize that such</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_316.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_317.png"/></span></p><h1 style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a69">Further Reading</a></h1><p class="s12" style="padding-top: 17pt;padding-left: 30pt;text-indent: -19pt;text-align: justify;">Chung J, et al. Clinical applications of Doppler ultrasonography for thyroid disease: consensus statement by the Korean Society of Thyroid Radiology. Ultrasonography. 2020;39:315–30.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: justify;">Pedersen OM, et al. The value of ultrasonography in predicting autoimmune thyroid disease. Thyroid. 2000;10(3):251–9.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Scappaticcio L, et al. Diagnostic testing for Graves’ or non-Graves’ hyperthy roidism: a comparison of two thyrotropin receptor antibody immunoas says with thyroid scintigraphy and ultrasonography. Clin Endocrinol (Oxf). 2020;92(2):169–78.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Solivetti FM, et al. “Hypoechoic triangle”: a new sonographic sign or marker of advanced autoimmune thyroiditis. Thyroid. 2011;21(3):285–9.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Vitti P, et al. Thyroid blood flow evaluation by color-flow Doppler sonogra phy  distinguishes  graves’  disease  from  Hashimoto’s  thyroiditis.  J Endocrinol Invest. 1995;18:857–61.</p><p style="padding-left: 385pt;text-indent: 0pt;text-align: left;"><span><a href="http://crossmark.crossref.org/dialog/?doi=10.1007/978-3-031-18448-2_7&amp;domain=pdf"><img width="69" height="61" src="Image_318.png"/></a></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s11" style="padding-left: 19pt;text-indent: 0pt;text-align: left;">Key Points</p><ul id="l58"><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Thyroid nodule composition can be described as solid, cystic, or complex, with &gt;50% of the nodule contents determining the overall composition.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Spongiform nodules contain numerous tiny cysts in</p><p style="padding-left: 39pt;text-indent: 0pt;text-align: justify;">&gt;50% of the nodule. The presence of colloid artifact must be distinguished from microcalcifications, as both can appear as tiny echogenic foci.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: left;">Fine needle aspiration (FNA) is recommended for solid nodules &gt;1–1.5 cm, and some smaller nodules, depend ing on other ultrasound characteristics.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: left;">FNA can be considered for spongiform nodules &gt;2 cm, though these nodules may also be observed clinically.</p></li></ul><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="226" height="1" src="Image_319.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_320.png"/></span></p><p class="s12" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">L. S. Eldeiry (<span class="s13">*</span>)</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Department of Endocrinology, Harvard Vanguard Medical Associates/ Atrius Health and Harvard Medical School, Boston, MA, USA</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;"><a href="mailto:Leslie_eldeiry@atriushealth.org" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">e-mail: </a><a href="mailto:Leslie_eldeiry@atriushealth.org" target="_blank">Leslie_eldeiry@atriushealth.org</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">© The Author(s), under exclusive license to Springer Nature Switzerland AG 2023</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">L. S. Eldeiry et al. (eds.), <i>Handbook of Thyroid and Neck Ultrasonography</i><a href="https://doi.org/10.1007/978-3-031-18448-2_7" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">, Contemporary Endocrinology, </a><a href="https://doi.org/10.1007/978-3-031-18448-2_7" target="_blank">https://doi.org/10.1007/978-3-031-18448-2_7</a></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_321.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><span><img width="575" height="154" src="Image_322.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">is based on the <b>ratio of cystic to solid components </b>nodules have no solid components, while solid nodules have no cystic components.</p><ul id="l59"><li data-list-text="•"><h3 style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Complex nodules: <span class="p">have both solid and cystic components, with predominantly cystic lesions comprised of</span></h3><p style="padding-left: 30pt;text-indent: 0pt;text-align: left;">fluid and predominantly solid lesions comprised of solid components.</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;"><b>Spongiform nodules: </b>are comprised of numerous tiny micro- and macro-cysts in &gt;50% of the nodule. Examples are pre sented later in the chapter (Images <span style=" color: #00F;">7.8 </span>and</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a70">Case Presentation</a></h3><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">A 29-year-old woman with no significant medical history or fam ily history of thyroid disease presented with a large midline neck mass. The mass was painless and non-tender, located in the mid line and lower neck, measured 4 × 6 cm on physical exam, elevated with swallowing, and was not associated with cervical adenopathy. Laryngoscopic examination was normal. TSH was</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">1.43 mIU/L. Neck ultrasound demonstrated a 6.3 × 6.2 × 3.3 cm midline complex neck nodule (Image</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">obtained for further evaluation and showed a 6.7 cm large cystic mass probably arising from the inferior thyroid containing a</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">2.1 cm enhancing nodule (Images <span style=" color: #00F;">7.2 </span>and <span style=" color: #00F;">7.3</span></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">The differential diagnosis of the neck mass is presented in Table <span style=" color: #00F;">7.1</span>.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_323.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="236" src="Image_324.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 7.1  <span class="s12">A complex, predominantly cystic nodule. Left: A cystic isthmic nodule extending into the right lobe of the thyroid. The solid component is pedunculated, irregular, with calcifications around the border and some inter nal echogenic foci (arrow). Right: Hypervascular solid component on color Doppler</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="209" src="Image_325.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 7.2  <span class="s12">Axial MRI. Left: Axial T1 fat-saturated precontrast image. Right: Axial T1 fat-saturated postcontrast image. This image shows the nodu lar enhancement of the solid component of the cystic lesion (arrows)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Ultrasound-guided FNA of the solid portion of the nodule was performed. Several mL’s of gelatinous, hemorrhagic fluid was drained from the cystic portion. Cytology evaluation was chal lenging because of the cystic changes in the lesion. Cytology showed groups of vacuolated plasmacytoid cells with basophilic cytoplasm (Image <span style=" color: #00F;">7.4a, b</span>). Cellblock preparation demonstrated</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_326.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="240" src="Image_327.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 7.3  <span class="s12">Sagittal MRI T1 and T2 sequences demonstrate the solid (arrows indicate solid component) and cystic components. Left: Coronal T1 fat-satu rated postcontrast image. Right: Sagittal T2 image without contrast</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse" cellspacing="0"><tr style="height:17pt"><td style="width:263pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">1. Thyroglossal duct cyst</p></td></tr><tr style="height:17pt"><td style="width:263pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">2. Benign cystic thyroid nodule</p></td></tr><tr style="height:17pt"><td style="width:263pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">3. Cystic papillary thyroid carcinoma</p></td></tr><tr style="height:17pt"><td style="width:263pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">4. Cystic parathyroid adenoma</p></td></tr><tr style="height:32pt"><td style="width:263pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 18pt;padding-right: 85pt;text-indent: -14pt;text-align: left;">5. Metastasis from e malignancy</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><p class="s17" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Table 7.1 <span class="s12">Differential diagnosis</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">papillary architecture with single detached vacuolated cells, pseudonuclear inclusions, and psammoma bodies. Positive immu nohistochemistry for CK7 stain highlighted the papillary frag ments (Image <span style=" color: #00F;">7.5a, b</span>). The overall findings were interpreted as consistent with papillary thyroid carcinoma (PTC).</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: justify;">The patient underwent total thyroidectomy. Histopathology showed a 6.7 cm cystic PTC in the isthmus and inferior right lobe, classical subtype with a 2.0 cm solid portion (Image</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">sub-centimeter metastatic paratracheal lymph nodes. Staining for BRAFV600E mutation was positive. She was subsequently treated with radioactive iodine. Post-therapy whole body imaging and subsequent surveillance testing indicated no distant metasta sis or persistent disease.</p><h3 style="padding-left: 30pt;text-indent: 0pt;text-align: left;"><a name="a71">Thyroid Nodule Composition: Additional Examples</a></h3><p style="padding-left: 30pt;text-indent: 0pt;text-align: left;">See Images <span style=" color: #00F;">7.7</span>, <span style=" color: #00F;">7.8</span>, <span style=" color: #00F;">7.9</span>, <span style=" color: #00F;">7.10 </span>and <span style=" color: #00F;">7.11</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_328.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="572" height="240" alt="2 microscopic images of follicular cells in clusters labeled a and b. A: an arrow indicates the cluster of follicular cells with nuclei and nucleoli. b. an arrow indicates the thick inspissated colloid in the follicular cells. " title="2 microscopic images of follicular cells in clusters labeled a and b. A: an arrow indicates the cluster of follicular cells with nuclei and nucleoli. b. an arrow indicates the thick inspissated colloid in the follicular cells. " src="Image_329.jpg"/></span></p><p class="s59" style="text-indent: 0pt;text-align: left;">a</p><p style="text-indent: 0pt;text-align: left;"/><p class="s59" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><span class="s17">Image 7.4 </span>(<b>a</b>) Follicular cells arranged in clusters (arrow) with hyperchro matic, enlarged nuclei and prominent nucleoli (Thin-prep cytology, PAP stain,</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">×40). (<b>b</b>) Cluster of follicular cells with enlarged, hyperchromatic nuclei and thick inspissated colloid (arrow) (Thin-prep cytology, PAP stain, ×40)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="572" height="323" alt="2 microscopic images of cellblock preparation display, a. the papillary architecture of separated stained vacuolated cells, and b. the papillary fragments with stained cells." title="2 microscopic images of cellblock preparation display, a. the papillary architecture of separated stained vacuolated cells, and b. the papillary fragments with stained cells." src="Image_330.jpg"/></span></p><p class="s59" style="text-indent: 0pt;text-align: left;">a</p><p style="text-indent: 0pt;text-align: left;"/><p class="s59" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><span class="s17">Image 7.5  </span>(<b>a</b>) Cellblock preparation demonstrated papillary architecture with single detached vacuolated cells (<b>a</b>, arrow, H&amp;E, ×40), pseudonuclear inclusions, and psammoma bodies (<b>a </b>insert, asterisk, H&amp;E, ×60). Positive immunohistochemistry for CK7 stain highlighted the papillary fragments ( CK7 immunohistochemical stain, ×20).</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_331.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="381" alt="A microscopic image of stained papillary thyroid carcinoma with a pattern of lines and cells with a thick border. The enlarged image displays an arrow pointing to the dark spots." title="A microscopic image of stained papillary thyroid carcinoma with a pattern of lines and cells with a thick border. The enlarged image displays an arrow pointing to the dark spots." src="Image_332.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 7.6 <span class="s12">Papillary thyroid carcinoma (H&amp;E, ×2); insert shows typical psammoma bodies (arrow, H&amp;E ×4)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="180" src="Image_333.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><span class="s17">Image 7.7  </span>Left, sagittal and Right, transverse views of the left mid thyroid. <b>Predominantly cystic </b>3.5 cm, benign left lobe nodule with peripheral soft tissue elements (arrows). Cystic lesions of this type are often initially spongi form nodules in which a macro-cystic component predominates. The fluid may contain low reflective echoes, representing either debris or recent or old spontaneous hemorrhage</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_334.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="580" height="193" alt=" 2 ultrasound images of the thyroid with a classic spongiform nodule. A scale measures the length of the node and is marked x. " title=" 2 ultrasound images of the thyroid with a classic spongiform nodule. A scale measures the length of the node and is marked x. " src="Image_335.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-top: 4pt;padding-left: 5pt;text-indent: 71pt;text-align: left;">Classic spongiform nodule <span class="s12">containing scattered tiny echogenic foci in the posterior portion of the cysts that most likely represent colloid. FNA is not recommended but may be considered for larger nodules. Observa tion and follow-up imaging in 1 year is another aproach</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><span><img width="579" height="218" alt="2 ultrasound images of the thyroid. The arrows indicate the microcystic components with the comet tail artifact." title="2 ultrasound images of the thyroid. The arrows indicate the microcystic components with the comet tail artifact." src="Image_336.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 7.9  <span class="s12">Microcystic components may contain bright reflective echoes with comet tail artifact. These represent colloid crystals/inspissated colloid rather than microcalcifications. They are often located in the dependent por tion of the cysts (arrows)</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_337.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><span><img width="574" height="172" src="Image_338.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 11pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">composition</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="311" src="Image_339.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 7.11 <span class="s12">Transverse image of a 2.5 cm </span><span class="s22">solid, heterogeneous</span></p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">nodule (arrow). FNA is recommended, with targeting of the heterogeneous, hypoechoic components of the nodule</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_340.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a72">Discussion</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">A purely cystic nodule is highly unlikely to be malignant. These nodules are either simple colloid cysts or may result from cystic degeneration or hemorrhage into a benign, hyperplastic nodule. The majority of predominantly cystic thyroid nodules are benign.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_341.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 19pt;text-align: left;">Sometimes the determination of composition of a thyroid nodule on ultrasound can be challenging. For example, in spongiform nod ules, which are essentially a cluster of numerous micro- and various sized macro-cysts, there are often high reflective echoes. Differentiating microcalcifications from colloid crystals/inspis sated colloid can sometimes be difficult. Colloid is classically iden tified either by a comet tail projecting posteriorly from the high reflective echo or by the presence of the high reflective echo in the most dependent portion of the micro- or macro-cyst (see Images and <span style=" color: #00F;">7.9</span>). When it is not possible to differentiate colloid artifact from microcalcifications, FNA may be necessary to confirm benign cytology. Spongiform nodules, which are often a feature of colloid nodules or goiter, can be avascular or hypervascular. Doppler evalu ation to assess vascularity may therefore not be helpful.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Another difficult distinction in the assessment of nodule com position is distinguishing cysts from pseudocystic nodules. Cysts usually contain homogeneous fluid, are anechoic, have smooth margins, and remain relatively stable or enlarge very slowly. Pseudocystic  nodules  often  contain  heterogeneous-appearing fluid with low level reflective echoes, sometimes with dependent debris. These lesions may appear suddenly, most commonly due to spontaneous bleeding in a spongiform nodule. They either slowly resolve on their own or the blood may be slowly resorbed, ultimately resulting in a remnant pure cyst.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Approximately 5–10% of solid thyroid nodules are malignant and depending on the size and ultrasound characteristics, evalua tion with FNA for cytology is usually necessary. FNA of the solid</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_342.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">FNA should be considered to resolve any uncertainties. When cytology is indeterminate, repeat sampling and molecular marker testing may be useful.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_343.png"/></span></p><h1 style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;"><a name="a73">Further Reading</a></h1><p style="padding-top: 17pt;padding-left: 30pt;text-indent: -19pt;text-align: left;"><a href="https://www.appliedradiology.com/Communities/Pediatric-Imaging/imaging-of-thyroid-nodules" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">Chung R, Kim D. Imaging of thyroid nodules. Appl Radiol. </a><a href="https://www.appliedradiology.com/Communities/Pediatric-Imaging/imaging-of-thyroid-nodules" target="_blank">appliedradiology.com/Communities/Pediatric-</a></p><p style="padding-left: 30pt;text-indent: 0pt;line-height: 14pt;text-align: left;"><a href="https://www.appliedradiology.com/Communities/Pediatric-Imaging/imaging-of-thyroid-nodules">thyroid-nodules</a></p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Haugen BR, et al. Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Kim JY, Kim E-K, Lee HS, Kwak JY. Conventional papillary thyroid carci noma: effects of cystic changes visible on ultrasonography on disease prognosis. Ultrasonography. 2014;33(4):291–7.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Mokhtari M, Kumar PV, Hayati K. Fine-needle aspiration study of cystic pap illary  thyroid  carcinoma:  rare  cytological  findings.  J  Cytol. 2016;33(3):120–4.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: justify;">Yang GCH, Stern CM, Messina AV. Cystic papillary thyroid carcinoma in fine needle aspiration may represent a subset of the encapsulated variant in WHO classification. Diagn Cytopathol. 2009;38(10):721–6.</p><p style="padding-left: 385pt;text-indent: 0pt;text-align: left;"><span><a href="http://crossmark.crossref.org/dialog/?doi=10.1007/978-3-031-18448-2_8&amp;domain=pdf"><img width="69" height="61" src="Image_344.png"/></a></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s11" style="padding-left: 19pt;text-indent: 0pt;text-align: left;">Key Points</p><ul id="l60"><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">The echogenicity of the thyroid is an important indicator of underlying thyroid disorders and/or the presence of focal thyroid masses.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: left;">Technical factors can affect the classification of echo genicity and may alter risk assessment. Settings may need to be adjusted carefully during real-time scanning to properly characterize lesions.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: left;">Recognition of certain patterns of echogenicity may pre vent unnecessary tissue sampling of common benign conditions.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: left;">Anechoic cysts and classic spongiform nodules are highly likely to be benign.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Hashimoto’s thyroiditis commonly has a diffuse hypoechoic, micronodular echotexture or a variegated pattern of hypoechoic bands and interspersed echogenic areas, similar to a giraffe hide.</p></li></ul><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="226" height="1" src="Image_345.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_346.png"/></span></p><p class="s12" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">P. L. Mok (<span class="s13">*</span>)</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><a href="mailto:Pamela_Mok@AtriusHealth.org" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">Department of Radiology, Atrius Health, Boston, MA, USA e-mail: </a><a href="mailto:Pamela_Mok@AtriusHealth.org" target="_blank">Pamela_Mok@AtriusHealth.org</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">© The Author(s), under exclusive license to Springer Nature Switzerland AG 2023</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">L. S. Eldeiry et al. (eds.), <i>Handbook of Thyroid and Neck Ultrasonography</i><a href="https://doi.org/10.1007/978-3-031-18448-2_8" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">, Contemporary Endocrinology, </a><a href="https://doi.org/10.1007/978-3-031-18448-2_8" target="_blank">https://doi.org/10.1007/978-3-031-18448-2_8</a></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_347.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 39pt;text-indent: 0pt;text-align: left;">ation.</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_348.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a74">Introduction</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Echogenicity refers to the grayscale appearance of an organ or structure on ultrasound based on the acoustic impedance of sound waves through the tissue. When sound waves are introduced into the body, they are both transmitted deeper into tissue and reflected back to the transducer to a variable degree, depending on the den sity of each tissue. Assessment of the echogenicity of the thyroid gland and of thyroid nodules is an important factor in thyroid evaluation.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l61"><li data-list-text="•"><h3 style="padding-left: 30pt;text-indent: -19pt;text-align: justify;">Anechoic: <span class="p">Anechoic refers to a fluid-filled structure that appears black on ultrasound. Fluid-filled structures allow sound waves to pass through easily, with no sound waves reflected back to the transducer. Examples include the urinary bladder, gallbladder, cysts, or blood vessels.</span></h3></li><li data-list-text="•"><h3 style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Hypoechoic: <span class="p">Hypoechoic structures transmit some sound waves and have a relatively dark appearance, but not to the same degree as simple cysts or other fluid-containing struc tures. Examples of hypoechoic tissue include muscle, kidney, or complicated cysts containing either protein (e.g. colloid) or hemorrhage.</span></h3></li></ul><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_349.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 25pt;text-indent: 0pt;text-align: left;">bright areas that reflect sound waves. The term “punctate echo genic foci” is often used to describe small areas within nodules that can represent microcalcifications or inspissated colloid (sometimes referred to as colloid crystals).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;"><a name="a75">Case Presentation</a></h3><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">A 64-year-old woman with hypertension and atrial fibrillation on anticoagulation presented with a rapidly enlarging left neck mass that was determined to be within the left thyroid lobe. She was asked to stop the anticoagulation pending a biopsy of the lesion and was admitted to the hospital for airway management. Thyroid ultrasound (Image <span style=" color: #00F;">8.1</span>) showed a diffusely enlarged, hypoechoic, and nodular thyroid gland with a very large 8 cm left thyroid mass. A contrast-enhanced neck CT scan (Image</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">marked deviation of the trachea to the right of midline by the large left thyroid mass and lateral displacement of the left carotid artery</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="172" alt="Two ultrasound images of the thyroid depict the enlarged thyroid gland with a very large thyroid mass." title="Two ultrasound images of the thyroid depict the enlarged thyroid gland with a very large thyroid mass." src="Image_350.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 8.1 <span class="s12">Transverse (left) and sagittal (right) US images demonstrate dif fuse thyroid enlargement with a large lobulated hypoechoic mass</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_351.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="216" src="Image_352.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Image 8.2  <span class="s12">Axial (left) and coronal (right) contrast-enhanced neck CT scan images show the large thyroid mass markedly displacing the trachea to the right of midline (arrow) and the left carotid artery to the left</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">Table 8.1 <span class="s12">Differential diagnosis</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:10.332pt" cellspacing="0"><tr style="height:17pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">1. Hashimoto’s thyroiditis</p></td></tr><tr style="height:17pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">2. Thyroid malignancy, such as anaplastic carcinoma</p></td></tr><tr style="height:17pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">3. Thyroid lymphoma</p></td></tr><tr style="height:17pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">4. Hemorrhage into the thyroid gland related to anticoagulation</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">to the left. Table <span style=" color: #00F;">8.1 </span>lists potential differential diagnoses in this case, including possible thyroiditis, thyroid malignancy, and hem orrhage related to anticoagulation.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">FNA and core biopsy done under ultrasound guidance revealed a B-cell lymphoma of the germinal cell type (Images</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">CD20 immunostain was positive (Image</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">diagnosis of high-grade B-cell lymphoma. Based on additional immunohistochemical and cytogenetic studies, the lymphoma was classified as diffuse large B-cell lymphoma with a germinal center phenotype.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">The patient was treated with 3 cycles of combination chemo therapy (R-EPOCH/Filgrastim/Neupogen) and responded well. Positron emission tomography (PET) scan obtained 4 months later revealed a dramatic response of the thyroid mass with return of the thyroid gland back to midline (Image</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">imaging of the mediastinum showed a PET-positive lymph node in the subcarinal region of the chest (Image</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_353.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="400" alt="A low magnification slide from the core biopsy of the thyroid done under ultrasound guidance depicts a B cell lymphoma of germinal cell type." title="A low magnification slide from the core biopsy of the thyroid done under ultrasound guidance depicts a B cell lymphoma of germinal cell type." src="Image_354.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 8.3  <span class="s12">Low magnification slide from the thyroid core biopsy shows a densely cellular lymphoid infiltrate that effaces the thyroid parenchyma</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="380" alt="A high-magnification slide from the biopsy of the thyroid done under ultrasound guidance depicts a high-grade lymphoma." title="A high-magnification slide from the biopsy of the thyroid done under ultrasound guidance depicts a high-grade lymphoma." src="Image_355.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 8.4 <span class="s12">High magnification pathology slide shows high-grade lymphoma with large, irregular nuclei and numerous apoptotic bodies</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_356.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="400" alt="An image demonstrates a positive C D 20 immunostain that supports the diagnosis of high-grade B cell lymphoma." title="An image demonstrates a positive C D 20 immunostain that supports the diagnosis of high-grade B cell lymphoma." src="Image_357.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 8.5 <span class="s12">Positive CD20 immunostain, supporting the diagnosis of high- grade B-cell lymphoma</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="400" src="Image_358.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 8.6 <span class="s12">Axial PET CT scan of the neck after treatment shows marked reduction in size of the thyroid with return of the trachea back to midline</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_359.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="327" src="Image_360.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 8.7 <span class="s12">Axial PET CT scan of the mediastinum shows a positive subcari nal lymph node (arrow)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">fore classified as a stage II B-cell lymphoma and was treated with three additional cycles of R-CHOP chemotherapy and Filgrastim/Neupogen and has subsequently been rendered free of disease. A small lung nodule has been followed and has remained stable.</p><h3 style="padding-left: 5pt;text-indent: 19pt;text-align: justify;"><a name="a76">Additional examples of different thyroid echogenicity pat terns from a variety of conditions are presented in</a></h3><p class="s15" style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">8.9<span style=" color: #2B2A29;">, </span>8.10<span style=" color: #2B2A29;">, </span>8.11<span style=" color: #2B2A29;">, </span>8.12<span style=" color: #2B2A29;">, </span>8.13<span style=" color: #2B2A29;">, </span>8.14<span style=" color: #2B2A29;">, </span>8.15<span style=" color: #2B2A29;">, </span>8.16<span style=" color: #2B2A29;">,</span></p><p class="s15" style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">8.21<span style=" color: #2B2A29;">, </span>8.22<span style=" color: #2B2A29;">, </span>8.23<span style=" color: #2B2A29;">, </span>8.24<span style=" color: #2B2A29;">, </span>8.25 <span style=" color: #2B2A29;">and </span>8.26<span style=" color: #2B2A29;">.</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_361.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="228" alt="Two scanned images depict the sagittal and transverse views of an anechoic cyst." title="Two scanned images depict the sagittal and transverse views of an anechoic cyst." src="Image_362.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 8.8 <span class="s12">Sagittal (left) and transverse (right) views of a benign anechoic cyst</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="203" alt="Two scanned images depict the sagittal and transverse views of an anechoic colloid cyst." title="Two scanned images depict the sagittal and transverse views of an anechoic colloid cyst." src="Image_363.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 8.9 <span class="s12">Sagittal (left) and transverse (right) images show a typical benign anechoic colloid cyst containing a punctate hyperechoic focus which demon strates characteristic echogenic comet tail artifact. The comet tail artifact is attributed to reverberation of sound waves within inspissated colloid and is rec ognized by the tapering attenuated V-shaped echoes beyond the echogenic focus</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="193" alt="Two scanned images depict the sagittal and transverse views of a hypoechoic nodule." title="Two scanned images depict the sagittal and transverse views of a hypoechoic nodule." src="Image_364.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 8.10 <span class="s12">Sagittal (left) and transverse (right) views of a hypoechoic nod ule. Pathology showed a benign follicular adenoma</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_365.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="290" alt="An ultrasound image illustrates the transverse view of a hypoechoic mass." title="An ultrasound image illustrates the transverse view of a hypoechoic mass." src="Image_366.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 8.11 <span class="s12">Transverse view demonstrates a slightly hypoechoic mass. Pathology showed a follicular carcinoma</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="574" height="324" src="Image_367.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 8.12  <span class="s12">Transverse view demonstrates a hypoechoic mass that was con firmed to be a papillary carcinoma. Note the anterior extrathyroidal extension of the mass (long white arrow)</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_368.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="316" alt="A scanned image illustrates the transverse view of a hypoechoic mass in the left lobe." title="A scanned image illustrates the transverse view of a hypoechoic mass in the left lobe." src="Image_369.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 8.13 <span class="s12">Transverse view demonstrates a hyperechoic mass in the left lobe. Pathology showed benign follicular cells</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="315" alt="A scanned image illustrates the sagittal view of an isoechoic nodule." title="A scanned image illustrates the sagittal view of an isoechoic nodule." src="Image_370.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Image 8.14  <span class="s12">Sagittal view demonstrating an isoechoic nodule. The nodule is the same echogenicity as the surrounding thyroid gland and is only visible due to the hypoechoic rim</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_371.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="186" alt="Two scanned images depict the sagittal and transverse views of a hypoechoic mass." title="Two scanned images depict the sagittal and transverse views of a hypoechoic mass." src="Image_372.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="574" height="203" src="Image_373.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 8.16  <span class="s12">Sagittal (left) and transverse (right) views of a hyperechoic cal cification (arrow, left) demonstrating posterior hypoechoic shadowing (arrow, right)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="183" alt="Two scanned images depict the sagittal and transverse views of a multinodular goiter having several hypoechoic nodules." title="Two scanned images depict the sagittal and transverse views of a multinodular goiter having several hypoechoic nodules." src="Image_374.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 8.17  <span class="s12">Transverse (left) and sagittal (right) images showing a multi nodular goiter with multiple hypoechoic nodules throughout the gland</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_375.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="292" alt="Four scanned images depict the sagittal and transverse views of the before treatment and after treatment conditions of acute thyroiditis." title="Four scanned images depict the sagittal and transverse views of the before treatment and after treatment conditions of acute thyroiditis." src="Image_376.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 8.18  <span class="s12">Thyroiditis. Top: Transverse and sagittal images during an epi sode of acute thyroiditis show a heterogeneous right lobe with an incidental simple cyst. Bottom, transverse and sagittal images: Exactly 1 year later, after complete resolution of the thyroiditis</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="255" alt="A scanned image demonstrates the transverse view of chronic thyroiditis." title="A scanned image demonstrates the transverse view of chronic thyroiditis." src="Image_377.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 8.19  <span class="s12">Transverse view showing chronic thyroiditis. The thyroid is dif fusely and markedly hypoechoic, similar to the adjacent muscle. This appear ance can be seen in chronic, end-stage Hashimoto’s thyroiditis or as a result of radioactive iodine therapy</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_378.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="184" alt="Two scanned images illustrate the sagittal and transverse views of Hashimotoђs thyroiditis." title="Two scanned images illustrate the sagittal and transverse views of Hashimotoђs thyroiditis." src="Image_379.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">resembling a giraffe hide. Sagittal (left) and transverse (right) views show a diffuse, “giraffe hide” appearance of thyroiditis</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="340" alt="A photograph of two giraffes in a standing position and facing in opposite directions of each other." title="A photograph of two giraffes in a standing position and facing in opposite directions of each other." src="Image_380.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 8.21 <span class="s12">Pair of giraffes with distinctive reticulated hide</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_381.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="187" src="Image_382.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">ing heterogeneous, patchy hypoechoic echotexture. These echogenic areas are termed “white knight” lesions and are essentially benign regenerative nodules superimposed on the background of thyroiditis. Sagittal (left) and transverse (right) views of a “white knight” nodule, representing a regenera tive nodule in Hashimoto’s thyroiditis</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="152" alt="Two scanned images depict the sagittal and transverse views of a hypoechoic mass." title="Two scanned images depict the sagittal and transverse views of a hypoechoic mass." src="Image_383.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Image 8.23  <span class="s12">Sagittal (left) and transverse (right) images of a hypoechoic mass with layering echoes and no central vascularity that was found to be a thyroglossal duct cyst containing proteinaceous debris</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_384.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="215" alt="Two scanned images demonstrate the sagittal and transverse views of a mixed echogenicity mass having hyperechoic, hypoechoic, anechoic, and central calcification areas." title="Two scanned images demonstrate the sagittal and transverse views of a mixed echogenicity mass having hyperechoic, hypoechoic, anechoic, and central calcification areas." src="Image_385.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 8.24  <span class="s12">Sagittal (left) and transverse (right) images show a mixed echo genicity mass with hyperechoic, hypoechoic, and anechoic areas as well as central calcification. Fine needle aspiration showed benign follicular cells, many macrophages, and colloid, consistent with a benign follicular nodule with cystic degeneration</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="241" alt="A scanned image demonstrates the sagittal view of a hypoechoic mass." title="A scanned image demonstrates the sagittal view of a hypoechoic mass." src="Image_386.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 8.25  <span class="s12">Sagittal view showing a slightly hypoechoic mass containing small echogenic foci without posterior shadowing consistent with microcalci fications. Pathology showed papillary thyroid carcinoma</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_387.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="124" alt="A scanned image on the left demonstrates the transverse view of a hypoechoic mass. The right image is the color doppler imaging that depicts the marked peripheral and central vascularity." title="A scanned image on the left demonstrates the transverse view of a hypoechoic mass. The right image is the color doppler imaging that depicts the marked peripheral and central vascularity." src="Image_388.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="575" height="2" src="Image_389.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a77">Discussion</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">During thyroid ultrasound, the initial task is to assess the thyroid echogenicity, which is normally homogeneous and hyperechoic. If the texture is heterogeneous, determine whether the process is diffuse, involving the entire gland as in multinodular goiter, or whether normal thyroid tissue is interspersed with patchy areas, such as in Hashimoto’s thyroiditis.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Whenever possible, the interpreting clinician should person ally scan the patient; however, when this is not feasible, review of cine images in addition to static images is preferable. Scanning in person or viewing cine images in multiple planes has several advantages, including more thorough assessment of the underly ing  thyroid  echogenicity  and  borders  of  an  entire  mass, differentiation of a true mass from a less-defined area of heteroge neity or “pseudonodule,” and discrimination of microcalcifica tions  from  other  types  of  echogenic  foci,  including  those associated with inspissated colloid (colloid crystals).</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Technical details, such as overall gain, frequency, focal zones, tissue harmonics, and spatial compound imaging are important factors to consider when assessing echogenicity and image qual ity. For example, an overall gain that is too low may make it dif ficult to distinguish a benign anechoic cyst from a very hypoechoic nodule, which has a higher risk of malignancy. Tissue harmonic imaging and spatial compound imaging help reduce reverberation and artifactual echoes, allowing differentiation of a benign cyst</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_390.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">assess. Isoechoic and hyperechoic masses are usually benign nod ules such as follicular adenomas; however, 5–10% of isoechoic or hyperechoic solid masses are malignant, such as follicular carci nomas. The presence of a well-defined hypoechoic sonographic halo surrounding an isoechoic or hyperechoic nodule increases the likelihood of benignity.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Hypoechoic masses harbor a higher risk of malignancy, espe cially if the mass is very hypoechoic relative to adjacent neck musculature, or if other suspicious findings are present. A single mass may also have mixed echogenicity with hyperechoic, hypoechoic, and anechoic cystic components, and the dominant echotexture should be considered along with other characteristics such as shape, borders, and presence of calcifications.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_391.png"/></span></p><h1 style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a78">Further Reading</a></h1><p class="s12" style="padding-top: 17pt;padding-left: 25pt;text-indent: -19pt;text-align: justify;">Grant EG, et al. Thyroid Ultrasound Reporting Lexicon. White paper of the ACR Thyroid Imaging, Reporting and Data System (TIRADS) Committee. J Am Coll Radiol. 2015;12(12 Pt A):1272.</p><p class="s12" style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Haugen  BR,  et  al.  2015  American  Thyroid  Association  Management Guidelines for adult patients with thyroid nodules and differentiated thy roid cancer. Thyroid. 2016;26(1):1–133.</p><p class="s12" style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">Lee JY, et al. Ultrasound malignancy risk stratification of thyroid nodules based on the degree of hypoechogenicity and echotexture. Eur Radiol. 2020 Mar;30(3):1653–63.</p><p class="s12" style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">Tessler FN, et al. Thyroid Imaging Reporting and Data System (TI-RADS): a user’s guide. Radiology. 2018;287:29.</p><p class="s12" style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">Xie C, et al. Ultrasonography of thyroid nodules: a pictorial review. Insights Imaging. 2016;7(1):77–86.</p><p style="padding-left: 385pt;text-indent: 0pt;text-align: left;"><span><a href="http://crossmark.crossref.org/dialog/?doi=10.1007/978-3-031-18448-2_9&amp;domain=pdf"><img width="69" height="61" src="Image_392.png"/></a></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s11" style="padding-left: 19pt;text-indent: 0pt;text-align: left;">Key Points</p><ul id="l62"><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Thyroid nodule margins are based on the sonographic border between the nodule and surrounding parenchyma and can help distinguish between benign and malignant nodules.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Infiltrative, irregular, and lobulated margins are associ ated with malignancy.</p></li></ul><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="226" height="1" src="Image_393.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_394.png"/></span></p><p class="s12" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">M. D. Otremba (<span class="s13">*</span>)</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;"><a href="mailto:Michael_Otremba@meei.harvard.edu" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">e-mail: </a><a href="mailto:Michael_Otremba@meei.harvard.edu" target="_blank">Michael_Otremba@meei.harvard.edu</a></p><p class="s12" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">C. A. Haddad</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Harvard Vanguard Medical Associates, Massachusetts Eye and Ear,</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><a href="mailto:Chia_Haddad@atriushealth.org" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">Harvard Medical School, Boston, MA, USA e-mail: </a><a href="mailto:Chia_Haddad@atriushealth.org" target="_blank">Chia_Haddad@atriushealth.org</a></p><p class="s12" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">G. W. Randolph</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Massachusetts Eye and Ear Infirmary, Boston, MA, USA</p><p style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a href="mailto:Gregory_Randolph@meei.harvard.edu" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">Massachusetts General Hospital, Boston, MA, USA e-mail: </a><a href="mailto:Gregory_Randolph@meei.harvard.edu" target="_blank">Gregory_Randolph@meei.harvard.edu</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">© The Author(s), under exclusive license to Springer Nature Switzerland AG 2023</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">L. S. Eldeiry et al. (eds.), <i>Handbook of Thyroid and Neck Ultrasonography</i><a href="https://doi.org/10.1007/978-3-031-18448-2_9" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">, Contemporary Endocrinology, </a><a href="https://doi.org/10.1007/978-3-031-18448-2_9" target="_blank">https://doi.org/10.1007/978-3-031-18448-2_9</a></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_395.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l63"><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: left;">Interobserver variability for nodule margin is common.</p></li></ul><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_396.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a79">Introduction</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">This chapter deals with two specific ultrasound characteristics of thyroid nodules and their influence in determining whether the nodule is of concern and a biopsy is indicated.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l64"><li data-list-text="•"><h3 style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Margins: <span class="p">The description of the margins of a thyroid nodule is based on the sonographic border between the nodule and sur rounding thyroid parenchyma. While a given nodule may have a variable margin along its entire circumference, nodule mar gins can be categorized as:</span></h3><ul id="l65"><li data-list-text="–"><p style="padding-left: 49pt;text-indent: -19pt;text-align: justify;"><b>Smooth: </b>a clear, continuous, rounded border between nod ule and parenchyma (Image <span style=" color: #00F;">9.4</span>).</p></li><li data-list-text="–"><h3 style="padding-left: 49pt;text-indent: -19pt;line-height: 110%;text-align: justify;">Irregular/Infiltrative: <span class="p">a non-uniform, jagged, or spicu lated border between nodule and parenchyma (Image</span></h3></li><li data-list-text="–"><h3 style="padding-left: 49pt;text-indent: -19pt;line-height: 110%;text-align: justify;">Lobulated: <span class="p">focal areas of bulging along the border between the nodule and parenchyma (Image</span></h3></li><li data-list-text="–"><h3 style="padding-left: 49pt;text-indent: -19pt;line-height: 110%;text-align: justify;">Poorly (ill)-defined: <span class="p">a poorly defined border between the nodule and parenchyma where more than 50% of the border is not clearly demarcated (Image </span><span class="s15">9.6</span></h3></li><li data-list-text="–"><h3 style="padding-left: 49pt;text-indent: -19pt;line-height: 16pt;text-align: justify;">Extrathyroidal Extension: <span class="p">Describes the border of the</span></h3></li></ul></li></ul><p style="padding-left: 49pt;text-indent: 0pt;text-align: justify;">nodule extending beyond the thyroid capsule into surround</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_397.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 45pt;text-indent: 0pt;text-align: left;">require a biopsy (Image <span style=" color: #00F;">9.9</span>).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a80">Case Presentation</a></h3><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">A 68-year-old man with no significant past medical history was found to have an enlarged right-sided thyroid mass on annual physical exam by his primary care physician and was referred for further evaluation. There was no family history of thyroid disease and he had no swallowing or voice complaints. TSH was 3.75 uIU/ mL (0.5–4.5 uIU/mL). On physical exam, there was an approxi mately 4 cm nontender, firm nodule within the right thyroid lobe that elevated with swallowing. Laryngoscopic examination was normal. Ultrasound demonstrated a 2.3 × 2.8 × 4.3 cm, hypoechoic solid, lobular nodule (Images <span style=" color: #00F;">9.1a, b</span>) occupying the majority of the right thyroid lobe. No suspicious adenopathy or contralateral nodules were present.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Ultrasound-guided fine needle aspiration (FNA) of the lobu lated nodule was performed. Cytology showed sheets and clusters of atypical oncocytic cells (Hurthle cells) with scattered psam moma bodies, favoring a malignant oncocytic neoplasm, includ ing in the differential diagnosis, papillary carcinoma with Hurthle cell differentiation. The patient subsequently underwent a total thyroidectomy. Histopathology showed a 4.3 cm invasive onco cytic thyroid carcinoma (Hurthle cell) with extensive capsular and angioinvasion (Image <span style=" color: #00F;">9.2</span>).</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: justify;">Postoperatively, serum thyroglobulin level was 38 ng/mL. computed tomography (CT) chest imaging revealed multiple bilateral “small lung nodules, with the largest measuring 8 mm,</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_398.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="362" src="Image_399.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="573" height="362" src="Image_400.png"/></span></p><p class="s21" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;"><span class="s17">Image 9.1 </span>Lobulated Margins. Transverse (<b>a</b>) and sagittal (</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">hypoechoic solid nodule with lobulated borders (Arrows) within the inferior pole of the right thyroid. The nodule was found to be an aggressive Hürthle cell carcinoma on surgical pathology</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_401.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="572" height="362" alt="4 histopathology images of thyroid carcinoma labeled a to d display, a: stained cells with lines, b, c, and d: the arrows point the patches of cells in different shapes formed due to capsular involvement and angioinvasion." title="4 histopathology images of thyroid carcinoma labeled a to d display, a: stained cells with lines, b, c, and d: the arrows point the patches of cells in different shapes formed due to capsular involvement and angioinvasion." src="Image_402.jpg"/></span></p><p class="s21" style="text-indent: 0pt;text-align: left;">a</p><p style="text-indent: 0pt;text-align: left;"/><p class="s21" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s21" style="text-indent: 0pt;text-align: left;">c</p><p style="text-indent: 0pt;text-align: left;"/><p class="s21" style="text-indent: 0pt;text-align: left;">d</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><span class="s17">Image 9.2  </span>Histopathology (H&amp;E) showing invasive oncocytic thyroid car cinoma (Hurthle cell) (<b>a</b>, 400x) with extensive capsular involvement ( arrows) and angioinvasion (<b>c</b>, 100x, arrows; and <b>d</b></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">concerning for metastatic disease. He was subsequently treated with radioactive iodine. Post-treatment, follow-up imaging with whole body positron emission tomography (PET)/CT scan and surveillance thyroglobulin testing remained suspicious for active pulmonary metastases (Image <span style=" color: #00F;">9.3a, b</span>). Biopsy of a lung nodule confirmed metastatic Hürthle cell carcinoma. Two years after ini tial therapy, he remains asymptomatic with slow-growing, low volume pulmonary disease that is being managed with active sur veillance.</p><h3 style="padding-left: 25pt;text-indent: 0pt;text-align: left;"><a name="a81">Thyroid Nodule Margins and Shape: Additional Examples</a></h3><p style="padding-left: 25pt;text-indent: 0pt;text-align: left;">See Images <span style=" color: #00F;">9.4</span>, <span style=" color: #00F;">9.5</span>, <span style=" color: #00F;">9.6</span>, <span style=" color: #00F;">9.7</span>, <span style=" color: #00F;">9.8 </span>and <span style=" color: #00F;">9.9</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_403.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="572" height="728" alt="2 C T and P E T scan images of lungs with arrows pointing to the suspicious nodule in the left lower lobe." title="2 C T and P E T scan images of lungs with arrows pointing to the suspicious nodule in the left lower lobe." src="Image_404.gif"/></span></p><p class="s21" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><span class="s17">Image 9.3  </span>CT scan of the chest showing a suspicious nodule in the left lower lung lobe (<b>a</b>, arrow) that was also FDG-PET-avid (</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">sistent with metastatic Hürthle cell carcinoma on biopsy</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_405.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="363" alt="An ultrasound image of the solid thyroid nodule with a smooth border. The transverse view exhibits a hypoechoic nodule in the superior pole of the right thyroid lobe with smooth borders, as well as a hypoechoic halo, which is indicated by arrows." title="An ultrasound image of the solid thyroid nodule with a smooth border. The transverse view exhibits a hypoechoic nodule in the superior pole of the right thyroid lobe with smooth borders, as well as a hypoechoic halo, which is indicated by arrows." src="Image_406.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 9.4  <span class="s12">A solid nodule with smooth margins . A solid, hypoechoic nod ule in the superior pole of the right thyroid lobe with smooth margins, trans verse view. In addition to smooth margins, this nodule also features a hypoechoic “halo” (arrows), which is often found in benign lesions. The halo is thought to result from the nodule compressing the vasculature within the adjacent thyroid parenchyma.</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_407.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="304" alt="A pair of ultrasound images of the thyroid nodules exhibit irregular or infiltrative margins. The arrows in (a) transverse view and (b) sagittal view indicate irregular margins in the mid-pole of the right thyroid lobe." title="A pair of ultrasound images of the thyroid nodules exhibit irregular or infiltrative margins. The arrows in (a) transverse view and (b) sagittal view indicate irregular margins in the mid-pole of the right thyroid lobe." src="Image_408.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="573" height="248" alt="A pair of ultrasound images of the thyroid nodules exhibit irregular or infiltrative margins. The arrows in (a) transverse view and (b) sagittal view indicate irregular margins in the mid-pole of the right thyroid lobe." title="A pair of ultrasound images of the thyroid nodules exhibit irregular or infiltrative margins. The arrows in (a) transverse view and (b) sagittal view indicate irregular margins in the mid-pole of the right thyroid lobe." src="Image_409.jpg"/></span></p><p class="s21" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Image 9.5  <span class="s12">Irregular/infiltrative margins. A nodule with irregular margins located in the mid pole of the right thyroid lobe on transverse (</span></p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">(<b>b</b>) views. Irregular margins (arrows) suggest malignant infiltration of adja cent thyroid parenchyma. This nodule was found to be diffuse sclerosing vari ant of papillary thyroid carcinoma on surgical pathology</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_410.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="572" height="727" alt="2 ultrasound images of the thyroid labeled a and b, with a large heterogeneous nodule with a poorly defined border in the left lobe. " title="2 ultrasound images of the thyroid labeled a and b, with a large heterogeneous nodule with a poorly defined border in the left lobe. " src="Image_411.gif"/></span></p><p class="s21" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 9.6 <span class="s12">Poorly defined margins. Transverse (</span><span class="s22">a</span></p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">a large, heterogeneous solid nodule within the left thyroid lobe with a poorly defined border between the nodule and the surrounding thyroid parenchyma. The nodule was confirmed to be benign on surgical pathology</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_412.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="572" height="563" alt="2 ultrasound images of the thyroid in transverse and sagittal view labeled a and b. It displays the carotid and arrows indicating the strap muscles, and thyroid capsule." title="2 ultrasound images of the thyroid in transverse and sagittal view labeled a and b. It displays the carotid and arrows indicating the strap muscles, and thyroid capsule." src="Image_413.jpg"/></span></p><p class="s21" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><span class="s17">Image 9.7  </span>Extrathyroidal extension. A right superior pole nodule with infil tration into the neighboring strap muscles (white arrows) on transverse ( and sagittal views (<b>b</b>). The red arrows show discontinuity of the thyroid cap sule. Papillary thyroid carcinoma with extrathyroidal invasion was confirmed on surgical pathology</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_414.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="364" alt="An ultrasound image of the thyroid displays the cystic nodule with the markings indicating transverse and anteroposterior diameters." title="An ultrasound image of the thyroid displays the cystic nodule with the markings indicating transverse and anteroposterior diameters." src="Image_415.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 9.8  <span class="s12">Wider than tall. A large, complex cystic nodule in the mid pole of the left thyroid lobe with greater transverse diameter than antero-posterior diameter. The nodule contains echogenic foci that most likely represent comet tail artifact. The nodule was benign on surgical pathology</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_416.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 32pt;text-indent: 0pt;text-align: left;"><span><img width="516" height="415" src="Image_417.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Image 9.9  <span class="s12">Taller than wide. A heterogeneous, solid nodule with a greater antero-posterior diameter than transverse diameter within the inferior pole of the left thyroid</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_418.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a82">Discussion</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Sonographic analysis of the shape and margins of a thyroid nod ule  can  help  differentiate  benign  from  malignant  nodules. Infiltrative, irregular, and lobulated margins have been associated with malignancy. The presence of any of these characteristics should raise the possibility of a malignant lesion for which further evaluation with ultrasound-directed needle biopsy is indicated.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Several challenges in describing a nodule margin on ultra sound should be kept in mind. If the background thyroid tissue is heterogeneous, as in Hashimoto’s thyroiditis, margin characteris tics may be more difficult to accurately visualize. Also, determin ing the difference between an infiltrative and indistinct border, particularly for small heterogeneous nodules, can be difficult.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_419.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">the border of a nodule interrupts this well-defined plane, malig nancy should be suspected. Malignant tumor can also be visual ized extending outside of the gland into surrounding structures, such as the strap musculature or carotid sheath. Intratracheal growth is difficult to appreciate on ultrasound. When present, extension beyond the gland suggests more advanced or aggressive disease and additional axial CT imaging with contrast will help to formulate an optimal surgical plan.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">The shape of a thyroid nodule can also provide valuable infor mation. It is important to consider the relationship between the antero-posterior diameter and transverse diameter. Several studies associate malignancy with a “taller than wide” shape, in which the antero-posterior to transverse ratio, as measured in the transverse plane, is greater than 1. This finding is not highly sensitive, but can be quite specific, particularly for smaller cancers.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_420.png"/></span></p><h1 style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a83">Further Reading</a></h1><p class="s12" style="padding-top: 17pt;padding-left: 25pt;text-indent: -19pt;text-align: justify;">Chan BK, Desser TS, McDougall IR, Weigel RJ, Jeffrey RB Jr. Common and uncommon  sonographic  features  of  papillary  thyroid  carcinoma. Ultrasound Med. 2003;22(10):1083–90.</p><p class="s12" style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">Hoang JK, Lee WK, Lee M, Johnson D, Farrell S. US features of thyroid malignancy: pearls and pitfalls. Radiographics. 2007;27:847–65.</p><p class="s12" style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Kim E-K, Park CS, Chung WY, Oh KK, Kim DI, Lee JT, Yoo HS. New sono graphic criteria for recommending fine-needle aspiration biopsy of non palpable  solid  nodules  of  the  thyroid.  AJR  Am  J  Roentgenol. 2002;178(3):687–91.</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="566" height="2" src="Image_421.png"/></span></p><p style="padding-left: 385pt;text-indent: 0pt;text-align: left;"><span><a href="http://crossmark.crossref.org/dialog/?doi=10.1007/978-3-031-18448-2_10&amp;domain=pdf"><img width="69" height="61" src="Image_422.png"/></a></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s11" style="padding-left: 19pt;text-indent: 0pt;text-align: left;">Key Points</p><ul id="l66"><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">“Hyperechoic foci” is a nonspecific term referring to focal, bright echogenic structures.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Sonographic pattern and distribution of calcification in a nodule can aid in estimating the risk of malignancy and determine whether a biopsy is needed.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: left;">Distinguishing ultrasound features is operator depen dent. Their negative or positive predictive value is influ enced by the presence or absence of other suspicious or reassuring features.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: left;">Correct identification of echogenic foci due to colloid (comet tail and dependency of the focus within a micro cyst) will suggest a benign lesion and can prevent unnec essary biopsies.</p></li></ul><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="226" height="1" src="Image_423.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_424.png"/></span></p><p class="s12" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">C. Baldwin</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Division of Endocrinology and Metabolism, The George Washington University, Washington, DC, USA</p><p class="s12" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">R. Pessah-Pollack (<span class="s13">*</span>)</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Division of Endocrinology, Diabetes and Metabolism, NYU School of Medicine, New York, NY, USA</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">© The Author(s), under exclusive license to Springer Nature Switzerland AG 2023</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">L. S. Eldeiry et al. (eds.), <i>Handbook of Thyroid and Neck Ultrasonography</i><a href="https://doi.org/10.1007/978-3-031-18448-2_10" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">, Contemporary Endocrinology, </a><a href="https://doi.org/10.1007/978-3-031-18448-2_10" target="_blank">https://doi.org/10.1007/978-3-031-18448-2_10</a></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_425.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 39pt;text-indent: 0pt;text-align: left;">History of prior ablative procedures including radiofre quency ablation (RFA) and radioactive iodine therapy can represent benign causes of both micro- and macro calcifications.</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_426.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a84">Introduction</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">The sonographic appearance of a thyroid nodule may be used to estimate the risk of malignancy and to decide whether a biopsy is indicated. While individual features are suggestive, combining fea tures and pattern recognition are key to ultrasound (US) risk strati fication of thyroid nodules. The specificity of a single ultrasound feature for identifying malignancy can partially depend on the pres ence or absence of other ultrasound features. The sensitivity, speci ficity, and diagnostic accuracy of ultrasound features associated with thyroid malignancy are variable in different series and appear to be partially operator-dependent. Real time</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">reliable, especially with nodules that may have ambiguous features (e.g. irregular borders versus infiltrative margins.) This chapter focuses specifically on the significance of calcifications and echo genic foci in the evaluation of thyroid nodules.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l67"><li data-list-text="•"><h3 style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Echogenic foci<span class="p">: The term echogenic foci is a nonspecific descrip tor of hyperechoic foci within or surrounding a thyroid nodule. Ultrasound waves are distorted as they traverse tissues of differ ent densities or encounter impenetrable structures or calcifica tions. The pattern and location of the structures, and whether the</span></h3></li></ul><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_427.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-top: 5pt;padding-left: 45pt;text-indent: 0pt;line-height: 110%;text-align: justify;">Microcalcifications <span class="p">are punctate (1 mm or less in size) hyperechoic spots without acoustic shadowing that may represent psammoma bodies. These are associated with a higher likelihood of PTC.</span></h3><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a85">Case Presentation 1</a></h3><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">A 30-year-old female presented after a bystander at a public event pointed out a visible lump in her neck. She had no significant past medical history; however, her mother had a history of PTC. Physical exam revealed a 3 cm firm nodule to the right of the midline that moved with swallowing. No cervical lymphadenopathy was palpated on exam. TSH was normal at 1.36 mIU/L. Neck ultrasound demon strated a 2.7 × 1.2 × 2.4 cm nodule in the right lobe (Image</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="217" alt="A scanned image of the right thyroid lobe in sagittal view represents the presence of a nodule." title="A scanned image of the right thyroid lobe in sagittal view represents the presence of a nodule." src="Image_428.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 10.1  <span class="s12">Sagittal image of a solid, hypoechoic nodule located within the right thyroid lobe that contains scattered non-shadowing hyperechoic foci consistent with microcalcifications (note macrocalcifications present as well)</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_429.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 186pt;text-indent: 0pt;text-align: left;"><span><img width="340" height="93" src="Image_430.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="400" alt="An image depicts the cytological demonstration of atypical follicular cells arranged in papillary groups with large irregular nuclei." title="An image depicts the cytological demonstration of atypical follicular cells arranged in papillary groups with large irregular nuclei." src="Image_431.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Image 10.2 <span class="s12">Cytological examination demonstrated enlarged, overlapping nuclei with powdery chromatin with intranuclear cytoplasmic inclusions (arrow), consistent with papillary thyroid carcinoma (Bethesda VI). (Wright Giemsa stain, ×10)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Biopsy was indicated based on the size and ultrasound appear ance of the nodule. Differential diagnosis is listed in Table Ultrasound-guided fine needle aspiration (FNA) of the right thy roid nodule was performed. Cytology demonstrated atypical fol licular cells arranged in papillary groups with enlarged oval, irregular nuclei with fine chromatin, intranuclear grooves, and intranuclear pseudo-inclusions, consistent with a diagnosis of PTC (Bethesda category VI) (Image <span style=" color: #00F;">10.2</span>).</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">The patient subsequently underwent a total thyroidectomy. Histopathology showed a 3.7 cm tall cell variant PTC (Image <span style=" color: #00F;">10.3a, b</span>). Thirteen examined central lymph nodes were positive for metastatic disease, with the largest metastatic deposit measur ing 6 mm. She was treated with radioactive iodine and currently remains disease free.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_432.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="573" height="801" src="Image_433.png"/></span></p><p class="s59" style="padding-top: 11pt;padding-left: 15pt;text-indent: 0pt;text-align: left;"><a name="a86">b</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><span class="s17">Image 10.3  </span>(<b>a</b>) Histopathology demonstrates features of classic PTC: crowded follicular cells with enlarged, overlapping nuclei forming papillae (H&amp;E, ×4). (<b>b</b>) At higher magnification, crowded follicular cells with enlarged nuclei and powdery chromatin can be appreciated next to psam moma bodies (arrowheads) (H&amp;E, ×20)</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_434.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="243" src="Image_435.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 10.4  <span class="s12">Macrocalcifications (arrows) are noted in this sub-centimeter thyroid nodule in both the inside of the nodule and the periphery (left: sagit tal, right: transverse)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="350" alt="A scanned image depicts the sagittal view of a nodule with microcalcifications." title="A scanned image depicts the sagittal view of a nodule with microcalcifications." src="Image_436.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 10.5 <span class="s12">Sagittal view of another small nodule with macrocalcifications</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_437.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="164" alt="Three scanned images depict examples of benign calcification." title="Three scanned images depict examples of benign calcification." src="Image_438.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 10.6  <span class="s12">Three examples of benign calcification: Macrocalcification (left and middle). Large, benign nodule with dense rim calcification (right)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="309" src="Image_439.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 10.7  <span class="s12">Echogenic foci within an anechoic nodule may be found within a colloid nodule and may demonstrate classic “comet tail” artifact (red arrows), which represents inspissated colloid. Echogenic foci with comet tail artifact freely distributed in a cystic component predict a benign nodule. Pos terior acoustic enhancement is a linear hyperechoic artifact, due to an increase in ultrasound wave reverberation against the normal thyroid parenchyma, that occurs at the posterior edge of a cyst (blue arrow) or even within a mixed solid and cystic nodule, posterior to cystic spaces (yellow arrow)</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_440.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><span><img width="574" height="176" src="Image_441.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">shadowing (blue bracket) and limiting further characterization of the nodule.</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">(<b>b</b>) Slightly irregular calcification with shadowing (yellow arrow), limiting evaluation of the deep component of the lesion</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="249" alt="A scanned image illustrates benign peripheral calcifications." title="A scanned image illustrates benign peripheral calcifications." src="Image_442.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 10.9 <span class="s12">Benign peripheral calcifications</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_443.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="326" alt="A scanned image demonstrates the discontinuous rim calcifications." title="A scanned image demonstrates the discontinuous rim calcifications." src="Image_444.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 10.10  <span class="s12">Discontinuous rim calcifications. Interruptions in eggshell calcifications are indeterminate. As a result, the finding warrants FNA. Biopsy of this nodule was consistent with PTC</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="159" alt="Two scanned images depict the diffusely scattered microcalcifications throughout the right lobe." title="Two scanned images depict the diffusely scattered microcalcifications throughout the right lobe." src="Image_445.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 10.11  <span class="s12">Microcalcifications are seen diffusely scattered throughout the right lobe (left transverse, right sagittal) of a patient with underlying Hashimoto’s disease. Pathology showed the diffuse sclerosing variant of PTC. The appearance indicates diffuse infiltration of the lobe or possibly local lymphatic spread</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_446.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="194" alt="Two scanned images illustrate the calcification due to thyroid nodule ablation." title="Two scanned images illustrate the calcification due to thyroid nodule ablation." src="Image_447.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">ule ablative procedures, e.g. ethanol ablation or radiofrequency ablation (RFA), can cause necrosis and subsequent calcification. Familiarity with these typical consequences and imaging appearance of nodule ablation can prevent unnecessary clinical concern and FNAs. Left: Pre-RFA right thyroid nodule (sagittal image). Right: 4 weeks post-RFA, scattered calcifications are noted due to radiofrequency-induced coagulative necrosis with both micro- and macrocalcification deposition</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_448.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a87">Discussion</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Echogenic foci are hyperechoic or bright echoes on B-mode ultra sound. Accurate interpretation of hyperechoic foci in addition to the other characteristics of a nodule is required to determine the risk of malignancy.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Hyperechoic foci are created by focal dense structures that cause a strong reflection of the ultrasound waves, represented as a bright echo on the image. Near-complete reflection of ultrasound waves with acoustic shadowing beyond the structure is caused by larger, macrocalcifications or densely concentrated microcalcifi cations, leading to posterior acoustic shadowing.</p><h3 style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Macrocalcifications <span class="p">are large flecks of calcium (larger than 1 mm at the longest diameter) that can be either within the thyroid nodule or on the periphery. These shadowing, hyper echoic foci are usually seen as large bright echoes on ultra sound. In addition to calcification, they can be caused by dense fibrosis. Macrocalcifications have a nonspecific clinical sig nificance. They are generally dystrophic, secondary to central necrosis or old hemorrhage in the lesion and do not indicate an</span></h3><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_449.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">(Image     ).  The  2015  American  Thyroid  Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer cite the presence of nodular extrusion as having a very high association with malignancy and a higher likelihood of tumor invasion in the region of disrupted calcifications.</p><h3 style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Microcalcifications <span class="p">are small flecks of calcification measuring 1 mm or less in size, appearing as bright hyperechoic foci on sonographic images. The presence of microcalcifications in a thy roid nodule is associated with a higher likelihood of PTC. On his topathology of thyroid tissue, microcalcifications are felt to correlate with the round, calcified psammoma bodies seen in PTC.</span></h3><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Psammoma bodies are not found within the follicular cell and are therefore uncommon in follicular variant PTC or follicular neoplasms. Microcalcifications can be limited to the nodule itself or scattered throughout the thyroid gland, concerning for lym phatic dissemination within the gland (Image microcalcifications within cervical lymph nodes are diagnostic of lymphatic locoregional spread of PTC. Benign causes of micro calcifications are possible, including benign involution or trauma due to procedures, such as FNA or nodule ablation (Image However those calcifications are usually larger and denser.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">It should be recognized that the ultrasonographic presentation of medullary thyroid carcinoma (MTC) includes both microcalci fications and macrocalcifications. The presence of visible micro calcifications in nodules with histopathology consistent with MTC has been noted to be as high as 50%–60% in some studies.</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_450.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 30pt;text-indent: -19pt;text-align: justify;">Malhi HS, Velez E, Kazmierski B, Gulati M, et al. Peripheral thyroid nodule calcifications on sonography: evaluation of malignant potential. Am J Roentgenol. 2019;213:672–5.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: justify;">Taki S, Terahata S, Yamashita R, Kinuya K, Nobata K, Kakuda K, Kodama Y, Yamamoto I. Thyroid calcifications: sonographic patterns and incidence of cancer. Clin Imaging. 2004;28(5):368–71.</p><p class="s58" style="padding-left: 30pt;text-indent: 0pt;line-height: 14pt;text-align: left;">S0899-7071(03)00190-6<span style=" color: #2B2A29;">.</span></p><p style="padding-left: 385pt;text-indent: 0pt;text-align: left;"><span><a href="http://crossmark.crossref.org/dialog/?doi=10.1007/978-3-031-18448-2_11&amp;domain=pdf"><img width="69" height="61" src="Image_451.png"/></a></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s11" style="padding-left: 19pt;text-indent: 0pt;text-align: left;">Key Points</p><ul id="l68"><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: left;">Thyroid nodule vascularity can be described based on location and pattern of flow.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: left;">Due to the poor sensitivity and specificity of vascularity as the sole predictor of malignancy, other ultrasound charac teristics (e.g. echogenicity, margins, calcifications, etc.) may play a more important role in nodule risk stratification.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">In light of its questionable utility, vascularity has not been included in the ATA, AACE, ITNUWG, or TIRADS scoring systems for thyroid nodules.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: left;">There have been many examples, including cases pre sented in this chapter, of hypervascular nodules that proved to be benign.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Future direction/research is exploring objective rather than subjective categorization of nodule vascularity and risk of malignancy.</p></li></ul><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="226" height="1" src="Image_452.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_453.png"/></span></p><p class="s12" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">N. M. Reddy (<span class="s13">*</span>) · M. J. Levine</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Division of Diabetes and Endocrinology, Scripps Clinic,</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">La Jolla, CA, USA</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><a href="mailto:levine.matthew@scrippshealth.org" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">e-mail: </a><a href="mailto:levine.matthew@scrippshealth.org" target="_blank">levine.matthew@scrippshealth.org</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">© The Author(s), under exclusive license to Springer Nature Switzerland AG 2023</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">L. S. Eldeiry et al. (eds.), <i>Handbook of Thyroid and Neck Ultrasonography</i><a href="https://doi.org/10.1007/978-3-031-18448-2_11" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">, Contemporary Endocrinology, </a><a href="https://doi.org/10.1007/978-3-031-18448-2_11" target="_blank">https://doi.org/10.1007/978-3-031-18448-2_11</a></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_454.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">that in some studies, thyroid vascularity was assessed subjec tively, rather than using a quantifiable, objective approach. We will discuss the need for further investigation of the significance of vascularity of thyroid nodules, particularly for the identifica tion of malignant nodules.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">It is also important to note that thyroid vascularity may have additional utility outside of the scope of malignancy risk evalua tion. For example, vascularity can be used to define a thyroid nod ule’s margin, with a vascular halo defining the border of the nodule; this is discussed elsewhere in the text. The vascularity of the gland may be increased in chronic autoimmune thyroiditis, in contrast to acute or subacute thyroiditis, postpartum or silent thy roiditis. Additionally, vascularity may be used to differentiate between the types of amiodarone-induced thyrotoxicosis. More specifically, there is absent vascularity in type 2 AIT, which is secondary to thyroid destruction, in contrast to the variable degree of vascularity encountered in type 1 AIT, where there is a hyper functioning gland.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l69"><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: justify;">The arterial supply to the thyroid gland is via two main arter ies, which are the superior thyroid artery and the inferior thy roid artery.</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">The venous drainage from the thyroid is carried by the supe rior, middle, and inferior thyroid veins, which form a venous plexus around the thyroid gland.</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">The vascularity of the thyroid parenchyma can be determined using a visual scale:</p></li></ul><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_455.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 25pt;text-indent: 0pt;text-align: justify;">ity is based on the ratio and distribution of blood flow within a particular nodule. This can be determined by the color Doppler component of the ultrasound exam.</p><ul id="l70"><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Central vascularity indicates that greater than 50% of the vas cularity is located in the center of the nodule, while peripheral vascularity denotes greater than 50% of vascularity is in the periphery of the nodule.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Avascular refers to the absence of blood flow within a nodule.</p></li><li data-list-text="•"><p style="padding-top: 1pt;padding-left: 25pt;text-indent: -19pt;text-align: left;">Thyroid nodule vascularity has been classified as follows:</p><ul id="l71"><li data-list-text="–"><p style="padding-left: 45pt;text-indent: -19pt;text-align: left;">type I vascularity refers to the complete absence of flow within the nodule,</p></li><li data-list-text="–"><p style="padding-left: 45pt;text-indent: -19pt;text-align: left;">type II refers to perinodular flow, and,</p></li><li data-list-text="–"><p style="padding-top: 1pt;padding-left: 45pt;text-indent: -19pt;line-height: 110%;text-align: justify;">type III vascularity indicates intranodular flow with multi ple vascular poles chaotically arranged, with or without sig nificant perinodular vessels.</p></li></ul></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a88">Case Presentation 1</a></h3><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Central Vascularity: A 41-year-old woman was seen in consulta tion regarding a thyroid nodule. She reported symptoms of upper respiratory infection followed by residual dry, nonproductive cough and pressure sensation in the lower throat region. She had no prior history of thyroid disease or risk factors for thyroid car cinoma. She denied dysphagia. A nodule was palpated on physi cal exam and ultrasound showed a 3.1 cm solid, hypoechoic right thyroid nodule with smooth borders, increased vascularity and microcalcifications (Images <span style=" color: #00F;">11.1 </span>and <span style=" color: #00F;">11.2</span>). The nodule was char acterized as highly suspicious FNA was recommended and that showed benign (Bethesda II) cytology.</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_456.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="215" alt="Two ultrasound images represent the right lobe nodule. The longitudinal view is on the left side and the transversal view is on the right side of the image." title="Two ultrasound images represent the right lobe nodule. The longitudinal view is on the left side and the transversal view is on the right side of the image." src="Image_457.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 11.1 <span class="s12">Longitudinal (left) and transverse (right) images of the right lobe nodule</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="124" alt="Two ultrasound images display the color doppler image of the central vascularity. The left image represents the transversal view and the right image depicts the longitudinal view." title="Two ultrasound images display the color doppler image of the central vascularity. The left image represents the transversal view and the right image depicts the longitudinal view." src="Image_458.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 11.2 <span class="s12">Color Doppler imaging of the nodule showing central vascular ity, transverse (left) and longitudinal (right)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a89">Case Presentation 2</a></h3><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Peripheral Vascularity: A 76-year-old woman with a past medical history   of   hypothyroidism,   hyperparathyroidism   with nephrolithiasis, hypertension, and hyperlipidemia was evaluated for a thyroid nodule that was incidentally discovered on CT scan performed for lung nodules. She underwent parathyroidectomy 40 years prior to her presentation, which resulted in left thyroid lobectomy. She was euthyroid on levothyroxine replacement and reported no prior exposure to radiation, history of cancer, or fam ily  history  of  thyroid  cancer.  Neck  ultrasound  showed  a</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">3.2 × 2.5 × 2.6 right lobe solid, smooth, hypoechoic nodule with no echogenic foci and with peripheral vascularity (Image</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">The nodule was classified as intermediate suspicion due to its size and hypo-echogenicity, and FNA was advised. Cytology was called benign (Bethesda II).</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_459.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="574" height="182" alt="Two ultrasound images of peripheral vascularity with the longitudinal view. The ring of fire in the right highlights the peripheral vascularity." title="Two ultrasound images of peripheral vascularity with the longitudinal view. The ring of fire in the right highlights the peripheral vascularity." src="Image_460.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="168" alt="Two ultrasound images depict the views of a solid left lobe nodule with some of the parts highlighted with + signs." title="Two ultrasound images depict the views of a solid left lobe nodule with some of the parts highlighted with + signs." src="Image_461.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 11.4 <span class="s12">Longitudinal (left) and transverse (right) views of a solid,</span></p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">2.8 × 2.3 × 2.4 cm hypoechoic, taller-than-wide left lobe nodule without vas cularity and with irregular borders</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a90">Case Presentation 3</a></h3><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Avascularity: A 71-year-old woman with a history of hypothy roidism on levothyroxine replacement was seen for a thyroid nod ule. While looking in the mirror, she noted a new neck growth that was palpable on physical exam. Ultrasound showed a left-sided nodule measuring 2.8 cm in the largest dimension; the nodule was avascular, without calcification, taller-than-wide, and had irregu lar borders (Images <span style=" color: #00F;">11.4 </span>and <span style=" color: #00F;">11.5</span>). A biopsy was recommended and cytology was called malignant (Bethesda VI). The specimen showed papillary thyroid carcinoma with papillary follicular groups with nuclear overlap, nucleomegaly, nuclear grooves, and rare intra-nuclear inclusions. She subsequently underwent total thyroidectomy with central neck dissection. Surgical pathology revealed multifocal papillary thyroid carcinoma, tall cell variant;</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_462.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="156" alt="Two ultrasound images illustrate longitudinal and transverse views of the left sided nodule." title="Two ultrasound images illustrate longitudinal and transverse views of the left sided nodule." src="Image_463.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="380" alt="A microscopic image represents one of the three central neck lymph nodes with a tumor." title="A microscopic image represents one of the three central neck lymph nodes with a tumor." src="Image_464.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 11.6  <span class="s12">Lymph node metastasis—papillary neoplasm present within a capsule (star) and associated with lymphocytes, consistent with tumor metas tasis in a lymph node (H&amp;E, ×10)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">the greatest area measuring 3.3 cm in the left lobe with perineural and extrathyroidal invasion. One of three central neck lymph nodes was involved with tumor, with the largest metastatic deposit measuring 4 mm (Images <span style=" color: #00F;">11.6 </span>and <span style=" color: #00F;">11.7</span>). The tumor was classi fied as pT3bN1a. She was subsequently treated with radioactive iodine. Post-therapy whole body imaging and subsequent surveil lance testing indicated no distant metastasis or persistent disease.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_465.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="379" alt="A microscopic image depicts the central neck lymph node with the largest metastatic deposit measuring 4 millimeters." title="A microscopic image depicts the central neck lymph node with the largest metastatic deposit measuring 4 millimeters." src="Image_466.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 11.7  <span class="s12">Nuclear detail of papillary thyroid cancer cells showing crowd ing, overlapping, and finely granular chromatin with small punctate nucleoli and occasional nuclear grooves (arrow) (PAP stain, ×40)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_467.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a91">Discussion</a></h1><p style="padding-top: 17pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">The role of thyroid nodule vascularity and vascular pattern in the prediction of thyroid cancer has been controversial. In addition, vascularity within a thyroid nodule may represent a variety of underlying processes, as listed in Table <span style=" color: #00F;">11.1</span></p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Several studies have examined the utility of vascularity in the identification of malignancy. In one study of consecutive patients with nonpalpable thyroid nodules measuring from 8 to 15 mm, 31 of 402 thyroid nodules were malignant. With Doppler ultrasound, an intranodular vascular pattern was present in 74% of the malig nant nodules. The addition of a second suspicious feature, such as microcalcifications, resulted in a higher specificity for the predic tion of malignancy (95%), although with a corresponding decrease in sensitivity (29%). The specificity of irregular margins or intra nodular vascularity was 85% and 80.8%, respectively, in this</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_468.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 179pt;text-indent: 0pt;text-align: left;"><span><img width="349" height="113" src="Image_469.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">sonography.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Hypervascularity, however, has been reported to be a more fre quently encountered feature of follicular and medullary thyroid carcinoma than papillary carcinoma. This is underscored in the American Thyroid Association (ATA) guidelines, which indicate that vascularity is less useful for predicting malignancy in papil lary thyroid carcinoma in contrast to follicular thyroid carcinoma.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">In contrast, however, other studies have not shown a correla tion between intranodular vascularity and malignancy. These reports have shown that most thyroid cancers lack intranodular vascularity, with most hypervascular nodules representing benign adenomas. In the case series we have presented, vascularity did not correlate with malignancy.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">The proposed explanation for these conflicting results relates to the subjective nature of the visual assessment of vascularity, leading to higher interobserver variability. Quantifiable, more objective approaches to the assessment of vascularity have been proposed to address this issue. In a study of a computer-aided approach that allowed for the quantification of thyroid parenchy mal vascularity and lymph node vascularity with color Doppler ultrasound, an algorithm was created to calculate a “vascular index” of the peripheral and central regions of thyroid nodules. The results indicated that central vascularity rather than periph eral vascularity was associated with thyroid malignancy.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Taken together, all of these findings suggest that increased vas cularity within a thyroid nodule is not a strong predictor of increased risk of malignancy, and therefore the significance of this</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_470.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_471.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s58" style="padding-top: 4pt;padding-left: 25pt;text-indent: -19pt;text-align: left;"><a href="https://doi.org/10.1159/000096013" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">Appetecchia M, Solivetti FM. The association of colour flow doppler sonog raphy and conventional ultrasonography improves the diagnosis of thy roid carcinoma. Horm Res. 2006;66(5):249–56. Epub 2006 Oct 2. PMID: 17016052. </a>https://doi.org/10.1159/000096013<span style=" color: #2B2A29;">.</span></p><p style="padding-left: 25pt;text-indent: -19pt;text-align: justify;"><a href="https://doi.org/10.1038/s41598-017-14432-7" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">Baig FN, van Lunenburg JT, Liu SYW, et al. Computer-aided assessment of regional vascularity of thyroid nodules for prediction of malignancy. Sci Rep. 2017;7:14350. </a><a href="https://doi.org/10.1038/s41598-017-14432-7" target="_blank">https://doi.org/10.1038/s41598-</a></p><p class="s12" style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">Bogazzi F, Bartalena L, Brogioni S, Mazzeo S, Vitti P, Burelli A, Bartolozzi C, Martino E. Color flow doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. Thyroid. 1997;7(4):541–</p><p class="s58" style="padding-left: 25pt;text-indent: 0pt;line-height: 14pt;text-align: justify;"><a href="https://doi.org/10.1089/thy.1997.7.541" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">5. </a>https://doi.org/10.1089/thy.1997.7.541<span style=" color: #2B2A29;">.</span></p><p class="s58" style="padding-left: 25pt;text-indent: -19pt;text-align: left;"><a href="https://doi.org/10.1530/eje.0.1400452" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">Bogazzi F, Bartalena L, Brogioni S, Burelli A, Manetti L, Tanda ML, Gasperi M, Martino E. Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels: studies in vivo by color flow doppler sonography.  Eur  J  Endocrinol.  1999;140(5):452–6. </a>org/10.1530/eje.0.1400452<span style=" color: #2B2A29;">.</span></p><p class="s58" style="padding-left: 25pt;text-indent: -19pt;text-align: left;"><a href="https://doi.org/10.14366/usg.20072" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">Chung J, Lee YJ, Choi YJ, et al. Clinical applications of doppler ultrasonog raphy for thyroid disease: consensus statement by the Korean Society of Thyroid  Radiology.  Ultrasonography.  2020;39(4):315–30. </a>org/10.14366/usg.20072<span style=" color: #2B2A29;">.</span></p><p class="s12" style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Haugen BR, et al. 2015 American Thyroid Association management guide lines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thy roid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–</p><p class="s58" style="padding-left: 25pt;text-indent: 0pt;line-height: 14pt;text-align: left;"><a href="https://doi.org/10.1089/thy.2015.0020" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">133. </a>https://doi.org/10.1089/thy.2015.0020<span style=" color: #2B2A29;">.</span></p><p class="s12" style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">Lai X, Liu M, Xia Y, et al. Hypervascularity is more frequent in medullary thyroid carcinoma: compared with papillary thyroid carcinoma. Medicine (Baltimore).      2016;95(49):e5502.</p><p class="s58" style="padding-left: 25pt;text-indent: 0pt;line-height: 14pt;text-align: left;">MD.0000000000005502<span style=" color: #2B2A29;">.</span></p><p class="s12" style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S, Nardi F, Panunzi C, Rinaldi R, Toscano V, Pacella CM. Risk of malignancy in non palpable thyroid nodules: predictive value of ultrasound and color-dop</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="566" height="2" src="Image_472.png"/></span></p><p style="padding-left: 385pt;text-indent: 0pt;text-align: left;"><span><a href="http://crossmark.crossref.org/dialog/?doi=10.1007/978-3-031-18448-2_12&amp;domain=pdf"><img width="69" height="61" src="Image_473.png"/></a></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s11" style="padding-left: 19pt;text-indent: 0pt;text-align: left;">Key Points</p><ul id="l72"><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: left;">Imaging should not be used to establish the diagnosis of hyperparathyroidism. It should be reserved for patients with established hyperparathyroidism who are candi dates for surgery.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: left;">Ultrasound should be the initial imaging study. It is safe, cost-effective, involves no radiation, and allows evalua tion of both the parathyroid and thyroid glands. A strongly positive exam may obviate the need for any additional imaging.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">The disadvantage of ultrasound is operator dependence. Even with expertise, the diagnosis of multi-gland disease is less accurate than for a single adenoma.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Demonstration of intra-lesional hypervascularity is a very helpful finding, but lack of vascularity does not exclude the lesion being a parathyroid adenoma.</p></li></ul><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="226" height="1" src="Image_474.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_475.png"/></span></p><p class="s12" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">B. Sacks (<span class="s13">*</span>)</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Department of Radiology, Beth Israel Deaconess Medical Center,</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Boston, MA, USA</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><a href="mailto:bsacks@bidmc.harvard.edu" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">e-mail: </a><a href="mailto:bsacks@bidmc.harvard.edu" target="_blank">bsacks@bidmc.harvard.edu</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">© The Author(s), under exclusive license to Springer Nature Switzerland AG 2023</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">L. S. Eldeiry et al. (eds.), <i>Handbook of Thyroid and Neck Ultrasonography</i><a href="https://doi.org/10.1007/978-3-031-18448-2_12" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">, Contemporary Endocrinology, </a><a href="https://doi.org/10.1007/978-3-031-18448-2_12" target="_blank">https://doi.org/10.1007/978-3-031-18448-2_12</a></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_476.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 39pt;text-indent: 0pt;text-align: justify;">Sestamibi should be considered a back-up exam when US and 4DCT are inconclusive, or performed if the patient has a contraindication to contrast injection.</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_477.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a92">Introduction</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">This chapter focuses predominantly on ultrasound (US) imaging in the work-up of patients with primary hyperparathyroidism. US examination of these patients is mandatory because it is safe, cost- effective, easily available, accurate, and involves no radiation exposure. However, US also has limitations and most patients usually require a complementary imaging study. For many years, the imaging algorithm in patients with confirmed primary hyper parathyroidism who were considered surgical candidates was nuclear imaging with Technetium Sestamibi scan (usually with SPECT/CT), followed by ultrasound. If those two studies were either inconclusive or discordant, 4DCT was performed. Although many institutions and endocrinologists still adhere to this sequence of exams, the accuracy of 4DCT has significantly impacted the initial imaging algorithm. The combination of US, followed by 4DCT provides the maximum “bang for the buck,” identifying both orthotopic (eutopic) and ectopic enlarged glands, in addition to multi-gland disease. Ultrasound as the initial exam provides the ability to both localize abnormal parathyroid glands and simulta neously evaluate the thyroid gland. If thyroid nodules are detected and require FNA preoperatively, this can be recommended or</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_478.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">stable, benign right thyroid nodule. Hyperparathyroidism was diagnosed, with serum calcium levels ranging from 10.8 to</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">11.5 mg/dL and elevated parathyroid hormone (PTH) levels of 95–105 pg/mL. 25 hydroxy-vitamin D level was low at 22 ng/mL.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Initial imaging with ultrasound demonstrated thyroid hetero geneity consistent with Hashimoto’s thyroiditis (Image</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">with the characteristic associated numerous, small reactive lymph nodes bilaterally, and the previously biopsied (benign) right thy roid nodule. A hypervascular extrathyroidal nodule at the left lower pole was also identified, with a slightly hyperechoic center. The differential diagnosis included an atypical parathyroid ade noma or a reactive lymph node (Table <span style=" color: #00F;">12.1</span></p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">The hypervascularity on ultrasound was more suggestive of a parathyroid adenoma. The patient subsequently underwent a 4DCT scan, which showed the left lower pole lesion brightly enhancing, consistent with a parathyroid adenoma. She under went surgery, where a left lower pole parathyroid adenoma was confirmed and resected. Intraoperative PTH level dropped from 93 pg/mL preoperatively to 15 pg/mL post-excision of the lesion, confirming a cure of her parathyroid disease.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">In an attempt to explain the unusual ultrasound findings, the histopathology was reviewed. Was the appearance due to a mod erate amount of central fat or fibrosis? As demonstrated in the slides below (Image <span style=" color: #00F;">12.2</span>), a few patchy areas of fat and fibrosis were present, with a prominent vessel; however, the findings essentially  confirmed  a  classical,  hypercellular  parathyroid adenoma.</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_479.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="299" alt="Five ultrasound images of the left thyroid lobe in sagittal, transverse, axial, and coronal view. A and B scans, the light shaded parts in the scans highlight P T H adenoma at the lower pole. C, The scan highlights vascularity of the lesion. D. An arrow highlights enlarged parathyroid. E. The arrow in the scan represents the light shaded part which is labeled P T H adenoma." title="Five ultrasound images of the left thyroid lobe in sagittal, transverse, axial, and coronal view. A and B scans, the light shaded parts in the scans highlight P T H adenoma at the lower pole. C, The scan highlights vascularity of the lesion. D. An arrow highlights enlarged parathyroid. E. The arrow in the scan represents the light shaded part which is labeled P T H adenoma." src="Image_480.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 12.1  <span class="s12">Upper left: Sagittal view of the left thyroid lobe demonstrating heterogeneous echotexture (left arrow) and an unusual nodule at the lower pole, extrathyroidal, suggestive of either a reactive lymph node with a fatty center (common in Hashimoto’s) or parathyroid adenoma (right arrow). Upper right: Transverse view of the left lower pole showing the same lesion. Bottom left: A color flow Doppler image showing vascularity of the lesion with a polar vessel. Bottom center: Four-dimensional CT (4DCT) was per formed (often necessary in patients with Hashimoto’s because of the diffi culty in differentiating lymph nodes from enlarged parathyroid glands on ultrasound). The axial arterial image shows dramatic enhancement of the nodule at the left lower pole (arrow). This prominent early enhancement is not consistent with a lymph node (which usually shows minimal and delayed slight enhancement) and strongly suggests a parathyroid adenoma. Bottom right: A coronal view (different window settings) demonstrating the left lower pole parathyroid adenoma</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Table 12.1 <span class="s12">Differential diagnosis</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:10.3325pt" cellspacing="0"><tr style="height:17pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">1. Reactive lymph node associated with Hashimoto’s thyroiditis</p></td></tr><tr style="height:17pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">2. Atypical parathyroid adenoma</p></td></tr></table><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_481.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="206" src="Image_482.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">vessels (blue arrows). Scattered pockets of adipose tissue at the periphery (red arrows). Right: Central portion exhibiting microfollicular architecture, with interspersed strips of fibrosis (blue arrows) and adipose tissue (red arrows)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_483.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a93">Parathyroid Embryology and Anatomy</a></h1><p style="padding-top: 17pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Briefly, the inferior parathyroid gland originates from the third pharyngeal pouch (together with the thymus) and travels down to the normal (orthotopic) location behind the lower pole of the thy roid lobe (Image <span style=" color: #00F;">12.3</span>, left panel). However, the lower pole gland can remain either in its original location (undescended), any place along the path on which it descends, or overshoot, ending up in the mediastinum—all ectopic locations. The upper gland origi nates from the fourth pharyngeal pouch and travels down, medial and in a posterior course ending behind the upper pole of the thy roid. The upper pole gland can also fail to descend, deposit along the descending path, or overshoot and end up in the posterior mediastinum. These ectopic locations are always posterior to the recurrent laryngeal nerve. All the orthotopic and possible ectopic locations are demonstrated in Image <span style=" color: #00F;">12.3</span>, right.</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_484.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="242" alt="Two illustrations exhibit the anatomical structure of the normal and ectopic parathyroid glands. The upper and lower pole glands are observed." title="Two illustrations exhibit the anatomical structure of the normal and ectopic parathyroid glands. The upper and lower pole glands are observed." src="Image_485.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 12.3  <span class="s12">Anatomy of the expected locations of NORMAL and ECTO PIC parathyroid glands/adenomas (yellow = lower pole gland, blue = upper pole gland, white = either upper or lower pole glands)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="212" alt="Five ultrasound images of the thyroid. The parathyroid adenomas are exhibited by the white arrows in each image." title="Five ultrasound images of the thyroid. The parathyroid adenomas are exhibited by the white arrows in each image." src="Image_486.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Image  12.4  <span class="s12">Multiple  examples  of  parathyroid  adenomas  (arrows). Hypoechoic compared to the thyroid and variable in size and shape. The shape is determined by the space in which the adenoma develops</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-left: 10pt;text-indent: 0pt;text-align: justify;"><a name="a94">Parathyroid Adenomas: Additional Examples</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: justify;"><b>Echotexture </b>While a classic parathyroid adenoma is hypoechoic relative to the thyroid gland, as discussed earlier, the distinction may not be as stark in patients with underlying thyroiditis. The texture may also be atypical as shown in the examples below (Image <span style=" color: #00F;">12.4</span>). Cystic change is also possible.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_487.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">hyperfunction and very large lesions may present with minimally elevated calcium and PTH levels.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;"><b>Vascularity </b>Parathyroid adenomas are typically hypervascular on color Doppler (Image <span style=" color: #00F;">12.5a, b</span>). Hypervascularity strongly supports the diagnosis, but a lack of hypervascularity on color Doppler does not exclude it (Image <span style=" color: #00F;">12.5c</span>).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="584" height="146" alt="Seven ultrasound images in sagittal and transverse view of a right lower pole adenoma." title="Seven ultrasound images in sagittal and transverse view of a right lower pole adenoma." src="Image_488.jpg"/></span></p><p class="s59" style="text-indent: 0pt;text-align: left;">a</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 6pt;text-indent: 0pt;text-align: left;"><span class="s17">Image 12.5  </span>(<b>a</b>) Sagittal and transverse views of a right lower pole adenoma demonstrate a hypoechoic, extrathyroidal lower pole nodule, hypervascular on Color Doppler (image right). (<b>b</b>) Transverse view of a hypoechoic parathy roid adenoma in the right thyroid bed (left panel) that is hypervascular on color Doppler (right panel). (<b>c</b>) Transverse view through the left lobe demon strating a small left upper pole parathyroid adenoma (left panel). Color Dop pler shows the adenoma is avascular (right panel). Vascularity is a very helpful US finding but the absence of vascularity does not rule out parathy roid adenoma</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_489.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="331" alt="Seven ultrasound images in sagittal and transverse view of a right lower pole adenoma." title="Seven ultrasound images in sagittal and transverse view of a right lower pole adenoma." src="Image_490.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 12.5 <span class="s12">(continued)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 12pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="223" alt="A transverse and a sagittal ultrasound image of a parathyroid adenoma. The hypo and hyperechoic elements are exhibited by the regions with arrows." title="A transverse and a sagittal ultrasound image of a parathyroid adenoma. The hypo and hyperechoic elements are exhibited by the regions with arrows." src="Image_491.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 12.6 <span class="s12">Unusual mixed echotexture of a parathyroid adenoma with hypoechoic and hyperechoic elements</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 10pt;text-indent: 0pt;line-height: 84%;text-align: left;"><span class="h2">Atypical Appearance of Parathyroid Adenomas (Images </span>12.6<span style=" color: #2B2A29;">, </span>12.7<span style=" color: #2B2A29;">, </span><span class="h2">and </span>12.8<span class="h2">)</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_492.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="152" alt="Four ultrasound images of different types of parathyroid adenoma. The cystic elements are observed." title="Four ultrasound images of different types of parathyroid adenoma. The cystic elements are observed." src="Image_493.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">IJ, likely located within the carotid sheath (third panel, arrowheads). Color Doppler shows very vascular solid tissue surrounded by cystic elements (right panel)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 8pt;text-indent: 0pt;text-align: left;"><span><img width="568" height="158" alt="Four D C T images of the thyroid with parathyroid adenoma. The cystic lesions are marked with arrows. " title="Four D C T images of the thyroid with parathyroid adenoma. The cystic lesions are marked with arrows. " src="Image_494.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 12.8  <span class="s12">Predominantly cystic lesion is noted adjacent to the right upper pole of the thyroid with solid, septal elements on US (left 2 panels with arrows). Also seen on the 4DCT images (right 2 panels with arrows: left image, axial view; right image, coronal view). Differential—exophytic, cystic thyroid nodule vs cystic parathyroid. FNA for PTH confirmed a parathyroid adenoma</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 5pt;text-indent: 0pt;line-height: 84%;text-align: left;"><span class="h2">Ectopic Locations of Parathyroid Adenomas (Images </span>12.9<span style=" color: #2B2A29;">, </span>12.10<span style=" color: #2B2A29;">, </span>12.11<span style=" color: #2B2A29;">, </span><span class="h2">and </span>12.12</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_495.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="154" alt="Four M R I image of the neck. The adenoma is observed in all 4 images." title="Four M R I image of the neck. The adenoma is observed in all 4 images." src="Image_496.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="571" height="223" alt="Two M R images in transverse view of the thyroid. The arrows in the images indicate a light shaded part near carotid depict intrathyroidal lesion." title="Two M R images in transverse view of the thyroid. The arrows in the images indicate a light shaded part near carotid depict intrathyroidal lesion." src="Image_497.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 12.10  <span class="s12">An unusual right-sided intrathyroidal lesion was noted, atypi cal for a thyroid nodule (left panel, transverse image). FNA for PTH (right panel with arrows pointing to the needle in the nodule) was markedly ele vated, confirming an intrathyroidal parathyroid adenoma</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 12pt;text-indent: 0pt;text-align: left;"><span><img width="567" height="165" alt="Three ultrasound images. The transverse and sagittal ultrasound images of the right lower pole of the thyroid gland highlight parathyroid adenoma in the ectopic right upper pole gland which is indicated by an arrow." title="Three ultrasound images. The transverse and sagittal ultrasound images of the right lower pole of the thyroid gland highlight parathyroid adenoma in the ectopic right upper pole gland which is indicated by an arrow." src="Image_498.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 12.11 <span class="s12">Ultrasound raises the possibility of a very posterior and medial, hypoechoic nodule below the right lower pole of the thyroid (left panel, transverse view; middle panel, sagittal view). Because it was at the lower limits of visibility by ultrasound, 4DCT was performed and confirmed a classic parathyroid ade noma adjacent to the esophagus (right image, arrow), representing a parathyroid adenoma arising in the ectopic right upper pole gland</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_499.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 8pt;text-indent: 0pt;text-align: left;"><span><img width="577" height="186" alt="Two ultrasound images of the lower pole of the thyroid gland highlight the parathyroid adenoma which is exhibited by the arrows. The clavicles and the subclavian artery are also highlighted." title="Two ultrasound images of the lower pole of the thyroid gland highlight the parathyroid adenoma which is exhibited by the arrows. The clavicles and the subclavian artery are also highlighted." src="Image_500.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">arrow). Repeat US with angling into the upper mediastinum demonstrated a mostly cystic lesion (right panel, right arrow), which also explained why the lesion demonstrated poor enhancement. Aspiration revealed a dramatic eleva tion in PTH</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="136" alt="Four ultrasound images in sagittal and transverse view of the thyroid of a patient with Hashimoto&#39;s thyroiditis." title="Four ultrasound images in sagittal and transverse view of the thyroid of a patient with Hashimoto&#39;s thyroiditis." src="Image_501.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 12.13  <span class="s12">Patient with Hashimoto’s thyroiditis: US demonstrates patchy thyroid texture and reactive lymph nodes at the lower pole (left panel, arrows). One nodule had an unusual triangular shape (middle 2 panels, sagittal and transverse views). Color Doppler showed hypervascularity, suggesting a parathyroid adenoma and differentiating it from the avascular lymph nodes (right panel)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-left: 5pt;text-indent: 0pt;line-height: 87%;text-align: left;"><a name="a95">Associated Thyroid Diseases Complicating Parathyroid Adenoma Localization (Images </a><span class="s19">12.14</span><span class="s73">, </span>and <span class="s19">12.15</span>)</h2><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_502.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="568" height="119" alt="Three ultrasound images of the thyroid. The thyroid nodule and parathyroid adenoma are exhibited by the arrows." title="Three ultrasound images of the thyroid. The thyroid nodule and parathyroid adenoma are exhibited by the arrows." src="Image_503.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">micro-calcification. Preoperative FNA was consistent with papillary thyroid carcinoma. Parathyroidectomy and thyroidectomy were performed at surgery</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="132" alt="Three ultrasound images of the thyroid gland. The thyroid nodule activities are exhibited by the arrows on the images." title="Three ultrasound images of the thyroid gland. The thyroid nodule activities are exhibited by the arrows on the images." src="Image_504.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 12.15  <span class="s12">False positive sestamibi scan: Dense activity is noted at the left lower pole of the thyroid gland, persisting on the delayed views (left panel, arrow). Ultrasound shows the activity correlates with a thyroid nodule in the same location (middle panel, sagittal view; right panel, transverse view). FNA of the thyroid nodule is recommended before proceeding to para thyroid surgery, due to its US characteristics</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><h2 style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a96">4DCT</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">This imaging modality has significantly improved the preopera tive localization of parathyroid adenomas. Adenomas in the nor mal (orthotopic) location are detectable, but the major advantage of 4DCT is its ability to identify ectopic adenomas (Images</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_505.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="121" alt="Four 4 D C T images of the thyroid gland. The parathyroid adenoma is exhibited in the images after each varying contrast." title="Four 4 D C T images of the thyroid gland. The parathyroid adenoma is exhibited in the images after each varying contrast." src="Image_506.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="186" height="171" alt="Four 4 D C T images of the thyroid gland. The parathyroid adenoma is exhibited in the images after each varying contrast." title="Four 4 D C T images of the thyroid gland. The parathyroid adenoma is exhibited in the images after each varying contrast." src="Image_507.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 12.16  <span class="s12">Classic 4DCT. Top left: Axial images pre-contrast show the parathyroid adenoma to be less dense than the thyroid (thyroid density is due to iodine content). Top middle: Following a bolus of IV contrast, there is dramatic enhancement of the adenoma. Top right: Delayed scans at 60–90 s show rapid washout of the contrast from the adenoma. Bottom left: A coronal view demonstrates the difference between enhancement of the adenoma on the right (white arrow) and the poorly enhancing nodes on the left (red arrows)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">and <span style=" color: #00F;">12.18</span>), both in the neck and chest, in addition to the detection of double adenomas and multi-gland disease. Interpretation can in some cases be extremely difficult when the adenomas are closely applied to or within the thyroid gland or are small. However, in those particular scenarios, they are usually easily identified by ultrasound,  making  the  two  studies  complementary.  4DCT requires the administration of a bolus of intravenous contrast (which may be contraindicated in patients with renal dysfunction or contrast allergy). Lastly, interpretation of the 4DCT scans requires both skill and experience.</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_508.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="289" alt="A coronal scanned image and a 3 D reconstruction represent the adenoma and pyramidal lobe in the thyroid glands. The 3 D reconstruction highlights two arrows indicating a point in the center part of the neck as P T H." title="A coronal scanned image and a 3 D reconstruction represent the adenoma and pyramidal lobe in the thyroid glands. The 3 D reconstruction highlights two arrows indicating a point in the center part of the neck as P T H." src="Image_509.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 12.17  <span class="s12">Left: Coronal view showing a parathyroid adenoma far poste rior, consistent with an ectopic right upper pole gland. Right: 3D reconstruc tion showing the adenoma (red arrow) and an incidental pyramidal lobe of the thyroid (white arrow)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="237" alt="Six 4 D C T images in axial left and right, coronal left and right, and sagittal left and right views of the thyroid glands. the arrows in the scans represent a light shaded part in the center P T H." title="Six 4 D C T images in axial left and right, coronal left and right, and sagittal left and right views of the thyroid glands. the arrows in the scans represent a light shaded part in the center P T H." src="Image_510.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Image 12.18  <span class="s12">Bilateral parathyroid adenomas. Top two left panels: Axial views of bilateral ectopic right and left upper pole adenomas (arrows). Top right panels. Coronal views of the adenomas. Lower left panels: Same ectopic upper pole double adenomas in sagittal projection</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_511.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Ultrasound identification of enlarged parathyroid glands is most accurate when the enlarged glands are in the expected normal (orthotopic) anatomic location, adjacent to and behind the thy roid. A major advantage of US is the ability to identify intrathy roidal adenomas. Double adenomas and multi-gland disease can be diagnosed, but it is a less accurate modality than for a single adenoma. The major disadvantage of ultrasound is that it is entirely operator-dependent. For parathyroid adenoma localiza tion in particular, US requires specific expertise and dedication, knowing where to search for both normally positioned glands and the potential ectopic glands. Image quality is important, influ enced by the ultrasound equipment, the type of transducer, patient anatomy, and the status of the thyroid gland.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Parathyroid adenomas are typically hypoechoic on ultrasound when compared to the adjacent thyroid gland. The textural differ ences are less obvious when there is underlying thyroid disease, particularly with Hashimoto’s thyroiditis. Graves’ disease, sub acute thyroiditis, and chronic lithium administration will have a similar effect in diminishing the textural difference, rendering the diagnosis of parathyroid adenoma by ultrasound more challeng ing.  An  additional  diagnostic  challenge  in  the  setting  of Hashimoto’s disease is the common finding of multiple reactive lymph nodes, particularly at the lower poles of the thyroid gland, given the potential large size of the nodes, for which distinction from a parathyroid adenoma can be difficult. Color Doppler is very helpful when classical hypervascularity or a polar artery is</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_512.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">high neck or those in the deep posterior neck; retro-esophageal lesions, or those within the carotid sheath or mediastinum).</p><ol id="l73"><li data-list-text="2."><p style="padding-left: 31pt;text-indent: -20pt;text-align: left;">Patients with a very large, short neck.</p></li><li data-list-text="3."><p style="padding-left: 31pt;text-indent: -20pt;text-align: left;">A very large multinodular goiter, where the thyroid lobes are large enough to limit visualization. Extension of the thyroid lobes or nodules into the thoracic inlet will also limit the eval uation of the lower pole glands.</p></li></ol><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_513.png"/></span></p><h1 style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a97">Further Reading</a></h1><p class="s12" style="padding-top: 17pt;padding-left: 30pt;text-indent: -19pt;text-align: justify;">Akerström G, Malmaeus J, Bergström R. Surgical anatomy of human para thyroid glands. Surgery. 1984;95:14–21.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: justify;">Lappas D, Noussios G, Anagnostis P, Adamidou F, Chatzigeorgiou A, Skandalakis P. Location, number and morphology of parathyroid glands: results from a large anatomical series. Anat Sci Int. 2012;87:160–4.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Lubitz CC, Stephen AE, Hodin RA, Pandharipande P. Preoperative localiza tion strategies for primary hyperparathyroidism: an economic analysis. Ann Surg Oncol. 2012;19:4202–9.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Sacks BA, Pallotta JA, Cole A, Hurwitz J. Diagnosis of parathyroid adeno mas: efficacy of measuring parathormone levels in needle aspirates of cervical masses. AJR Am J Roentgenol. 1994 Nov;163(5):1223–6.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: justify;">Solorzano CC, Carneiro-Pla D. Minimizing cost and maximizing success in the preoperative localization strategy for primary hyperparathyroidism. Surg Clin North Am. 2014;94:587–605.</p><p style="padding-left: 385pt;text-indent: 0pt;text-align: left;"><span><a href="http://crossmark.crossref.org/dialog/?doi=10.1007/978-3-031-18448-2_13&amp;domain=pdf"><img width="69" height="61" src="Image_514.png"/></a></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s11" style="padding-left: 19pt;text-indent: 0pt;text-align: left;">Key Points</p><ul id="l74"><li data-list-text="•"><p style="padding-top: 5pt;padding-left: 39pt;text-indent: -19pt;line-height: 110%;text-align: left;">Enlarged cervical lymph nodes are a common finding and the differentiation of benign vs malignant lymphade nopathy is done with a combination of imaging and fine needle biopsy.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;line-height: 110%;text-align: left;">A persistently enlarged lymph node in an adult that does not have reassuringly benign characteristics on ultra sound should be considered suspicious until proven oth erwise.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;line-height: 110%;text-align: left;">Benign lymph nodes most often appear ovoid, well- circumscribed, and have a preserved echogenic hilum.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;line-height: 110%;text-align: justify;">Malignant lymph nodes most often appear rounded, hypoechoic, and have an absent echogenic hilum. Prominent vascularity may also be present.</p></li></ul><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="226" height="1" src="Image_515.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_516.png"/></span></p><p class="s12" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">H. Tierney (<span class="s13">*</span>)</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><a href="mailto:hientue_tierney@atriushealth.org" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">Atrius Health/Harvard Medical School, Boston, MA, USA e-mail: </a><a href="mailto:hientue_tierney@atriushealth.org" target="_blank">hientue_tierney@atriushealth.org</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">© The Author(s), under exclusive license to Springer Nature Switzerland AG 2023</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">L. S. Eldeiry et al. (eds.), <i>Handbook of Thyroid and Neck Ultrasonography</i><a href="https://doi.org/10.1007/978-3-031-18448-2_13" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">, Contemporary Endocrinology, </a><a href="https://doi.org/10.1007/978-3-031-18448-2_13" target="_blank">https://doi.org/10.1007/978-3-031-18448-2_13</a></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_517.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><span><img width="575" height="271" src="Image_518.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_519.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a98">Introduction</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Cervical lymphadenopathy may be broadly classified as benign or malignant in nature, with management being determined by the underlying disorder associated with the lymphadenopathy. A careful physical exam is an important component of the initial evaluation of cervical lymphadenopathy and multiple large, firm nodes should raise the level of suspicion for possible malignancy. However, physical examination alone is an unreliable method for assessing lymphadenopathy and ultrasound is considered the pre ferred imaging modality for the initial evaluation of metastatic lymph nodes. Ultrasound can significantly inform the diagnostic process by assessing the size, morphology, and position of such lymph nodes.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Lymph nodes are described based on their location in the neck (Fig. <span style=" color: #00F;">13.1</span>).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l75"><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;line-height: 110%;text-align: justify;">Level I extends from the mandible to the hyoid bone in the submental midline region.</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;line-height: 110%;text-align: justify;">Level II encompasses the region from the skull base to the hyoid bone along the submandibular gland anteriorly to the posterior border of the sternocleidomastoid muscle posteriorly.</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;line-height: 16pt;text-align: justify;">Level III represents lymph nodes between the hyoid bone</p></li></ul><p style="padding-left: 30pt;text-indent: 0pt;text-align: justify;">superiorly and the cricoid cartilage inferiorly, between the</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_520.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="541" alt="An illustration of a person&#39;s head and neck represents the lymph nodes based on their location in the neck. The different levels of the nodes are marked on the neck with roman numbers." title="An illustration of a person&#39;s head and neck represents the lymph nodes based on their location in the neck. The different levels of the nodes are marked on the neck with roman numbers." src="Image_521.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 13.1 <span class="s12">Anatomic boundaries of the levels of the neck used to describe the location of cervical lymphadenopathy</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 25pt;text-indent: 0pt;text-align: justify;">anterior and posterior borders of the sternocleidomastoid muscle.</p><ul id="l76"><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: justify;">Level IV extends from the cricoid cartilage to the clavicle, from the anterior border of the sternocleidomastoid muscle to the lateral edge of the anterior scalene muscle.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;text-align: left;">Level V represents the posterior triangle from the posterior border of the sternocleidomastoid muscles to the anterior bor der of the trapezius muscle.</p></li><li data-list-text="•"><p style="padding-left: 25pt;text-indent: -19pt;line-height: 110%;text-align: justify;">Level VI represents the central compartment from the hyoid bone above to the suprasternal notch below, between the medial borders of both common carotid arteries.</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_522.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-top: 5pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a99">Malignant</a></h3><ul id="l77"><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Hyper- or hypo-echogenicity</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Round shape</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Loss of the central hila</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Abnormal or peripheral vascularity on color Doppler</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Irregular borders</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Calcifications (usually micro-calcification)</p></li><li data-list-text="•"><p style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Cystic degeneration or focal cysts</p></li></ul></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a100">Case Presentation</a></h3><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">A 64-year-old man presented with a 2-month history of dyspho nia. He had no sore throat or dysphagia and no personal or fam ily history of thyroid disease. He was a nonsmoker. On clinical examination, a firm, 3 cm right-sided thyroid mass was noted. Laryngoscopy demonstrated right vocal fold paresis. TSH was normal. Neck ultrasound showed a right thyroid nodule, taller than  wide,  that  was  markedly  hypoechoic,  measuring</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">2.7 × 2.1 × 3.0 cm with internal vascularity. In the central neck, there was a 0.8 cm round lymph node with indistinct borders and lack of a central hilum (Image <span style=" color: #00F;">13.1</span>) and in level IV, there was another  2.5  cm  enlarged  abnormal-appearing  lymph  node (Image <span style=" color: #00F;">13.2</span>). A subsequent CT scan confirmed the ultrasound findings.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: justify;">The patient underwent ultrasound-guided FNA and cytology was consistent with medullary thyroid carcinoma (MTC) (Image <span style=" color: #00F;">13.3</span>). Preoperative evaluation for MTC was performed including RET oncogene testing and testing for pheochromocytoma, which</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_523.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="571" height="372" alt="An ultrasound of the central neck. It has captured a 0.8-centimeter round lymph node that has an indistinct border." title="An ultrasound of the central neck. It has captured a 0.8-centimeter round lymph node that has an indistinct border." src="Image_524.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 13.1  <span class="s12">Level VI abnormal-appearing lymph node. Note the round shape, indistinct borders, and lack of a central hilum</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="325" src="Image_525.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 13.2  <span class="s12">Level IV abnormal-appearing lymph node. The node appears enlarged, heterogeneous, and demonstrates peripheral vascularity. Again note the lack of a central hilum. There are 2 micro-calcifications (arrows)</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_526.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="481" alt="An enlarged cell image depicts the consistency of the cytology with medullary thyroid carcinoma." title="An enlarged cell image depicts the consistency of the cytology with medullary thyroid carcinoma." src="Image_527.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 13.3  <span class="s12">Round to ovoid, and multinucleated plasmacytoid-shaped cells (arrow) with thick amorphous amyloid deposits (star), consistent with a diag nosis of MTC (Thin-prep cytology, PAP stain, ×60)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 11pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">was negative. Preoperative calcitonin and CEA values were mark edly elevated at 5108 pg/mL (&lt;10 pg/mL) and 163 ng/mL (0–2.5 ng/mL), respectively. The patient underwent total thyroid ectomy with bilateral central and lateral neck dissection. Pathology showed a 3.2 cm MTC with extensive bilateral lymph node involvement in 19 of 44 lymph nodes (Image</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_528.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="392" alt="A pathology image depicts 3 point 2 centimeter M T C with involvement of extensive bilateral lymph nodes in 19 of the 44 lymph nodes." title="A pathology image depicts 3 point 2 centimeter M T C with involvement of extensive bilateral lymph nodes in 19 of the 44 lymph nodes." src="Image_529.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 13.4  <span class="s12">Nests of irregular spindled and plasmocytoid-shaped cells with amyloid deposits (star) typical of MTC (H&amp;E, ×60)</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_530.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">suspicion for malignancy until proven otherwise. Lymph nodes that remain enlarged for more than 4 weeks without any other identifiable cause should have further evaluation.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">On physical exam, assessment of nodal distribution is one important factor in the initial evaluation. Lymph nodes up to 3 cm may be followed for a short period of time in level 2, but those that are larger than 2 cm in other regions in the neck are more suspi cious for a malignant process. Fixed, firm nodes in multiple regions of the neck are a worrisome finding.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">Table 13.1 <span class="s12">Differential diagnosis</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:10.332pt" cellspacing="0"><tr style="height:17pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">1. Malignant lymphadenopathy</p></td></tr><tr style="height:46pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><ol id="l78"><li data-list-text="2."><p class="s24" style="padding-left: 18pt;text-indent: -14pt;text-align: left;">Benign reactive lymphadenopathy</p><ol id="l79"><li data-list-text="(a)"><p class="s24" style="padding-left: 37pt;text-indent: -19pt;text-align: left;">Infectious</p></li><li data-list-text="(b)"><p class="s24" style="padding-left: 38pt;text-indent: -19pt;text-align: left;">Inflammatory (e.g. Hashimoto’s thyroiditis)</p></li></ol></li></ol></td></tr><tr style="height:120pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><ol id="l80"><li data-list-text="3."><p class="s24" style="padding-left: 18pt;text-indent: -14pt;text-align: left;">Benign neck masses</p><ol id="l81"><li data-list-text="(a)"><p class="s24" style="padding-left: 37pt;text-indent: -19pt;text-align: left;">Branchial cleft cyst</p></li><li data-list-text="(b)"><p class="s24" style="padding-left: 38pt;text-indent: -19pt;text-align: left;">Thyroglossal duct cyst</p></li><li data-list-text="(c)"><p class="s24" style="padding-left: 37pt;text-indent: -19pt;text-align: left;">Lipoma</p></li><li data-list-text="(d)"><p class="s24" style="padding-left: 38pt;text-indent: -19pt;text-align: left;">Neurogenic tumors (paraganglioma, schwannoma)</p></li><li data-list-text="(e)"><p class="s24" style="padding-left: 37pt;text-indent: -18pt;text-align: left;">Vascular lesions</p></li><li data-list-text="(f)"><p class="s24" style="padding-left: 36pt;text-indent: -17pt;text-align: left;">Congenital lesions (dermoid cyst, teratoma)</p></li><li data-list-text="(g)"><p class="s24" style="padding-left: 38pt;text-indent: -19pt;text-align: left;">Parathyroid adenomas</p></li></ol></li></ol></td></tr></table><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_531.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">with benign lymph nodes most often having an L/S ratio &gt; 2 (Image <span style=" color: #00F;">13.5a–c</span>). In contrast, malignant lymph nodes usually dis play a rounded contour with an L/S ratio &lt; 2, are hypoechoic, and have no visible echogenic hilum. A peripheral halo and prominent vascularity are more commonly seen in malignant processes. Metastatic lymph nodes from papillary thyroid carcinoma may demonstrate  punctate  calcifications  and  hyper-echogenicity (Image <span style=" color: #00F;">13.6</span>). Intra-nodal cystic necrosis is also suggestive of metastases (Images <span style=" color: #00F;">13.7 </span>and <span style=" color: #00F;">13.8</span>). However, cystic change can be seen in benign processes, such as in thyroglossal duct cysts, which present high in the midline at the level of the hyoid bone, and in congenital branchial cleft cysts which most often present in the lateral mid-neck (Images <span style=" color: #00F;">13.9 </span>and <span style=" color: #00F;">13.10</span></p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Fine needle aspiration is recommended for any suspicious- appearing or persistently enlarged cervical lymph node. In most solid lymph nodes, fine needle aspiration is both highly sensitive and specific for distinguishing benign reactive lymphadenopathy from malignancy. Cystic lymph nodes may be harder to diagnose with needle biopsy because often the biopsy demonstrates only acellular cyst fluid. In some cases, repeat needle biopsy, core biopsy, and even excisional biopsy can be considered if fine nee dle biopsy is non-diagnostic. Excisional biopsy combined with</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_532.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">spread of differentiated thyroid cancer. Caution should be taken when sampling thyroglobulin in lymph nodes found in level VI (the central neck), because of a higher risk of inadvertently sam pling thyroid tissue in this region, which can lead to false positive results. In contrast, thyroglobulin washout may be less useful in cases of undifferentiated thyroid tumors, such as anaplastic carci noma, as these thyroid cancers do not reliably produce thyroglob ulin. Similarly, MTC will not be detected by thyroglobulin washout and testing will lead to false negative results if this condi tion is not considered. In some institutions, calcitonin levels can be measured in lymph node aspirates to help diagnose suspected MTC. Ultimately, a high level of suspicion based on patient and ultrasound factors followed by fine needle biopsy are the key components of the evaluation of persistent lymphadenopathy in the cervical region.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_533.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="516" height="404" src="Image_534.png"/></span></p><p class="s21" style="text-indent: 0pt;text-align: left;">a</p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><span><img width="516" height="396" src="Image_535.png"/></span></p><p class="s21" style="text-indent: 0pt;text-align: left;">b</p><p style="text-indent: 0pt;text-align: left;"/><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;"><span class="s17">Image 13.5  </span>(<b>a</b>–<b>c</b>) Benign cervical lymph nodes, each with preservation of the echogenic hilum (red arrows). Benign lymph nodes appear elongated or ovoid and have well-defined borders</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_536.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="569" height="399" src="Image_537.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Image 13.5 <span class="s12">(continued)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="310" src="Image_538.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Image 13.6  <span class="s12">Solid level IV lymph node metastasis from papillary thyroid carcinoma. Note the rounded nodular contour of the node, irregular border, and scattered micro-calcifications (arrow)</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_539.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="562" height="443" alt="An ultrasound for the metastasis of cystic lymph nodes from papillary thyroid carcinoma. The middle area of the ultrasound is dark." title="An ultrasound for the metastasis of cystic lymph nodes from papillary thyroid carcinoma. The middle area of the ultrasound is dark." src="Image_540.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 13.7 <span class="s12">Cystic lymph node metastasis from papillary thyroid carci noma</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_541.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 32pt;text-indent: 0pt;text-align: left;"><span><img width="517" height="360" src="Image_542.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 13.8  <span class="s12">Metastatic squamous cell carcinoma to a level II lymph node demonstrating irregular shape with an area of cystic necrosis (arrow)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="162" alt="Two ultrasounds depict the midline thyroglossal duct cyst. It also shows that the thyrohyoid membrane lies along with thyroglossal duct cyst." title="Two ultrasounds depict the midline thyroglossal duct cyst. It also shows that the thyrohyoid membrane lies along with thyroglossal duct cyst." src="Image_543.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 13.9  <span class="s12">Ultrasound of a midline thyroglossal duct cyst (left panel sagit tal, right panel transverse). These well-circumscribed congenital lesions can be confused with prelaryngeal “Delphian” nodes, which can harbor malig nancies from laryngeal and thyroid tumors. Thyroglossal duct cysts usually lie along the thyrohyoid membrane, while prelaryngeal nodes are found along the cricothyroid region</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_544.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 29pt;text-indent: 0pt;text-align: left;"><span><img width="462" height="563" alt="A C T scan of the lateral mid-neck represents the cystic change in the congenital branchial cleft cysts. An arrow marks the cyst." title="A C T scan of the lateral mid-neck represents the cystic change in the congenital branchial cleft cysts. An arrow marks the cyst." src="Image_545.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 13.10 <span class="s12">Axial contrast CT image of a congenital branchial cleft cyst in left level II of the neck. Note the lesion may be confused with a cystic lymph node and has slight mural wall thickening (arrow), likely due to previous infection</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_546.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 32pt;text-indent: 0pt;text-align: left;"><span><img width="516" height="366" alt="A C T scan of the lymphoma node. It highlights several lymphocytic cells." title="A C T scan of the lymphoma node. It highlights several lymphocytic cells." src="Image_547.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Image 13.11  <span class="s12">Lymphoma node that is enlarged, round, and does not have a hilum. These lymph nodes are usually homogeneous, with relatively low level internal echoes. They can be diffusely vascular on color Doppler</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_548.png"/></span></p><h1 style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;"><a name="a101">Further Reading</a></h1><p class="s12" style="padding-top: 17pt;padding-left: 30pt;text-indent: -19pt;text-align: justify;">Asimakopoulos P, Nixon IJ, Shaha AR. Differentiated and medullary thyroid cancer: surgical management of cervical lymph nodes. Clin Oncol (R Coll Radiol). 2017;29(5):283–9.</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;line-height: 14pt;text-align: justify;">Cervical SM. Lymphadenopathy. In: Head and neck and endocrine surgery.</p><p class="s12" style="padding-left: 30pt;text-indent: 0pt;text-align: justify;">Thieme Medical Publishers; 2016. p. 163–90.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: justify;">Grani G, Fumarola A. Thyroglobulin in lymph node fine-needle aspiration washout: a systematic review and meta-analysis of diagnostic accuracy. J Clin Endocrinol Metab. 2014;99(6):1970–82.</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: justify;">Gupta A, et al. Sonographic assessment of cervical lymphadenopathy: role of high-resolution and color doppler imaging. Head Neck. 2011;33(3):297– 302.</p><p style="padding-left: 30pt;text-indent: -19pt;text-align: justify;"><a href="https://doi.org/10.1186/1477-7819-9-29" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">Khanna R, Sharma AD, Khanna S, Kumar M, Shukla RC. Usefulness of ultrasonography for the evaluation of cervical lymphadenopathy. World J Surg Oncol. 2011;9:29. </a><a href="https://doi.org/10.1186/1477-7819-9-29" target="_blank">https://doi.org/10.1186/1477-</a></p><p style="padding-left: 385pt;text-indent: 0pt;text-align: left;"><span><a href="http://crossmark.crossref.org/dialog/?doi=10.1007/978-3-031-18448-2_14&amp;domain=pdf"><img width="69" height="61" src="Image_549.png"/></a></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s11" style="padding-left: 19pt;text-indent: 0pt;text-align: left;">Key Points</p><ul id="l82"><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: left;">Incidental masses in the neck, other than thyroid nod ules, are uncommon.</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: left;">In select cases, a definitive benign diagnosis can be made on US alone. These include simple lipoma, thyroglossal duct cyst without solid tissue or calcification, plunging ranula, and diffuse inflammatory conditions of the sali vary glands (sialadenitis), without or with an obstructive sialolith (the latter may also be visible on ultrasound).</p></li><li data-list-text="•"><p style="padding-left: 39pt;text-indent: -19pt;text-align: justify;">Outside of these specific examples, a patient with a newly identified mass in the neck should be referred for ENT evaluation and contrast-enhanced CT or MRI for further characterization prior to biopsy.</p></li></ul><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="226" height="1" src="Image_550.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_551.png"/></span></p><p class="s12" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">M. B. Cunnane (<span class="s13">*</span>) · A. Juliano</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Department of Radiology, Massachusetts Eye and Ear Institute,</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Boston, MA, USA</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><a href="mailto:MaryBeth_Cunnane@MEEI.HARVARD.EDU" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">e-mail: </a><a href="mailto:amy_juliano@meei.harvard.edu" class="s20" target="_blank">MaryBeth_Cunnane@MEEI.HARVARD.EDU amy_juliano@meei.harvard.edu</a></p><p class="s12" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">G. Randolph</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Department of Otorhinolaryngology, Head and Neck Surgery, Massachusetts Eye and Ear Institute, Boston, MA, USA</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">© The Author(s), under exclusive license to Springer Nature Switzerland AG 2023</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">L. S. Eldeiry et al. (eds.), <i>Handbook of Thyroid and Neck Ultrasonography</i><a href="https://doi.org/10.1007/978-3-031-18448-2_14" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">, Contemporary Endocrinology, </a><a href="https://doi.org/10.1007/978-3-031-18448-2_14" class="s20" target="_blank">https://doi.org/10.1007/978-3-031-18448-2_14</a></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_552.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="387" height="412" alt="An anatomical figure of a humanђs neck with labelled parts." title="An anatomical figure of a humanђs neck with labelled parts." src="Image_553.jpg"/></span></p><p class="s75" style="padding-top: 4pt;padding-left: 294pt;text-indent: 0pt;text-align: left;">Greater horn of the hyoid bone</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 14.1  <span class="s12">Surface anatomy of the neck (source: Lumley, J. Surface Anat omy: The Anatomical Basis of Clinical Examination. 2008, 4th ed.)</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_554.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="275" alt="An X ray demonstrates the strap muscles and the trachea with arrows and triangles." title="An X ray demonstrates the strap muscles and the trachea with arrows and triangles." src="Image_555.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 14.2  <span class="s12">In this transverse image at the level of the thyroid isthmus, double lined arrows mark the strap muscles bilaterally. A solid arrow indi cates the trachea; note the echogenic line along the anterior aspect and the shadowing along the lateral aspects. White triangles denote the location of the “danger triangle” of the tracheoesophageal groove, so named because it rep resents a potential location of the recurrent laryngeal nerves</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="572" height="302" alt="An X ray of the esophagus wall illustrates this to be a multilayered wall." title="An X ray of the esophagus wall illustrates this to be a multilayered wall." src="Image_556.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 14.3  <span class="s12">In this image, the multilayered wall of the esophagus is clearly seen in the left tracheoesophageal groove (arrow)</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_557.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="350" alt="An X ray demonstrates the location of the hyoid bone with an arrow." title="An X ray demonstrates the location of the hyoid bone with an arrow." src="Image_558.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 14.4  <span class="s12">The hyoid bone (arrow) can be recognized as a curved echo genic focus in the superior midline neck with posterior acoustic shadowing. This is an important landmark for the recognition of thyroglossal duct cysts</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="307" alt="An ultrasound image of a patientђs neck that depicts a neck mass." title="An ultrasound image of a patientђs neck that depicts a neck mass." src="Image_559.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 14.5  <span class="s12">The thyroid cartilage is easily seen during thyroid ultrasound. As a patient ages, the thyroid cartilage progressively mineralizes, but this can occur in a discontinuous fashion with ossified and non-ossified components coexisting. In this image, the straight arrow indicates non-ossified thyroid cartilage. The curved arrow indicates ossified thyroid cartilage which is echo genic with posterior acoustic shadowing. The larynx is partially visualized through the non-ossified components</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_560.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">conditions such as sialadenitis, benign masses, and malignancies (either primary malignancies or metastatic nodes) may all present as neck masses.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">There are certain neck lesions with characteristic appearances that can safely be considered benign. These include simple lipo mas, plunging ranulas, and thyroglossal duct cysts that do not contain solid components or calcification. Sialadenitis and sialo lith with ductal dilation are additional benign inflammatory con ditions that can be appreciated on neck US.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: justify;">Outside of these examples, a mass in the adult neck should be considered malignant until proven otherwise. It is extremely important for the thyroid sonographer to avoid generalizing the approach to characterizing thyroid nodules to the remainder of the neck. For example, while cystic composition is a benign feature of thyroid nodules, cystic change within a lymph node is concerning for malignancy. Table <span style=" color: #0000F9;">14.1 </span>outlines typical differential diagnoses for abnormalities at various sites within the neck.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;"><a name="a102">Case Presentation 1</a></h3><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">A patient presented with a neck mass located immediately to the left of midline, under the jaw. Ultrasound imaging is shown below (Image <span style=" color: #0000F9;">14.6</span>).</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">Although thyroglossal duct cysts can occur anywhere along the path of descent of the thyroid, the majority are at or just infe rior to the hyoid bone, as in this case. They may be entirely cystic or contain echogenic debris. Papillary thyroid carcinoma may occur within thyroglossal duct cysts, arising in fewer than 5% of cases; however, FNA of any solid or vascular component is war ranted to exclude this possibility.</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_561.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:10.332pt" cellspacing="0"><tr style="height:32pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:149pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Lipoma</p></td></tr><tr style="height:17pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s76" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">II. Submandibular space</p></td></tr><tr style="height:119pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;padding-right: 27pt;text-indent: 0pt;text-align: left;">Abnormal submandibular lymph node (metastasis, lymphoma) Abnormal submandibular gland</p><p class="s24" style="padding-left: 17pt;padding-right: 140pt;text-indent: 0pt;text-align: left;">Benign or malignant submandibular tumors Acute sialadenitis</p><p class="s24" style="padding-left: 18pt;padding-right: 13pt;text-indent: 0pt;text-align: left;">IgG4, Sjogren, other chronic inflammatory/autoimmune conditions Stone</p><p class="s24" style="padding-left: 4pt;padding-right: 297pt;text-indent: 0pt;text-align: left;">Plunging ranula Lipoma</p></td></tr><tr style="height:17pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s76" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">III. Parotid gland</p></td></tr><tr style="height:75pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;padding-right: 180pt;text-indent: 0pt;text-align: left;">Benign and malignant parotid tumors Acute sialadenitis (with or without abscess)</p><p class="s24" style="padding-left: 4pt;padding-right: 27pt;text-indent: 0pt;text-align: left;">IgG4, Sjogren, other chronic inflammatory/autoimmune conditions Stone</p><p class="s24" style="padding-left: 4pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Benign and malignant intraparotid lymph nodes</p></td></tr><tr style="height:17pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s76" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">IV. Carotid space</p></td></tr><tr style="height:46pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;padding-right: 272pt;text-indent: 0pt;text-align: left;">Schwannoma Paraganglioma Aneurysm/pseudoaneurysm</p></td></tr><tr style="height:17pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s76" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">V. Supraclavicular space</p></td></tr><tr style="height:76pt"><td style="width:431pt;border-top-style:solid;border-top-width:1pt;border-top-color:#FFFFFF;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#FFFFFF" bgcolor="#E2E7F5"><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Reactive lymph node</p><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Metastatic lymph nodes from thyroid cancer</p><p class="s24" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Metastatic lymph nodes from chest or abdomen primary malignancies Lymphoma</p><p class="s24" style="padding-left: 4pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Lipoma</p></td></tr></table><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_562.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="578" height="628" alt="Two ultrasound images of a patientђs neck depict a palpable neck mass." title="Two ultrasound images of a patientђs neck depict a palpable neck mass." src="Image_563.gif"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 14.6  <span class="s12">Transverse image (top) showing a cystic and solid lesion (between white arrows) just to the left of midline that contacts the medial border of the left submandibular gland. Sagittal image (bottom) where the mass is labeled with a star. Note the curved arrow, which indicates shadowing by the hyoid bone superior to the lesion, and the straight arrow indicating the thyroid cartilage inferior to the lesion</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_564.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="271" src="Image_565.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="269" src="Image_566.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Image 14.7  <span class="s12">Transverse image (top) of a rounded, well-circumscribed soft tissue nodule. Sagittal view (bottom) showing the nodule to be cystic and solid and to have linear structures extending from it (arrows). FNA was attempted but was aborted due to severe lancinating pain in the hand which the patient experienced when a needle was placed in the mass</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_567.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">focus is identified in the parotid tail (Image</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: left;">The tail of the parotid gland lies adjacent to the upper jugu lodigastric lymph nodes at the angle of the mandible and can be visualized during evaluation of this region. There are normally occurring lymph nodes in the parotid that have the same appear ance as benign lymph nodes in other regions of the neck. Occasionally, nodules in the parotid gland are encountered. Most parotid nodules are benign (e.g. parotid pleomorphic adenomas) and demonstrate well-defined margins. They may be markedly hypoechoic and demonstrate posterior acoustic enhancement</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="306" src="Image_568.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 14.8  <span class="s12">This  well-circumscribed  nodule,  demonstrates  enhanced through transmission/posterior acoustic enhancement (arrow), but there is a small amount of blood flow within the lesion, suggesting the nodule is solid rather than cystic</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_569.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">patient reported a posterior neck mass. Sagittal images demon strate a mass in the subcutaneous soft tissues that is hyperechoic to the adjacent muscle (Image <span style=" color: #0000F9;">14.9</span>).</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Lipomas present clinically as palpable, soft masses. They may slowly enlarge over time and are a common finding in an other wise well patient. On ultrasound, lipomas are usually hyperechoic relative to adjacent muscle and typically contain linear echo genicities. Lipomas should be carefully examined for solid com ponents or vascularized septations as these features may be seen in liposarcomas (Image <span style=" color: #0000F9;">14.9</span>).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="228" src="Image_570.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Image 14.9  <span class="s12">There are linear echogenic bands within the mass (arrow), which are parallel to the skin surface. Physical examination revealed a soft neck mass that had been present for many years</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_571.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">tumors, are rare neck masses arising from chromaffin cells, which tend to be closely associated with the internal carotid artery or carotid bifurcation. Involvement of the carotid space may also be seen with vagal Schwannoma. As these tumors can be very vascu lar and may secrete catecholamines, further work-up should be performed prior to FNA, and should include biochemical testing and contrast-enhanced CT or MRI.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="438" src="Image_572.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 14.10  <span class="s12">Sagittal image through the neck demonstrates a large, hetero geneous solid nodule without significant internal vascularity (arrow)</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_573.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="506" src="Image_574.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Image 14.11 <span class="s12">Transverse images through the lesion demonstrate tumor sur rounding the carotid bifurcation (arrows)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-left: 10pt;text-indent: 0pt;text-align: justify;"><a name="a103">Case Presentation 6</a></h3><p style="padding-left: 10pt;text-indent: 0pt;text-align: justify;">A 65 year old woman reported a lump in the submandibular space. Scanning over the site of the palpable abnormality demonstrated an enlarged submandibular gland with heterogeneous echotexture and dilated ducts (Images <span style=" color: #0000F9;">14.12 </span>and <span style=" color: #0000F9;">14.13</span></p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Sialoliths are concretions within the salivary ducts and are more common in the submandibular gland than in the parotid gland. They result in pain and swelling of the gland, which is par ticularly noticeable during eating. They can be recognized as a focus of increased echogenicity associated with posterior shad owing. There is often dilation of the duct proximal to the stone and there may be swelling and inflammatory change within the gland as a result of the obstruction.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_575.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="574" height="311" src="Image_576.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Image 14.12  <span class="s12">Sagittal view through the submandibular gland demonstrates heterogeneous echotexture. The submandibular duct (arrow) is dilated</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="309" src="Image_577.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 14.13  <span class="s12">An image obtained closer to the hilum of the gland shows an echogenic curvilinear focus with posterior shadowing (arrow), representing an obstructing sialolith within the submandibular duct</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><h3 style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="a104">Case Presentation 7</a></h3><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">A 25-year-old man reported swelling in the submandibular region. Ultrasound demonstrated a fluid-filled structure in the subman dibular space (Images <span style=" color: #0000F9;">14.14 </span>and <span style=" color: #0000F9;">14.15</span>).</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_578.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="354" src="Image_579.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Image 14.14 <span class="s12">Transverse image through the submandibular space demon strates a well-circumscribed hypoechoic structure without internal flow (arrow)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="317" src="Image_580.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: justify;">Image 14.15  <span class="s12">The cystic structure is shown to be contiguous with the left sublingual gland (straight arrows) which has herniated through a defect in the mylohyoid muscle (curved arrows), consistent with plunging ranula</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_581.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 19pt;text-align: justify;">Direct laryngoscopy with biopsy diagnosed HPV-associated squamous cell carcinoma of the tongue base, and this cystic mass was recognized to be a metastasis.</p><p style="padding-left: 5pt;text-indent: 19pt;text-align: justify;">In thyroid nodules, cystic composition is a reassuring finding. In the lateral neck, most masses encountered in an adult are lymph</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="573" height="345" src="Image_582.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s17" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Image 14.16  <span class="s12">Transverse image demonstrates a predominantly cystic mass (arrow) just lateral to the carotid artery, with a small focus of solid tissue or debris within it (curved arrow)</span></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_583.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_584.png"/></span></p><h1 style="padding-top: 3pt;padding-left: 10pt;text-indent: 0pt;text-align: left;"><a name="a105">Discussion</a></h1><p style="padding-top: 17pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">A wide variety of abnormalities may be seen and evaluated on physical examination of the neck. A history of a new neck mass occurring in the setting of pain or redness suggests infection or inflammation. Thus, incidental neck infections and masses are rare on thyroid US. It is useful to understand some basic princi ples of differential diagnosis when an abnormality is encountered. In the salivary glands, swelling may represent obstruction, sialad enitis, or tumor. At the angle of the mandible, a mass may repre sent a malignant lymph node. In the central neck superiorly, thyroglossal duct cysts, abnormal submandibular lymph nodes, and plunging ranulas are possibilities. Table</p><p style="padding-left: 10pt;text-indent: 0pt;text-align: left;">tional possibilities organized by location.</p><p style="padding-left: 10pt;text-indent: 19pt;text-align: left;">Unless a benign diagnosis can be definitively made with imag ing (sialolith, lipoma, etc.), newly discovered masses in the adult neck will require FNA or core biopsy to establish a diagnosis. It is critical to remember that cystic change within a lesion does not exclude malignancy, as both papillary thyroid cancer and HPV- associated oropharyngeal cancer may present with cystic lymph nodes. A reasonable strategy for the work-up of a newly diag nosed indeterminate mass lesion in the neck includes ENT evalu ation and contrast-enhanced CT or MRI.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_585.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 10pt;padding-left: 25pt;text-indent: 0pt;text-align: left;">DR, Stern WB, Youngerman JS, Corrigan MD. Clinical practice guide line: evaluation of the neck mass in adults. Otolaryngol Head Neck Surg. 2017;157(2_suppl):S1–S30.</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;line-height: 16pt;text-align: left;">Stoia S, Băciu<span class="s77">ț </span>G, Lenghel M, Badea R, Băciu</p><p class="s12" style="padding-left: 25pt;text-indent: 0pt;line-height: 13pt;text-align: left;">D. Ultrasonography techniques in the preoperative diagnosis of parotid</p><p class="s12" style="padding-left: 25pt;text-indent: 0pt;text-align: left;">gland tumors - an updated review of the literature. Med Ultrason. 2021;23(2):194–202.</p><p class="s74" style="padding-left: 25pt;text-indent: -19pt;text-align: left;"><a href="https://doi.org/10.1007/s12105-016-0724-7" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">Thompson LD, Herrera HB, Lau SK. A clinicopathologic series of 685 thy roglossal duct remnant cysts. Head Neck Pathol. 2016;10(4):465–74. </a>https://doi.org/10.1007/s12105-016-0724-7<span style=" color: #2B2A29;">.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="688" height="4" src="Image_586.png"/></span></p><p class="s22" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">A</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Abnormal lymph nodes, 19 Acoustic shadowing, 3 American College of Radiology</p><p class="s12" style="padding-left: 65pt;text-indent: 0pt;text-align: left;">Thyroid Imaging Reporting and Data System (ACR TI-RADS), 35, 42</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">American Thyroid Association</p><p class="s12" style="padding-left: 65pt;text-indent: 0pt;text-align: left;">(ATA), 70, 89, 184</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Anaplastic thyroid carcinoma, 83 Anatomic variants, 13–14</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Anechoic cyst, 134, 148</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Anechoic nodule, 171</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Artificial intelligence (AI), 35, 36 Atypia of undetermined significance</p><p class="s12" style="padding-left: 65pt;text-indent: 0pt;line-height: 14pt;text-align: left;">(AUS), 74, 75</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Autoimmune thyroid disease</p><p class="s12" style="padding-left: 65pt;text-indent: 0pt;text-align: left;">(AITD), 121</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Autoimmune thyrotoxicosis, 116</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">B</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Benign calcification, 171</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Benign cervical lymph nodes, 213 Benign follicular cells, 73, 142 Benign inflammatory conditions, 223 Benign peripheral calcifications, 172 Benign reactive lymph nodes, 211 Benign thyroid follicles, 120</p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Bethesda category, 51, 167 Bethesda System for Reporting</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Bilateral parathyroid</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Brigham and Women’s Hospital</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">B-type RAF kinase (BRAF), 91 Butterfly point of care system, 5</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">C</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Calcification, 17, 165–176 Carotid Doppler scanning, 170 CD20 immunostain, 136</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Cellblock preparation, 127</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Central vascularity, 179 Cervical lymph nodes</p><p class="s12" style="padding-left: 25pt;text-indent: 0pt;text-align: left;">case presentation, 206–209 and lateral neck masses, 209,</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-left: 25pt;text-indent: 0pt;text-align: left;">ultrasonography, 220</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Cervical lymphadenopathy, 210 Chronic autoimmune thyroiditis, 178 Chronic lymphocytic (Hashimoto)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Chronic thyroiditis, 144</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Classic spongiform nodule, 129</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">L. S. Eldeiry et al. (eds.), <i>Handbook of Thyroid and Neck Ultrasonography</i><a href="https://doi.org/10.1007/978-3-031-18448-2" style=" color: #2B2A29; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12.5pt;" target="_blank">, Contemporary Endocrinology, </a><a href="https://doi.org/10.1007/978-3-031-18448-2" class="s20" target="_blank">https://doi.org/10.1007/978-3-031-18448-2</a></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_587.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Cytokeratin-19, 90</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Cytology, 168</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Cytopathology, 99</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">D</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">4DCT, 198</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Destructive thyroiditis, 116 Diffuse thyroid enlargement, 135 Direct laryngoscopy, 233</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Discontinuous rim calcifications, 173 Doppler imaging, 21, 148, 180</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Double adenomas, 201</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">E</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Echogenic foci, 135, 166</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Echogenicity, defined, 134</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Eggshell calcifications, 173</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Elastography, 8</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Enlarged thyroid gland, 6 Ethanol ablation, 174</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;line-height: 14pt;text-align: left;">EU-TIRADS, 37, 38</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Extrathyroidal extension, 160, 163 Extrathyroidal parathyroid</p><p class="s12" style="padding-left: 69pt;text-indent: 0pt;line-height: 14pt;text-align: left;">adenoma, 198</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">F</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Fine needle aspiration (FNA), 26,</p><p class="s12" style="padding-left: 69pt;text-indent: 0pt;text-align: left;">70, 119, 211, 227</p><p class="s12" style="padding-left: 30pt;text-indent: 0pt;text-align: left;">benign nodule characteristics, 97 biopsy techniques, 60, 62</p><p class="s12" style="padding-top: 4pt;padding-left: 30pt;text-indent: 0pt;text-align: left;">mutation and miRNA</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-left: 30pt;text-indent: 0pt;text-align: left;">needles and core biopsy</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-left: 30pt;text-indent: 0pt;text-align: left;">parathyroid adenomas, 64, 67 salivary gland and miscellaneous</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-left: 30pt;text-indent: 0pt;text-align: left;">solutions and media, 58 specimens, 64</p><p class="s12" style="padding-left: 30pt;text-indent: 0pt;line-height: 14pt;text-align: left;">thyroid cyst aspiration and</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-left: 30pt;text-indent: 0pt;text-align: left;">thyroid nodule biopsy, 59 thyroid nodule diagnosis, 91</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Follicular carcinoma, 141, 149</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Follicular cells, 127, 169 Follicular lesion of undetermined</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-top: 10pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">G</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Genetic alterations, 99 Genetic translocation</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Glomus vagale, 229</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Graves’ disease, 112, 114, 201</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">H</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Hashimoto’s thyroiditis, 12, 73, 78,</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_588.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Hypoechoic parathyroid adenoma,</p><p class="s12" style="padding-left: 65pt;text-indent: 0pt;text-align: left;">193</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Hypoechoic structures, 134</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">I</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Indeterminate thyroid nodule, 103 Inflammatory conditions, 223</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Intranodular vascularity, 183, 184</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Intratracheal growth, 163</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Irregular/Infiltrative margins, 158 Isoechoic and hyperechoic masses,</p><p class="s12" style="padding-left: 65pt;text-indent: 0pt;line-height: 14pt;text-align: left;">149</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Isoechoic nodules, 32</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">K</p><p class="s12" style="padding-left: 65pt;text-indent: -59pt;text-align: left;">Korean Thyroid Imaging Reporting and Data System</p><p class="s12" style="padding-left: 65pt;text-indent: 0pt;line-height: 14pt;text-align: left;">(K-TIRADS), 38, 39</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">KRAS, 91</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">L</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Laryngoscopic examination, 153</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Larynx, 222</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Linear array transducers, 6 Lipomas, 228</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Lobulated margins, 154</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Lymph node, 59, 60</p><p class="s12" style="padding-left: 25pt;text-indent: 0pt;text-align: left;">assessment, 18</p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Microcalcifications, 167, 173, 175</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Microcystic components, 129</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Molecular testing, 76 Multinucleated plasmacytoid-</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Multiple hypoechoic nodules, 143 Multiple nodules, 118</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Myelohyoid muscle, 232, 233</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Margins and shape, 155, 161</p><p class="s12" style="padding-left: 25pt;text-indent: 0pt;text-align: left;">case presentation, 153, 155</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">N</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;line-height: 204%;text-align: left;">Next-generation sequencing (NGS), Non-invasive follicular thyroid</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Normal lymph nodes, 19 Normal parathyroid glands, 20 Normal thyroid texture, 11–12 Normal ultrasound anatomy, 221 NRAS, 91</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Nuclear debris, 132</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">P</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Papillary carcinoma, 141</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Papillary thyroid cancer (PTC), 81,</p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_589.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 19pt;text-align: left;">embryology and anatomy, 191 Peripheral rim, 175</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Point-of-care handheld ultrasound</p><p class="s12" style="padding-left: 69pt;text-indent: 0pt;text-align: left;">system technology, 4</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Poorly-defined margins, 159 Positive CD20 immunostain, 138 Positron emission tomography</p><p class="s12" style="padding-left: 10pt;text-indent: 59pt;text-align: left;">(PET) scan, 136 Posterior acoustic enhancement, 3 Primary thyroid lymphomas, 84 Psammoma bodies, 175</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Pseudocystic nodules, 131</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Pseudonodules, 122, 145</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Pyramidal lobe, 13</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Q</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Qualitative color flow Doppler</p><p class="s12" style="padding-left: 69pt;text-indent: 0pt;text-align: left;">(CFD), 112</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">R</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Radiofrequency ablation (RFA), 174 Retrovirus-associated DNA</p><p class="s12" style="padding-left: 69pt;text-indent: 0pt;text-align: left;">sequences (RAS) point mutations, 91</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Reverberation artifact, 3 Reverse transcriptase-PCR</p><p class="s12" style="padding-left: 69pt;text-indent: 0pt;line-height: 14pt;text-align: left;">(RT-PCR), 90</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Risk of malignancy (RoM), 26, 70 Risk stratification tools, 40</p><p class="s12" style="padding-top: 4pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">Strap muscles, 221</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Subacute thyroiditis, 119</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Sublingual gland, 233</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Submandibular gland, 231</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Submandibular space, 230, 232</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Suboptimal penetration, 5</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">T</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;line-height: 204%;text-align: left;">Telomerase reverse transcriptase The Bethesda System for Reporting</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-left: 30pt;text-indent: 0pt;text-align: left;">AUS/FLUS, 74, 75</p><p class="s12" style="padding-left: 30pt;text-indent: 0pt;text-align: left;">benign, 72, 73</p><p class="s12" style="padding-left: 30pt;text-indent: 0pt;text-align: left;">follicular neoplasm/suspicious</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-left: 30pt;text-indent: 0pt;text-align: left;">nondiagnostic, 71</p><p class="s12" style="padding-left: 10pt;text-indent: 19pt;line-height: 204%;text-align: left;">suspicious for malignancy, 79, Thyroglossal duct cyst, 13, 14, 146,</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Thyroid anatomy, 10–11</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Thyroid autoantibodies, 117</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Thyroid cartilage, 222</p><p class="s12" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">Thyroid echogenicity patterns, 139 Thyroid gland, 142</p><p class="s12" style="padding-left: 30pt;text-indent: -19pt;text-align: left;">Thyroid nodule, 14, 26, 70, 233 ultrasonography</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="578" height="2" src="Image_590.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Thyroid ultrasound, 135, 148, 223</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Thyroiditis, 106</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">ThyroSeq®, 95, 96</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Tracheoesophageal groove, 221</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Transducer frequency, 5</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Transducer selection, 5, 6</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Transverse scans, 7</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">U</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Ultrasound (US), 211, 223, 231</p><p class="s12" style="padding-left: 25pt;text-indent: 0pt;text-align: left;">artifact, 3</p><p class="s12" style="padding-left: 25pt;text-indent: 0pt;text-align: left;">branchial cleft cyst, 22 carotid body tumor, 22, 23</p><p class="s12" style="padding-left: 25pt;text-indent: 0pt;line-height: 14pt;text-align: left;">clinical ultrasound, 2</p><p class="s12" style="padding-left: 65pt;text-indent: -39pt;text-align: left;">contrast-enhanced ultrasound, 8–10</p><p class="s12" style="padding-left: 65pt;text-indent: -39pt;text-align: left;">elastography and ultrasound contrast enhancement, 8</p><p class="s12" style="padding-left: 25pt;text-indent: 0pt;line-height: 14pt;text-align: left;">equipment, 3–5</p><p class="s12" style="padding-left: 25pt;text-indent: 0pt;text-align: left;">EU-TIRADS, 37, 38</p><p class="s12" style="padding-top: 4pt;padding-left: 25pt;text-indent: 0pt;text-align: left;">risk stratification tools, 40 salivary glands, 21</p><p class="s12" style="padding-left: 25pt;text-indent: 0pt;line-height: 14pt;text-align: left;">scoring systems, 29, 30</p><p class="s12" style="padding-left: 25pt;text-indent: 0pt;text-align: left;">solid nodule, 16, 17</p><p class="s12" style="padding-left: 25pt;text-indent: 0pt;text-align: left;">spongiform nodules, 15</p><p class="s12" style="padding-left: 25pt;text-indent: 0pt;text-align: left;">Thyroid Nodule App, 44, 45</p><p class="s12" style="padding-left: 5pt;text-indent: 19pt;text-align: left;">transducer selection, 5, 6 Ultrasound-guided fine needle</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">US guidance techniques, 61</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">V</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Vagal schwannoma, 229 Vascularity</p><p class="s12" style="padding-left: 25pt;text-indent: 0pt;text-align: left;">benignity vs. malignancy, 178 case presentation, 179–182</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">W</p><p class="s12" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Well-circumscribed nodule, 227</p>	
      <!-- Вставьте произвольный фрагмент HTML-кода здесь -->
    </div>
  </div>
</body>
</html>
